WO2026080706A1 - Recombinant chimeric bovine/human parainfluenza virus 3 expressing avian influenza virus proteins and use thereof - Google Patents

Abstract

Recombinant chimeric bovine/human parainfluenza virus 3 (rB/HPIV3) vectors expressing a heterologous avian influenza virus (AIV) protein as well as methods of their use and manufacture, are provided. The disclosed rB/HPIV3 vectors can be used, for example, to induce an immune response to AIV and HPIV3 in a subject.

Description

^{4239-112370-02} RECOMBINANT CHIMERIC BOVINE/HUMAN PARAINFLUENZA VIRUS 3 EXPRESSING AVIAN INFLUENZA VIRUS PROTEINS AND USE THEREOF CROSS REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Application No.63/705,659, filed October 10, 2024, which is incorporated by reference in its entirety. FIELD This relates to recombinant chimeric bovine/human parainfluenza virus 3 (rB/HPIV3) vectors expressing avian influenza virus (AIV) proteins, for example, to induce an immune response to AIV in a subject. INCORPORATION OF ELECTRONIC SEQUENCE LISTING The Sequence Listing is submitted as an XML file named “Sequence.xml,” created on October 7, 2025, 144,900 bytes, which is incorporated by reference herein. BACKGROUND Influenza viruses remain at the forefront of viral pathogens that can cause animal panzootics and human pandemics. Genetic diversity and the natural avian reservoir drive the evolution of novel strains that have caused several pandemics in the recent century. Influenza viruses are classified in the family Orthomyxoviridae and are comprised of four types including A, B, C, and D. Influenza A, B, and C cause disease in humans with A and B associated with seasonal epidemics, causing up to 710,000 hospitalizations and 4,900-51,000 deaths annually in the United States during the period of 2010-2023. A large natural reservoir of antigenically distinct influenza A viruses (IAV) exists in the wild aquatic birds that serves as a virus gene pool for the evolution of novel strains posing a risk of zoonotic infections and possibly a pandemic. The highly pathogenic avian influenza virus (HPAIV) subtype H7N9 can be transmitted from poultry to humans causing severe disease with 40% mortality. Effective vaccines are needed for pandemic preparedness, however, low immunogenicity in humans of HPAIV H7N9 presents a significant challenge. SUMMARY Disclosed are recombinant chimeric bovine/human parainfluenza virus 3 (rB/HPIV3) vectors including a heterologous gene encoding an avian influenza virus (AIV) antigenic protein. The disclosed rB/HPIV3 vectors include a full complement of PIV3 genes, thus the rB/HPIV3 vectors disclosed herein are infectious and replication-competent, however, are attenuated in humans at least due to the BPIV3 backbone. In some aspects, the disclosed rB/HPIV3 vectors include a bovine parainfluenza virus 3 (BPIV3) genome, with the BPIV3 F and HN genes replaced by those from human PIV3 (HPIV3). ^{4239-112370-02} In some aspects, the genome of a rB/HPIV3 vector disclosed herein includes in a 3’ to 5’ order: a 3’ leader region, BPIV3 N gene, heterologous gene, BPIV3 P gene, BPIV3 M gene, HPIV3 F gene, HPIV3 HN gene, BPIV3 L gene, and 5’ trailer region. Exemplary sequences of a 3’ leader region, BPIV3 N gene, BPIV3 P gene, BPIV3 M gene, HPIV3 F gene, HPIV3 HN gene, BPIV3 L gene, and 5’ trailer region, are provided herein. In some aspects, the heterologous gene encodes an avian influenza virus hemagglutinin (HA) or an avian influenza virus neuraminidase (NA) protein. In some aspects, the heterologous gene encodes an avian influenza virus H7N9 hemagglutinin (HA) or an avian influenza virus H7N9 neuraminidase (NA) protein. Exemplary amino acid sequences of AIV H7N9 HA and NA are provided herein. In some aspects, the heterologous gene is codon-optimized for expression in a human cell. When administered to a subject, the rB/HPIV3 vectors disclosed herein induce an immune response to AIV (e.g., H7N9) and/or HPIV3. Also disclosed are nucleic acid molecules (e.g., DNA or RNA) encoding a genome or antigenome of a rB/HPIV3 vector disclosed herein, and vectors (e.g., viral vector or plasmid vector) including such nucleic acids. Further provided are host cells including a rB/HPIV3 vector, or nucleic acid, disclosed herein. In some aspects, the host cell is a virus or vaccine production cell line (e.g., Vero cells). Further disclosed are methods of producing rB/HPIV3 virus, including: transfecting a host cell with a vector disclosed herein; culturing the host cell, thereby forming a cell culture; and purifying the virus from the cell culture, thereby producing the rB/HPIV3 virus. The rB/HPIV3 virus is useful, for example, for use as a live attenuated viral vaccine. Immunogenic compositions including a rB/HPIV3 vector or virus disclosed herein and a pharmaceutically acceptable carrier are also provided. In some aspects, an immunogenic composition disclosed herein is administered to a subject to elicit an immune response to AIV (e.g., H7N9) and/or HPIV3. In some aspects, administration is intranasal. In some aspects, the subject is a human subject, for example, a human pediatric subject. The foregoing and other objects, features, and advantages of this disclosure will become more apparent from the following detailed description, which proceeds with reference to the accompanying figures. BRIEF DESCRIPTION OF THE DRAWINGS FIGS.1A-1B show genome maps of chimeric B/HPIV3 containing supernumerary HPAIV H7N9 HA and/or NA genes. B/HPIV3 is BPIV3 in which the F and HN genes have been substituted with those of HPIV3 (green) using unique restriction sites introduced into the downstream non-coding regions of the M and HN genes. Six B/HPIV3 constructs were designed containing an additional gene encoding the H7 and/or N9 genes (A/Guangdong/17SF003/2016 strain); all genes are shown as rectangles flanked by bars indicating gene start (GS; light gray shading) and gene end (GE; dark gray shading) signals. Four viruses have H7 or N9 inserted between the N and P genes: B/HPIV3/HA, B/HPIV3/HA-TMCT, B/HPIV3/NA and B/HPIV3/NA-TMCT. The amino acid sequence below the HA-TMCT version shows the downstream end ^{4239-112370-02} of the HA ectodomain linked to the TMCT regions of BPIV3 F. The amino acid sequence below the NA- TMCT version shows the HN TMCT region linked to the ectodomain of NA (FIG.1A). The HA or NA genes were inserted at the AscI site between the B/HPIV3 N and P genes. The HPIV3 F and HN genes were deleted from the B/HPIV3^∆FHN/HA-NA and B/HPIV3^∆FHN/HA-TMCT-NA-TMCT constructs (FIG.1B). Nucleotide sequence elements (plus sense) that were engineered to flank the HA and/or NA ORF, including AscI sites for insertion into B/HPIV3, are shown at the bottom of FIG.1B. FIGS.2A-2C show that the B/HPIV3 vector replicates efficiently in Vero cells. FIGS.2A-2B show plaque phenotype and stability of HA, HA-TMCT, NA, and NA-TMCT insert expression in vitro. Vero cells were infected with serial dilutions of each P2 virus in duplicate and incubated at 32°C for 6 days with methylcellulose overlay. Cells were fixed and immunostained with HPIV3 and HA or NA antibodies followed by IR-dye conjugated secondary antibodies. FIG.2C shows multicycle growth kinetics in Vero cells. Triplicate wells of Vero cell monolayers in six-well plates were infected at an MOI of 0.01 TCID₅₀/cell with indicated viruses and incubated at 32 °C. Supernatant samples were collected, replaced with the same volume of fresh medium, and frozen daily for 7 days. Virus titers were determined in LLC- MK2 cells by immunostaining and presented as log₁₀TCID₅₀/ml. FIGS.3A-3I show viral protein expression in cells infected with the four vaccine viruses. Expression of the H7N9 HA and HA-TMCT proteins (FIGS.3A-3B), the NA and NA-TMCT proteins (FIGS.3C-3D), and the B/HPIV3 vector proteins (FIGS.3E-3I) in the infected (MOI 3) LLC-MK2 cells at 48 h post-infection, from 3 independent infections, were analyzed by Western blot. Lysates of HEK293 cells expressing recombinant H7N9 HA or NA protein were included as positive controls. Proteins were visualized by immunostaining the membranes with primary followed by IR-dye labeled secondary antibodies. Representative images of the HA, HA-TMCT, NA, NA-TMCT, B/HPIV3 proteins, and tubulin loading control are shown (FIGS.3A, 3C, and 3E). The respective protein bands (3 blots per protein from 3 independent infections) were quantified and shown normalized to tubulin (FIGS.3B, 3D, 3F, 3G, 3H, and 3I). Quantifications of B/HPIV3 N, P, F, and HN proteins are shown relative to B/HPIV3 without insert. The quantification values for HA and HA-TMCT (FIG.3B), NA and NA-TMCT (FIG.3D) were analyzed by unpaired t-test and those for N, P, F, and HN (FIG.3F-3I) by one-way ANOVA and Dunnett’s multiple comparisons post-test using GraphPad Prism software (version 9.3.1). The statistical significance of the differences is indicated as *, p<0.05; and ***, p<0.001. FIGS.4A-4I show protein packaging in virus particles. Two micrograms of total protein from the sucrose purified virus preparations were subjected to Western blot to visualize proteins and their relative amounts packaged in the virions. Representative blot images from a set of 3 independent blots for HA, HA- TMCT, NA, NA-TMCT, and B/HPIV3 proteins are shown (FIGS.4A, 4C, and 4E). Protein bands were quantified for HA and HA-TMCT (FIG.4B), NA and NA-TMCT (FIG.4D), and B/HPIV3 N, P, F, and HN proteins (normalized to B/HPIV3 without insert) (FIG.4F-4I). The amounts of each B/HPIV3 protein expressed by the candidate vaccine viruses were statistically compared with those of the B/HPIV3 vector ^{4239-112370-02} without the insert using the same tests as described for FIGS.3B, 3D, 3F, 3G, 3H, and 3I above, and shown as **, p<0.01; ***, p<0.001. FIGS.5A-5D show evaluation of candidate vaccines in African green monkeys (AGM). FIG.5A shows experimental design: animal grouping, immunization dose and route, and sample collection schedule. AGMs, in groups of 4, were immunized by the combined intranasal (IN) and intratracheal (IT) routes with 10⁶ TCID₅₀ per route with the indicated vaccine viruses. On day 28, two animals from each group received a second identical dose. A control group of 3 AGMs was immunized IM with BPL-inactivated PR8-H7N9 virus (PR8-H7N9-BPL) without adjuvant that contains H7N9 HA and NA proteins. Two animals from this group received a second identical dose on day 28. Nasal-pharyngeal (NP) swabs and tracheal lavage (TL) specimens were collected daily and every other day, respectively, from all groups to determine virus replication. FIGS.5B and 5C show viral titers in the NP and TL specimens, representing replication in the upper and lower respiratory tract, respectively. Mean titers + SD are shown as log₁₀TCID₅₀/ml in NP (FIG. 5B) and TL (FIG.5C). FIG.5D shows clinical observations (respiration, pulse, temperature, and weight) throughout the study. Data were analyzed by 2-way ANOVA and Tukey’s multiple comparisons test (*, p<0.05). FIGS.6A-6D show stability of the HA, HA-TMCT, NA, and NA-TMCT insert expression during replication in the AGM respiratory tract. The NP and TL samples collected from AGMs on day 1-8 and 2-8, respectively, were analyzed by dual antigen staining plaque assay and the data are shown for each individual sample as % plaques expressing the inserted gene in the NP (FIG.6A) and TL (FIG.6B). FIG.6C shows median values of the % PFUs positive for HA, HA-TMCT, NA, or NA-TMCT protein in the NP and TL samples for each immunogen group. FIG.6D shows mutations found in one tracheal lavage sample from day 8 post-immunization (mutated N gene-end is SEQ ID NO: 38; mutated P gene-start is SEQ ID NO: 39. For FIGS.6A-6B, *, p<0.05; **, p<0.01; ***, p<0.001; and ****, p<0.0001). FIGS.7A-7B show immunogenicity of candidate vaccines against AIV H7N9 after one and two doses. AGMs were immunized with the indicated viruses (IN and IT) or the inactivated PR8-H7N9-BPL (IM) on day 0. Sera were collected on day 0 (prior to dosing) and on week 2, 3, and 4. Two animals per group were boosted at week 4 (after serology) receiving a second dose (identical to the first) followed by weekly serology till week 8. FIG.7 A shows serum H7N9-neutralizing antibody response. Sera collected at week 2 and weekly thereafter were analyzed by a micro-neutralization assay using PR8-H7N9 virus. Titers are shown for each AGM as log₂ of the highest serum dilutions showing virus neutralization. FIG.7B shows serum hemagglutination-inhibition (HAI) antibody titers. Serum samples from AGMs immunized with B/HPIV3/HA, B/HPIV3/HA-TMCT, or PR8-H7N9-BPL were also evaluated for HAI antibodies using PR8- H7N9 virus. Titers are shown for each AGM as log10 of the highest serum dilutions that were HAI positive. Data were analyzed by two-way ANOVA and Tukey’s multiple comparisons test (*, p<0.05; **, p<0.01; and ***, p<0.001; and ****, p<0.0001). For statistical comparison, each group (boosted and unboosted) of four AGMs, was compared with every other candidate vaccine group. Since two AGMs were boosted and ^{4239-112370-02} two remained unboosted, the comparison of boosted to unboosted could not be performed due to the small sample size. FIG.8 shows serum HPIV3-neutralizing antibody response. AGM sera were analyzed by a serum HPIV3-neutralization assay. The serum antibody level of each AGM is shown after the first and second dose as log₂60% plaque reduction neutralization titer. The significance of the differences in titers among groups were determined by two-way ANOVA and Tukey’s multiple comparisons test (*, p<0.05; **, p<0.01). SEQUENCE LISTING The nucleic and amino acid sequences listed below are shown using standard letter abbreviations for nucleotide bases, and three letter code for amino acids, as defined in 37 C.F.R.1.822. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood as included by any reference to the displayed strand. It is further understood that “T” indicates “U” when a nucleic acid sequence is in RNA form. SEQ ID NO: 1 is an exemplary amino acid sequence of the BPIV3 N protein (GENBANK^TM Accession No.: AAF28254.1, encoded by nucleotides 111-1658 of GENBANK^TM Accession No. AF178654.1). MLSLFDTFSARRQENITKSAGGAVIPGQKNTVSIFALGPSITDDNDKMTLALLFLSHSLDNEKQHAQRAGFLVSLLSMAY ANPELYLTSNGSNADVKYVIYMIEKDPGRQKYGGFVVKTREMVYEKTTDWMFGSDLEYDQDNMLQNGRSTSTIEDLVHTF GYPSCLGALIIQVWIILVKAITSISGLRKGFFTRLEAFRQDGTVKSSLVLSGDAVEQIGSIMRSQQSLVTLMVETLITMN TGRNDLTTIEKNIQIVGNYIRDAGLASFFNTIRYGIETRMAALTLSTLRPDINRLKALIELYLSKGPRAPFICILRDPVH GEFAPGNYPALWSYAMGVAVVQNKAMQQYVTGRSYLDIEMFQLGQAVARDAESQMSSILEDELGVTQEAKQSLKKHMKNI SSSDTTFHKPTGGSAIEMAIDEEAGQPESRGDQDQGDEPRSSIVPYAWADETGNDNQTESTTEIDSIKTEQRNIRDRLNK RLNEKRKQSDPRSTDITNNTNQTEIDDLFSAFGSN SEQ ID NO: 2 is an exemplary amino acid sequence of the BPIV3 P protein (GENBANK™ Accession No.: AAF28255, encoded by nucleotides 1784-3574 of GENBANK™ Accession No. AF178654). MEDNVQNNQIMDSWEEGSGDKSSDISSALDIIEFILSTDSQENTADSNEINTGTTRLSTTIYQPESKTTETSKENSGPA NKNRQFGASHERATETKDRNVNQETVQGGYRRGSSPDSRTETMVTRRISRSSPDPNNGTQIQEDIDYNEVGEMDKDSTK REMRQFKDVPVKVSGSDAIPPTKQDGDGDDGRGLESISTFDSGYTSIVTAATLDDEEELLMKNNRPRKYQSTPQNSDKG IKKGVGRPKDTDKQSSILDYELNFKGSKKSQKILKASTNTGEPTRPQNGSQGKRITSWNILNSESGNRTESTNQTHQTS TSGQNHTMGPSRTTSEPRIKTQKTDGKEREDTEESTRFTERAITLLQNLGVIQSAAKLDLYQDKRVVCVANVLNNADTA SKIDFLAGLMIGVSMDHDTKLNQIQNEILSLKTDLKKMDESHRRLIENQKEQLSLITSLISNLKIMTERGGKKDQPEPS GRTSMIKTKAKEEKIKKVRFDPLMETQGIEKNIPDLYRSIEKTPENDTQIKSEINRLNDESNATRLVPRRISSTMRSLI IIINNSNLSSKAKQSYINELKLCKSDEEVSELMDMFNEDVSSQ SEQ ID NO: 3 is an exemplary amino acid sequence of the BPIV3 M protein (GENBANK^TM Accession No.: AAF28256, encoded by nucleotides 3735-4790 of GENBANK^TM Accession No. AF178654). MSITNSTIYTFPESSFSENGNIEPLPLKVNEQRKAIPHIRVVKIGDPPKHGSRYLDVFLLGFFEMERSKDRYGSISDLD DDPSYKVCGSGSLPLGLARYTGNDQELLQAATKLDIEVRRTVKATEMIVYTVQNIKPELYPWSSRLRKGMLFDANKVAL APQCLPLDRGIKFRVIFVNCTAIGSITLFKIPKSMALLSLPNTISINLQVHIKTGVQTDSKGVVQILDEKGEKSLNFMV ^{4239-112370-02} HLGLIKRKMGRMYSVEYCKQKIEKMRLLFSLGLVGGISFHVNATGSISKTLASQLAFKREICYPLMDLNPHLNSVIWAS SVEITRVDAVLQPSLPGEFRYYPNIIAKGVGKIRQ SEQ ID NO: 4 is an exemplary amino acid sequence of the HPIV3 F protein (encoded by nucleotides 5072-6691 of GENBANK™ Accession No. Z11575). MPTSILLIITTMIMASFCQIDITKLQHVGVLVNSPKGMKISQNFETRYLILSLIPKIEDSNSCGDQQIKQYKKLLDRLII PLYDGLRLQKDVIVTNQESNENTDPRTKRFFGGVIGTIALGVATSAQITAAVALVEAKQARSDIEKLKEAIRDTNKAVQS VQSSIGNLIVAIKSVQDYVNKEIVPSIARLGCEAAGLQLGIALTQHYSELTNIFGDNIGSLQEKGIKLQGIASLYRTNIT EIFTTSTVDKYDIYDLLFTESIKVRVIDVDLNDYSITLQVRLPLLTRLLNTQIYKVDSISYNIQNREWYIPLPSHIMTKG AFLGGADVKECIEAFSSYICPSDPGFVLNHEIESCLSGNISQCPRTTVTSDIVPRYAFVNGGVVANCITTTCTCNGIGNR INQPPDQGVKIITHKECSTIGINGMLFNTNKEGTLAFYTPNDITLNNSVALDPIDISIELNKAKSDLEESKEWIRRSNQK LDSIGNWHQSSTTIIIILIMIIILFIINITIITIAIKYYRIQKRNRVDQNDKPYVLTNK SEQ ID NO: 5 is an exemplary amino acid sequence of the HPIV3 HN protein (encoded by nucleotides 6806-8524 of GENBANK™ Accession No. Z11575). MEYWKHTNHGKDAGNELETSMATHGNKLTNKIIYILWTIILVLLSIVFIIVLINSIKSEKAHESLLQDINNEFMEITEK IQMASDNTNDLIQSGVNTRLLTIQSHVQNYIPISLTQQMSDLRKFISEITIRNDNQEVLPQRITHDVGIKPLNPDDFWR CTSGLPSLMKTPKIRLMPGPGLLAMPTTVDGCVRTPSLVINDLIYAYTSNLITRGCQDIGKSYQVLQIGIITVNSDLVP DLNPRISHTFNINDNRKSCSLALLNTDVYQLCSTPKVDERSDYASSGIEDIVLDIVNYDGSISTTRFKNNNISFDQPYA ALYPSVGPGIYYKGKIIFLGYGGLEHPINENVICNTTGCPGKTQRDCNQASHSPWFSDRRMVNSIIVVDKGLNSIPKLK VWTISMRQNYWGSEGRLLLLGNKIYIYTRSTSWHSKLQLGIIDITDYSDIRIKWTWHNVLSRPGNNECPWGHSCPDGCI TGVYTDAYPLNPTGSIVSSVILDSQKSRVNPVITYSTATERVNELAILNRTLSAGYTTTSCITHYNKGYCFHIVEINHK SLNTFQPMLFKTEIPKSCS SEQ ID NO: 6 is an exemplary amino acid sequence of the BPIV3 L protein (GENBANK^TM Accession No.: AAF28259, encoded by nucleotides 8640-15341 of GENBANK^TM Accession No. AF178654). MDTESHSGTTSDILYPECHLNSPIVKGKIAQLHTIMSLPQPYDMDDDSILIITRQKIKLNKLDKRQRSIRKLRSVLMER VSDLGKYTFIRYPEMSSEMFQLCIPGINNKINELLSKASKTYNQMTDGLRDLWVTILSKLASKNDGSNYDINEDISNIS NVHMTYQSDKWYNPFKTWFTIKYDMRRLQKAKNEITFNRHKDYNLLEDQKNILLIHPELVLILDKQNYNGYIMTPELVL MYCDVVEGRWNISSCAKLDPKLQSMYYKGNNLWEIIDGLFSTLGERTFDIISLLEPLALSLIQTYDPVKQLRGAFLNHV LSEMELIFAAECTTEEIPNVDYIDKILDVFKESTIDEIAEIFSFFRTFGHPPLEASIAAEKVRKYMYTEKCLKFDTINK CHAIFCTIIINGYRERHGGQWPPVTLPVHAHEFIINAYGSNSAISYENAVDYYKSFIGIKFDKFIEPQLDEDLTIYMKD KALSPKKSNWDTVYPASNLLYRTNVSHDSRRLVEVFIADSKFDPHQVLDYVESGYWLDDPEFNISYSLKEKEIKQEGRL FAKMTYKMRATQVLSETLLANNIGKFFQENGMVKGEIELLKRLTTISMSGVPRYNEVYNNSKSHTEELQAYNAISSSNL SSNQKSKKFEFKSTDIYNDGYETVSCFLTTDLKKYCLNWRYESTALFGDTCNQIFGLKELFNWLHPRLEKSTIYVGDPY CPPSDIEHLPLDDHPDSGFYVHNPKGGIEGFCQKLWTLISISAIHLAAVKIGVRVTAMVQGDNQAIAVTTRVPNNYDYK VKKEIVYKDVVRFFDSLREVMDDLGHELKLNETIISSKMFIYSKRIYYDGRILPQALKALSRCVFWSETIIDETRSASS NLATSFAKAIENGYSPVLGYVCSIFKNIQQLYIALGMNINPTITQNIKDQYFRNIHWMQYASLIPASVGGFNYMAMSRC ^{FVRNIGDPTVAALADIKRFIKANLLDRGVLYRIMNQEPGESSFLDWASDPYSCNLPQSQNITTMIKNITARNVLQDSPN} PLLSGLFTSTMIEEDEELAEFLMDRRIILPRVAHDILDNSLTGIRNAIAGMLDTTKSLIRVGISRGGLTYNLLRKISNY DLVQYETLSKTLRLIVSDKIKYEDMCSVDLAISLRQKMWMHLSGGRMINGLETPDPLELLSGVIITGSEHCRICYSTEG ESPYTWMYLPGNLNIGSAETGIASLRVPYFGSVTDERSEAQLGYIKNLSKPAKAAIRIAMIYTWAFGNDEISWMEASQI AQTRANFTLDSLKILTPVTTSTNLSHRLKDTATQMKFSSTSLIRVSRFITISNDNMSIKEANETKDTNLIYQQVMLTGL SVFEYLFRLEESTGHNPMVMHLHIEDGCCIKESYNDEHINPESTLELIKYPESNEFIYDKDPLKDIDLSKLMVIRDHSY TIDMNYWDDTDIVHAISICTAVTIADTMSQLDRDNLKELVVIANDDDINSLITEFLTLDILVFLKTFGGLLVNQFAYTL YGLKIEGRDPIWDYIMRTLKDTSHSVLKVLSNALSHPKVFKRFWDCGVLNPIYGPNTASQDQVKLALSICEYSLDLFMR EWLNGASLEIYICDSDMEIANDRRQAFLSRHLAFVCCLAEIASFGPNLLNLTYLERLDELKQYLDLNIKEDPTLKYVQV SGLLIKSFPSTVTYVRKTAIKYLRIRGINPPETIEDWDPIEDENILDNIVKTVNDNCSDNQKRNKSSYFWGLALKNYQV VKIRSITSDSEVNEASNVTTHGMTLPQGGSYLSHQLRLFGVNSTSCLKALELSQILMREVKKDKDRLFLGEGAGAMLAC YDATLGPAINYYNSGLNITDVIGQRELKIFPSEVSLVGKKLGNVTQILNRVRVLFNGNPNSTWIGNMECESLIWSELND KSIGLVHCDMEGAIGKSEETVLHEHYSIIRITYLIGDDDVVLVSKIIPTITPNWSKILYLYKLYWKDVSVVSLKTSNPA STELYLISKDAYCTVMEPSNLVLSKLKRISSIEENNLLKWIILSKRKNNEWLQHEIKEGERDYGIMRPYHTALQIFGFQ INLNHLAREFLSTPDLTNINNIIQSFTRTIKDVMFEWVNITHDNKRHKLGGRYNLFPLKNKGKLRLLSRRLVLSWISLS LSTRLLTGRFPDEKFENRAQTGYVSLADIDLESLKLLSRNIVKNYKEHIGLISYWFLTKEVKILMKLIGGVKLLGIPKQ YKELEDRSSQGYEYDNEFDID ^{4239-112370-02} SEQ ID NO: 7 is an exemplary amino acid sequence of HPAIV H7N9 HA protein. MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVVNATETVERTNTPRICSKGKRTVDLGQCGLLGTIT GPPQCDQFLEFSADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEPMGFTYNGIRTNGVTSACRRSGSSFYAEM KWLLSNTDNAAFPQMTKSYKNTKESPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGQSG RIDFHWLILNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSRVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPR YVKQRSLLLATGMKNVPEVPKRKRTARGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKL NRLIAKTNQQFKLIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAE EDGTGCFEIFHKCDDDCMASIRNNTYDHRKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICV KNGNMRCTICI SEQ ID NO: 8 is an exemplary amino acid sequence of HPAIV H7N9 NA protein. MNPNQKILCTSATAITIGAITVLIGIANIGLNIGLHLKSGCNCSRSQPETTNPSQTIINNYYNETNITNIQMGERTSRN FNNLTKGLCTINSWHIYGKDNAVRIGESSDVLVTREPYVSCDPDECRFYALSQGTTIRGKHSNGTIHDRSQYRALISWP LSSPPTVYNSRVECIGWSSTSCHDGKSRMSICISGPNNNASAVIWYNRRPVAEINTWARNILRTQESECVCHNGVCPVV FTDGPATGPADTRIYYFKEGKILKWESLTGTAKHIEECSCYGKRTGITCTCKDNWQGSNRPVIQIDPVAMTHTSQYICS PVLTDSPRPNDPNIGKCNDPYPGNNNNGVKGFSYLDGDNTWLGRTISTASRSGYEMLKVPNALTDDRSKPIQGQTIVLN ADWSGYSGSFMDYWAEGDCYRACFYVELIRGKPKEDKVWWTSNSIVSMCSSTEFLGQWNWPDGAKIEYFL SEQ ID NO: 9 is an exemplary amino acid sequence of HA-TMCT chimeric protein. ^{MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVVNATETVERTNTPRICSKGKRTVDLGQCGLLGTIT} GPPQCDQFLEFSADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEPMGFTYNGIRTNGVTSACRRSGSSFYAEM KWLLSNTDNAAFPQMTKSYKNTKESPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGQSG RIDFHWLILNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSRVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPR YVKQRSLLLATGMKNVPEVPKRKRTARGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKL NRLIAKTNQQFKLIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAE EDGTGCFEIFHKCDDDCMASIRNNTYDHRKYREEAMQNRIQIDPVKLSSGYKDITIIIVMIIILVIINITIIVVIIKFH RIQGKDQNDKNSEPYILTNRQ SEQ ID NO: 10 is an exemplary amino acid sequence of NA-TMCT chimeric protein. MEYWKHTNSINNTNNETETARGKHSSKVTNIIMYTFWTITLTILSVIFIMILTNLINIGLHLKSGCNCSRSQPETTNPS QTIINNYYNETNITNIQMGERTSRNFNNLTKGLCTINSWHIYGKDNAVRIGESSDVLVTREPYVSCDPDECRFYALSQG TTIRGKHSNGTIHDRSQYRALISWPLSSPPTVYNSRVECIGWSSTSCHDGKSRMSICISGPNNNASAVIWYNRRPVAEI NTWARNILRTQESECVCHNGVCPVVFTDGPATGPADTRIYYFKEGKILKWESLTGTAKHIEECSCYGKRTGITCTCKDN WQGSNRPVIQIDPVAMTHTSQYICSPVLTDSPRPNDPNIGKCNDPYPGNNNNGVKGFSYLDGDNTWLGRTISTASRSGY ^{EMLKVPNALTDDRSKPIQGQTIVLNADWSGYSGSFMDYWAEGDCYRACFYVELIRGKPKEDKVWWTSNSIVSMCSSTEF} LGQWNWPDGAKIEYFL SEQ ID NO: 11 is an exemplary rB/HPIV3/HA antigenomic cDNA sequence. ACCAAACAAGAGAAGAGACTGGTTTGGGAATATTAATTCAAATAAAAATTAACTTAGGATTAAAGAACTTTACCGAAAG GTAAGGGGAAAGAAATCCTAAGAGCTTAGCCATGTTGAGTCTATTCGACACATTCAGTGCGCGTAGGCAGGAGAACATA ACGAAATCAGCTGGTGGGGCTGTTATTCCCGGGCAAAAAAACACTGTGTCTATATTTGCTCTTGGACCATCAATAACAG ATGACAATGATAAAATGACATTGGCTCTTCTCTTTTTGTCTCATTCTTTAGACAATGAAAAGCAGCATGCGCAAAGAGC TGGATTTTTAGTTTCTCTGTTATCAATGGCTTATGCCAACCCAGAATTATATTTAACATCAAATGGTAGTAATGCAGAT GTTAAATATGTTATCTACATGATAGAGAAAGACCCAGGAAGACAGAAATATGGTGGGTTTGTCGTCAAGACTAGAGAGA ^{TGGTTTATGAAAAGACAACTGATTGGATGTTCGGGAGTGATCTTGAGTATGATCAAGACAATATGTTGCAAAATGGTAG} AAGCACTTCTACAATCGAGGATCTTGTTCATACTTTTGGATATCCATCGTGTCTTGGAGCCCTTATAATCCAAGTTTGG ATAATACTTGTTAAGGCTATAACCAGTATATCAGGATTGAGGAAAGGATTCTTTACTCGGTTAGAAGCATTTCGACAAG ATGGAACAGTTAAATCCAGTCTAGTGTTGAGCGGTGATGCAGTAGAACAAATTGGATCAATTATGAGGTCCCAACAGAG CTTGGTAACACTCATGGTTGAAACACTGATAACAATGAACACAGGCAGGAATGATCTGACAACAATAGAAAAGAATATA CAGATTGTAGGAAACTACATCAGAGATGCAGGTCTTGCTTCATTTTTCAACACAATCAGATATGGCATTGAGACTAGAA TGGCAGCTCTAACTCTGTCTACCCTTAGACCGGATATCAACAGACTCAAGGCACTGATCGAGTTATATCTATCAAAGGG GCCACGTGCTCCTTTTATATGCATTTTGAGAGATCCCGTGCATGGTGAGTTTGCACCAGGCAACTATCCTGCCCTCTGG AGTTATGCGATGGGTGTAGCAGTTGTACAAAACAAGGCCATGCAACAGTATGTAACAGGAAGGTCTTATCTGGATATTG AAATGTTCCAACTTGGTCAAGCAGTGGCACGTGATGCCGAGTCGCAGATGAGTTCAATATTAGAGGATGAACTGGGGGT CACACAAGAAGCCAAGCAAAGCTTGAAGAAACACATGAAGAACATCAGCAGTTCAGATACAACCTTTCATAAGCCTACA GGGGGATCAGCCATAGAAATGGCGATAGATGAAGAAGCAGGGCAGCCTGAATCCAGAGGAGATCAGGATCAAGGAGATG AGCCTCGGTCATCCATAGTTCCTTATGCATGGGCAGACGAAACCGGGAATGACAATCAAACTGAATCAACTACAGAAAT TGACAGCATCAAAACTGAACAAAGAAACATCAGAGACAGGCTGAACAAAAGACTCAACGAGAAAAGGAAACAGAGTGAC ^{4239-112370-02} CCGAGATCAACTGACATCACAAACAACACAAATCAAACTGAAATAGATGATTTGTTCAGTGCATTCGGAAGCAACTAGT CACAAAGAGATGACCAGGCGCGCCAAGTAAGAAAAACTTAGGATTAATGGACCTGCAGGATGAACACCCAGATCCTGGT GTTCGCCCTGATCGCCATCATCCCAACAAATGCCGATAAGATCTGTCTGGGCCACCACGCCGTGTCTAACGGCACCAAA GTGAATACCCTGACAGAGAGGGGAGTGGAGGTGGTGAACGCAACCGAGACAGTGGAGAGAACCAATACACCCAGGATCT GCTCCAAGGGCAAGCGGACAGTGGACCTGGGACAGTGTGGACTGCTGGGAACCATCACAGGCCCACCTCAGTGCGATCA GTTCCTGGAGTTTAGCGCCGACCTGATCATCGAGCGGAGAGAGGGCTCCGACGTGTGCTACCCCGGCAAGTTCGTGAAC GAGGAGGCCCTGAGGCAGATCCTGAGGGAGAGCGGCGGAATCGACAAGGAGCCTATGGGCTTTACCTACAACGGCATCC GCACCAATGGCGTGACCAGCGCCTGCCGGCGGAGCGGCAGCTCCTTCTATGCAGAGATGAAGTGGCTGCTGTCCAACAC AGACAATGCCGCCTTTCCCCAGATGACCAAGTCCTATAAGAACACAAAGGAGTCTCCTGCCATCATCGTGTGGGGAATC CACCACAGCGTGTCCACCGCCGAGCAGACAAAGCTGTACGGCAGCGGCAACAAGCTGGTGACAGTGGGCTCTAGCAATT ATCAGCAGTCCTTCGTGCCATCTCCCGGCGCCCGCCCTCAGGTGAACGGACAGTCCGGCCGGATCGATTTTCACTGGCT GATCCTGAACCCTAATGACACCGTGACATTCTCTTTTAATGGAGCCTTCATCGCCCCAGATAGGGCCAGCTTTCTGCGG GGCAAGAGCATGGGCATCCAGTCTCGCGTGCAGGTGGATGCCAACTGCGAGGGCGACTGTTACCACAGCGGCGGCACCA TCATCTCCAACCTGCCATTCCAGAATATCGACAGCCGGGCCGTGGGCAAGTGTCCCAGATATGTGAAGCAGAGGTCTCT ^{GCTGCTGGCCACCGGCATGAAGAATGTGCCTGAGGTGCCAAAGCGGAAGAGAACAGCCAGAGGCCTGTTCGGAGCAATC} GCAGGCTTTATCGAGAACGGCTGGGAGGGCCTGATCGATGGCTGGTACGGCTTTAGGCACCAGAATGCACAGGGAGAGG GAACCGCCGCCGATTATAAGTCTACACAGAGCGCCATCGACCAGATCACCGGCAAGCTGAACAGACTGATCGCCAAGAC AAATCAGCAGTTCAAGCTGATCGATAACGAGTTTAATGAGGTGGAGAAGCAGATCGGCAACGTGATCAATTGGACCAGG GACTCTATCACAGAAGTGTGGAGCTACAACGCCGAGCTGCTGGTGGCTATGGAGAATCAGCACACCATCGATCTGGCCG ^{ACAGCGAGATGGATAAGCTGTATGAGAGGGTGAAGAGGCAGCTGAGGGAGAACGCAGAGGAGGACGGAACCGGCTGCTT} CGAGATCTTTCACAAGTGCGACGATGACTGTATGGCCTCCATCAGAAACAATACATACGACCACAGAAAGTATAGGGAG GAGGCCATGCAGAATAGGATCCAGATCGATCCCGTGAAGCTGTCCTCTGGCTACAAGGACGTGATCCTGTGGTTCAGCT TTGGCGCCTCCTGTTTCATCCTGCTGGCCATCGTGATGGGCCTGGTGTTTATCTGCGTGAAGAACGGCAATATGAGGTG CACCATCTGTATCTGATAGCTAGCGGCGCGCCAGCAACAAGTAAGAAAAACTTAGGATTAATGGAAATTATCCAATCCA GAGACGGAAGGACAAATCCAGAATCCAACCACAACTCAATCAACCAAAGATTCATGGAAGACAATGTTCAAAACAATCA AATCATGGATTCTTGGGAAGAGGGATCAGGAGATAAATCATCTGACATCTCATCGGCCCTCGACATCATTGAATTCATA CTCAGCACCGACTCCCAAGAGAACACGGCAGACAGCAATGAAATCAACACAGGAACCACAAGACTTAGCACGACAATCT ACCAACCTGAATCCAAAACAACAGAAACAAGCAAGGAAAATAGTGGACCAGCTAACAAAAATCGACAGTTTGGGGCATC ACACGAACGTGCCACAGAGACAAAAGATAGAAATGTTAATCAGGAGACTGTACAGGGAGGATATAGGAGAGGAAGCAGC CCAGATAGTAGAACTGAGACTATGGTCACTCGAAGAATCTCCAGAAGCAGCCCAGATCCTAACAATGGAACCCAAATCC AGGAAGATATTGATTACAATGAAGTTGGAGAGATGGATAAGGACTCTACTAAGAGGGAAATGCGACAATTTAAAGATGT TCCAGTCAAGGTATCAGGAAGTGATGCCATTCCTCCAACAAAACAAGATGGAGACGGTGATGATGGAAGAGGCCTGGAA TCTATCAGTACATTTGATTCAGGATATACCAGTATAGTGACTGCCGCAACACTAGATGACGAAGAAGAACTCCTTATGA AGAACAACAGGCCAAGAAAGTATCAATCAACACCCCAGAACAGTGACAAGGGAATTAAAAAAGGGGTTGGAAGGCCAAA AGACACAGACAAACAATCATCAATATTGGACTACGAACTCAACTTCAAAGGATCGAAGAAGAGCCAGAAAATCCTCAAA GCCAGCACGAATACAGGAGAACCAACAAGACCACAGAATGGATCCCAGGGGAAGAGAATCACATCCTGGAACATCCTCA ACAGCGAGAGCGGCAATCGAACAGAATCAACAAACCAAACCCATCAGACATCAACCTCGGGACAGAACCACACAATGGG ACCAAGCAGAACAACCTCCGAACCAAGGATCAAGACACAAAAGACGGATGGAAAGGAAAGAGAGGACACAGAAGAGAGC ACTCGATTTACAGAAAGGGCGATTACATTATTACAGAATCTTGGTGTAATCCAATCTGCAGCAAAATTAGACCTATACC ^{AAGACAAGAGAGTTGTGTGTGTGGCGAATGTCCTAAACAATGCAGATACTGCATCAAAGATAGACTTCCTAGCAGGTTT} GATGATAGGAGTGTCAATGGATCATGATACCAAATTAAATCAGATTCAGAACGAGATATTAAGTTTGAAAACTGATCTT AAAAAGATGGATGAATCACATAGAAGACTAATTGAGAATCAAAAAGAACAATTATCACTGATCACATCATTAATCTCAA ATCTTAAAATTATGACAGAGAGAGGAGGGAAGAAGGACCAACCAGAACCTAGCGGGAGGACATCCATGATCAAGACAAA AGCAAAAGAAGAGAAAATAAAGAAAGTCAGGTTTGACCCTCTTATGGAAACACAGGGCATCGAGAAAAACATCCCTGAC CTCTATAGATCAATAGAGAAAACACCAGAAAACGACACACAGATCAAATCAGAAATAAACAGATTGAATGATGAATCCA ATGCCACTAGATTAGTACCTAGAAGAATAAGCAGTACAATGAGATCATTAATAATAATCATTAACAACAGCAATTTATC ATCAAAAGCAAAGCAATCATACATCAACGAACTCAAGCTCTGCAAGAGTGACGAGGAAGTGTCTGAGTTGATGGACATG TTCAATGAGGATGTCAGCTCCCAGTAAACCGCCAACCAAGGGTCAACACCAAGAAAACCAATAGCACAAAACAGCCAAT CAGAGACCACCCCAATACACCAAACCAATCAACACATAACAAAGATCGCGGCCGCATAGATGATTAAGAAAAACTTAGG ATGAAAGGACTAATCAATCCTCCGAAACAATGAGCATCACCAACTCCACAATCTACACATTCCCAGAATCCTCTTTCTC CGAGAATGGCAACATAGAGCCGTTACCACTCAAGGTCAATGAACAGAGAAAGGCCATACCTCATATTAGGGTTGTCAAG ATAGGAGATCCGCCCAAACATGGATCCAGATATCTGGATGTCTTTTTACTGGGCTTCTTTGAGATGGAAAGGTCAAAAG ACAGGTATGGGAGCATAAGTGATCTAGATGATGATCCAAGTTACAAGGTTTGTGGCTCTGGATCATTGCCACTTGGGTT GGCTAGATACACCGGAAATGATCAGGAACTCCTACAGGCTGCAACCAAGCTCGATATAGAAGTAAGAAGAACTGTAAAG GCTACGGAGATGATAGTTTACACTGTACAAAACATCAAACCTGAACTATATCCATGGTCCAGTAGATTAAGAAAAGGGA TGTTATTTGACGCTAATAAGGTTGCACTTGCTCCTCAATGTCTTCCACTAGATAGAGGGATAAAATTCAGGGTGATATT TGTGAACTGCACAGCAATTGGATCAATAACTCTATTCAAAATCCCTAAGTCCATGGCATTGTTATCATTGCCTAATACA ATATCAATAAATCTACAAGTACATATCAAAACAGGAGTTCAGACAGATTCCAAAGGAGTAGTTCAGATTCTAGATGAAA AAGGTGAAAAATCACTAAATTTCATGGTTCATCTCGGGTTGATCAAAAGGAAGATGGGCAGAATGTACTCAGTTGAATA ^{TTGTAAGCAGAAGATCGAGAAGATGAGATTATTATTCTCATTGGGATTAGTTGGAGGGATCAGCTTCCACGTCAACGCA} ACTGGCTCTATATCAAAGACATTAGCAAGTCAATTAGCATTCAAAAGAGAAATCTGCTATCCCCTAATGGATCTGAATC CACACTTAAATTCAGTTATATGGGCATCATCAGTTGAAATTACAAGGGTAGATGCAGTTCTCCAGCCTTCATTACCTGG ^{4239-112370-02} CGAATTCAGATACTACCCAAACATCATAGCAAAAGGGGTCGGGAAAATCAGACAGTAAAATCAACAACCCTGATATCCA CCGGTGTATTAAGCCGAAGCAAATAAAGGATAATCAAAAACTTAGGACAAAAGAGGTCAATACCAACAACTATTAGCAG TCACACTCGCAAGAATAAGAGAGAAGGGACCAAAAAAGTCAAATAGGAGAAATCAAAACAAAAGGTACAGAACACCAGA ACAACAAAATCAAAACATCCAACTCACTCAAAACAAAAATTCCAAAAGAGACCGGCAACACAACAAGCACTGAACACAA TGCCAACTTCAATACTGCTAATTATTACAACCATGATCATGGCATCTTTCTGCCAAATAGATATCACAAAACTACAGCA CGTAGGTGTATTGGTCAACAGTCCCAAAGGGATGAAGATATCACAAAACTTTGAAACAAGATATCTAATTTTGAGCCTC ATACCAAAAATAGAAGACTCTAACTCTTGTGGTGACCAACAGATCAAGCAATACAAGAAGTTATTGGATAGACTGATCA TCCCTTTATATGATGGATTAAGATTACAGAAAGATGTGATAGTAACCAATCAAGAATCCAATGAAAACACTGATCCCAG AACAAAACGATTCTTTGGAGGGGTAATTGGAACCATTGCTCTGGGAGTAGCAACCTCAGCACAAATTACAGCGGCAGTT GCTCTGGTTGAAGCCAAGCAGGCAAGATCAGACATCGAAAAACTCAAAGAAGCAATTAGGGACACAAACAAAGCAGTGC AGTCAGTTCAGAGCTCCATAGGAAATTTAATAGTAGCAATTAAATCAGTCCAGGATTATGTTAACAAAGAAATCGTGCC ATCGATTGCGAGGCTAGGTTGTGAAGCAGCAGGACTTCAATTAGGAATTGCATTAACACAGCATTACTCAGAATTAACA AACATATTTGGTGATAACATAGGATCGTTACAAGAAAAAGGAATAAAATTACAAGGTATAGCATCATTATACCGCACAA ATATCACAGAAATATTCACAACATCAACAGTTGATAAATATGATATCTATGATCTGTTATTTACAGAATCAATAAAGGT ^{GAGAGTTATAGATGTTGACTTGAATGATTACTCAATCACCCTCCAAGTCAGACTCCCTTTATTAACTAGGCTGCTGAAC} ACTCAGATCTACAAAGTAGATTCCATATCATATAACATCCAAAACAGAGAATGGTATATCCCTCTTCCCAGCCATATCA TGACGAAAGGGGCATTTCTAGGTGGAGCAGACGTCAAAGAATGTATAGAAGCATTCAGCAGCTATATATGCCCTTCTGA TCCAGGATTTGTATTAAACCATGAAATAGAGAGCTGCTTATCAGGAAACATATCCCAATGTCCAAGAACAACGGTCACA TCAGACATTGTTCCAAGATATGCATTTGTCAATGGAGGAGTGGTTGCAAACTGTATAACAACCACCTGTACATGCAACG ^{GAATTGGTAATAGAATCAATCAACCACCTGATCAAGGAGTAAAAATTATAACACATAAAGAATGTAGTACAATAGGTAT} CAACGGAATGCTGTTCAATACAAATAAAGAAGGAACTCTTGCATTCTATACACCAAATGATATAACACTAAACAATTCT GTTGCACTTGATCCAATTGACATATCAATCGAGCTCAACAAGGCCAAATCAGATCTAGAAGAATCAAAAGAATGGATAA GAAGGTCAAATCAAAAACTAGATTCTATTGGAAATTGGCATCAATCTAGCACTACAATCATAATTATTTTGATAATGAT CATTATATTGTTTATAATTAATATAACGATAATTACAATTGCAATTAAGTATTACAGAATTCAAAAGAGAAATCGAGTG GATCAAAATGACAAGCCATATGTACTAACAAACAAATAACATATCTACAGATCATTAGATATTAAAATTATAAAAAACT TAGGAGTAAAGTTACGCAATCCAACTCTACTCATATAATTGAGGAAGGACCCAATAGACAAATCCAAATTCGAGATGGA ATACTGGAAGCATACCAATCACGGAAAGGATGCTGGTAATGAGCTGGAGACGTCTATGGCTACTCATGGCAACAAGCTC ACTAATAAGATAATATACATATTATGGACAATAATCCTGGTGTTATTATCAATAGTCTTCATCATAGTGCTAATTAATT CCATCAAAAGTGAAAAGGCCCACGAATCATTGCTGCAAGACATAAATAATGAGTTTATGGAAATTACAGAAAAGATCCA AATGGCATCGGATAATACCAATGATCTAATACAGTCAGGAGTGAATACAAGGCTTCTTACAATTCAGAGTCATGTCCAG AATTACATACCAATATCATTGACACAACAGATGTCAGATCTTAGGAAATTCATTAGTGAAATTACAATTAGAAATGATA ATCAAGAAGTGCTGCCACAAAGAATAACACATGATGTAGGTATAAAACCTTTAAATCCAGATGATTTTTGGAGATGCAC GTCTGGTCTTCCATCTTTAATGAAAACTCCAAAAATAAGGTTAATGCCAGGGCCGGGATTATTAGCTATGCCAACGACT GTTGATGGCTGTGTTAGAACTCCGTCTTTAGTTATAAATGATCTGATTTATGCTTATACCTCAAATCTAATTACTCGAG GTTGTCAGGATATAGGAAAATCATATCAAGTCTTACAGATAGGGATAATAACTGTAAACTCAGACTTGGTACCTGACTT AAATCCTAGGATCTCTCATACCTTTAACATAAATGACAATAGGAAGTCATGTTCTCTAGCACTCCTAAATACAGATGTA TATCAACTGTGTTCAACTCCCAAAGTTGATGAAAGATCAGATTATGCATCATCAGGCATAGAAGATATTGTACTTGATA TTGTCAATTATGATGGTTCAATCTCAACAACAAGATTTAAGAATAATAACATAAGCTTTGATCAACCATATGCTGCACT ATACCCATCTGTTGGACCAGGGATATACTACAAAGGCAAAATAATATTTCTCGGGTATGGAGGTCTTGAACATCCAATA ^{AATGAGAATGTAATCTGCAACACAACTGGGTGCCCCGGGAAAACACAGAGAGACTGTAATCAAGCATCTCATAGTCCAT} GGTTTTCAGATAGGAGGATGGTCAACTCCATCATTGTTGTTGACAAAGGCTTAAACTCAATTCCAAAATTGAAAGTATG GACGATATCTATGCGACAAAATTACTGGGGGTCAGAAGGAAGGTTACTTCTACTAGGTAACAAGATCTATATATATACA AGATCTACAAGTTGGCATAGCAAGTTACAATTAGGAATAATTGATATTACTGATTACAGTGATATAAGGATAAAATGGA CATGGCATAATGTGCTATCAAGACCAGGAAACAATGAATGTCCATGGGGACATTCATGTCCAGATGGATGTATAACAGG AGTATATACTGATGCATATCCACTCAATCCCACAGGGAGCATTGTGTCATCTGTCATATTAGACTCACAAAAATCGAGA GTGAACCCAGTCATAACTTACTCAACAGCAACCGAAAGAGTAAACGAGCTGGCCATCCTAAACAGAACACTCTCAGCTG GATATACAACAACAAGCTGCATTACACACTATAACAAAGGATATTGTTTTCATATAGTAGAAATAAATCATAAAAGCTT AAACACATTTCAACCCATGTTGTTCAAAACAGAGATTCCAAAAAGCTGCAGTTAATCATAATTAACCATAATATGCATC AATCTATCTATAATACAAGTATATGATAAGTAATCAGCAATCAGACAATAGACGTACGGAAATAATAAAAAACTTAGGA GAAAAGTGTGCAAGAAAAATGGACACCGAGTCCCACAGCGGCACAACATCTGACATTCTGTACCCTGAATGTCACCTCA ATTCTCCTATAGTTAAAGGAAAGATAGCACAACTGCATACAATAATGAGTTTGCCTCAGCCCTACGATATGGATGATGA TTCAATACTGATTATTACTAGACAAAAAATTAAACTCAATAAATTAGATAAAAGACAACGGTCAATTAGGAAATTAAGA TCAGTCTTAATGGAAAGAGTAAGTGATCTAGGTAAATATACCTTTATCAGATATCCAGAGATGTCTAGTGAAATGTTCC AATTATGTATACCCGGAATTAATAATAAAATAAATGAATTGCTAAGTAAAGCAAGTAAAACATATAATCAAATGACTGA TGGATTAAGAGATCTATGGGTTACTATACTATCGAAGTTAGCATCGAAAAATGATGGAAGTAATTATGATATCAATGAA GATATTAGCAATATATCAAATGTTCACATGACTTATCAATCAGACAAATGGTATAATCCATTCAAGACATGGTTTACTA TTAAGTATGACATGAGAAGATTACAAAAAGCCAAAAATGAGATTACATTCAATAGGCATAAAGATTATAATCTATTAGA AGACCAAAAGAATATATTGCTGATACATCCAGAACTCGTCTTAATATTAGATAAACAAAATTACAATGGGTATATAATG ACTCCTGAATTGGTACTAATGTATTGTGATGTAGTTGAAGGGAGGTGGAATATAAGTTCATGTGCAAAATTGGATCCTA ^{AGTTACAATCAATGTATTATAAGGGTAACAATTTATGGGAAATAATAGATGGACTATTCTCGACCTTAGGAGAAAGAAC} ATTTGACATAATATCACTATTAGAACCACTTGCATTATCGCTCATTCAAACTTATGACCCGGTTAAACAGCTCAGGGGG GCTTTTTTAAATCACGTGTTATCAGAAATGGAATTAATATTTGCAGCTGAGTGTACAACAGAGGAAATACCTAATGTGG ^{4239-112370-02} ATTATATAGATAAAATTTTAGATGTGTTCAAAGAATCAACAATAGATGAAATAGCAGAAATTTTCTCTTTCTTCCGAAC TTTTGGACACCCTCCATTAGAGGCGAGTATAGCAGCAGAGAAAGTTAGAAAGTATATGTATACTGAGAAATGCTTGAAA TTTGATACTATCAATAAATGTCATGCTATTTTTTGTACAATAATTATAAATGGATATAGAGAAAGACATGGTGGTCAAT GGCCTCCAGTTACATTACCTGTCCATGCACATGAATTTATCATAAATGCATACGGATCAAATTCTGCCATATCATATGA GAATGCTGTAGATTATTATAAGAGCTTCATAGGAATAAAATTTGACAAGTTTATAGAGCCTCAATTGGATGAAGACTTA ACTATTTATATGAAAGATAAAGCATTATCCCCAAAGAAATCAAACTGGGACACAGTCTATCCAGCTTCAAACCTGTTAT ACCGCACTAATGTGTCTCATGATTCACGAAGATTGGTTGAAGTATTTATAGCAGATAGTAAATTTGATCCCCACCAAGT ATTAGATTACGTAGAATCAGGATATTGGCTGGATGATCCTGAATTTAATATCTCATATAGTTTAAAAGAGAAAGAAATA AAACAAGAAGGTAGACTTTTTGCAAAAATGACATACAAGATGAGGGCTACACAAGTATTATCAGAAACATTATTGGCGA ATAATATAGGGAAATTCTTCCAAGAGAATGGGATGGTTAAAGGAGAAATTGAATTACTCAAGAGACTAACAACAATATC TATGTCTGGAGTTCCGCGGTATAATGAGGTATACAATAATTCAAAAAGTCACACAGAAGAACTTCAAGCTTATAATGCA ATTAGCAGTTCCAATTTATCTTCTAATCAGAAGTCAAAGAAGTTTGAATTTAAATCTACAGATATATACAATGATGGAT ACGAAACCGTAAGCTGCTTCTTAACGACAGATCTTAAAAAATATTGTTTAAATTGGAGGTATGAATCAACAGCTTTATT CGGTGATACTTGTAATCAGATATTTGGGTTAAAGGAATTATTTAATTGGCTGCACCCTCGCCTTGAAAAGAGTACAATA ^{TATGTTGGAGATCCTTATTGCCCGCCATCAGATATTGAACATTTACCACTTGATGACCATCCTGATTCAGGATTTTATG} TTCATAATCCTAAAGGAGGAATAGAAGGGTTTTGCCAAAAGTTATGGACACTCATATCTATCAGTGCAATACATTTAGC AGCTGTCAAAATCGGTGTAAGAGTTACTGCAATGGTTCAAGGGGATAATCAAGCCATAGCTGTTACCACAAGAGTACCT AATAATTATGATTATAAAGTTAAGAAAGAGATTGTTTATAAAGATGTGGTAAGATTTTTTGATTCCTTGAGAGAGGTGA TGGATGATCTGGGTCATGAGCTCAAACTAAATGAAACTATAATAAGTAGTAAAATGTTTATATATAGCAAAAGGATATA ^{CTATGACGGAAGAATCCTTCCTCAGGCATTAAAAGCATTGTCTAGATGTGTTTTTTGGTCTGAAACAATCATAGATGAG} ACAAGATCAGCATCCTCAAATCTGGCTACATCGTTTGCAAAGGCCATTGAGAATGGCTACTCACCTGTATTGGGATATG TATGCTCAATCTTCAAAAATATCCAACAGTTGTATATAGCGCTTGGAATGAATATAAACCCAACTATAACCCAAAATAT TAAAGATCAATATTTCAGGAATATTCATTGGATGCAATATGCCTCCTTAATCCCTGCTAGTGTCGGAGGATTTAATTAT ATGGCCATGTCAAGGTGTTTTGTCAGAAACATTGGAGATCCTACAGTCGCTGCGTTAGCCGATATTAAAAGATTTATAA AAGCAAATTTGTTAGATCGAGGTGTCCTTTACAGAATTATGAATCAAGAACCAGGCGAGTCTTCTTTTTTAGACTGGGC CTCAGATCCCTATTCATGTAACTTACCACAATCTCAAAATATAACCACCATGATAAAGAATATAACTGCAAGAAATGTA CTACAGGACTCACCAAACCCATTACTATCTGGATTATTTACAAGTACAATGATAGAAGAGGATGAGGAATTAGCTGAGT TCCTAATGGACAGGAGAATAATCCTCCCAAGAGTTGCACATGACATTTTAGATAATTCTCTTACTGGAATTAGGAATGC TATAGCTGGTATGTTGGATACAACAAAATCACTAATTCGAGTAGGGATAAGCAGAGGAGGATTAACCTATAACTTATTA AGAAAGATAAGCAACTATGATCTTGTACAATATGAGACACTTAGTAAAACTTTAAGACTAATAGTCAGTGACAAGATTA AGTATGAAGATATGTGCTCAGTAGACCTAGCCATATCATTAAGACAAAAAATGTGGATGCATTTATCAGGAGGAAGAAT GATAAATGGACTTGAAACTCCAGATCCTTTAGAGTTACTGTCTGGAGTAATAATAACAGGATCTGAACATTGTAGGATA TGTTATTCAACTGAAGGTGAAAGCCCATATACATGGATGTATTTACCAGGCAATCTTAATATAGGATCAGCTGAGACAG GAATAGCATCATTAAGGGTCCCTTACTTTGGATCAGTTACAGATGAGAGATCTGAAGCACAATTAGGGTATATCAAAAA TCTAAGCAAACCAGCTAAGGCTGCTATAAGAATAGCAATGATATATACTTGGGCATTTGGGAATGACGAAATATCTTGG ATGGAAGCATCACAGATTGCACAAACACGTGCAAACTTTACATTGGATAGCTTAAAGATTTTGACACCAGTGACAACAT CAACAAATCTATCACACAGGTTAAAAGATACTGCTACTCAGATGAAATTTTCTAGTACATCACTTATTAGAGTAAGCAG GTTCATCACAATATCTAATGATAATATGTCTATTAAAGAAGCAAATGAAACTAAAGATACAAATCTTATTTATCAACAG GTAATGTTAACAGGATTAAGTGTATTTGAATATCTATTTAGGTTAGAGGAGAGTACAGGACATAACCCTATGGTCATGC ^{ATCTACATATAGAGGATGGATGTTGTATAAAAGAGAGTTACAATGATGAGCATATCAATCCGGAGTCTACATTAGAGTT} AATCAAATACCCTGAGAGTAATGAATTTATATATGATAAGGACCCTTTAAAGGATATAGATCTATCAAAATTAATGGTT ATAAGAGATCATTCTTATACAATTGACATGAATTACTGGGATGACACAGATATTGTACATGCAATATCAATATGTACTG CAGTTACAATAGCAGATACAATGTCGCAGCTAGATCGGGATAATCTTAAGGAGCTGGTTGTGATTGCAAATGATGATGA TATTAACAGTCTGATAACTGAATTTCTGACCCTAGATATACTAGTGTTTCTCAAAACATTTGGAGGGTTACTCGTGAAT CAATTTGCATATACCCTTTATGGATTGAAAATAGAAGGAAGGGATCCCATTTGGGATTATATAATGAGAACATTAAAAG ACACCTCACATTCAGTACTTAAAGTATTATCTAATGCACTATCTCATCCAAAAGTGTTTAAGAGATTTTGGGATTGTGG AGTTTTGAATCCTATTTATGGTCCTAATACTGCTAGTCAAGATCAAGTTAAGCTTGCTCTCTCGATTTGCGAGTACTCC TTGGATCTATTTATGAGAGAATGGTTGAATGGAGCATCACTTGAGATCTATATCTGTGATAGTGACATGGAAATAGCAA ATGACAGAAGACAAGCATTTCTCTCAAGACATCTTGCCTTTGTGTGTTGTTTAGCAGAGATAGCATCTTTTGGACCAAA TTTATTAAATCTAACATATCTAGAGAGACTTGATGAATTAAAACAATACTTAGATCTGAACATCAAAGAAGATCCTACT CTTAAATATGTGCAAGTATCAGGACTGTTAATTAAATCATTCCCCTCAACTGTTACGTATGTAAGGAAAACTGCGATTA AGTATCTGAGGATTCGTGGTATTAATCCGCCTGAAACGATTGAAGATTGGGATCCCATAGAAGATGAGAATATCTTAGA CAATATTGTTAAAACTGTAAATGACAATTGCAGTGATAATCAAAAGAGAAATAAAAGTAGTTATTTCTGGGGATTAGCT CTAAAGAATTATCAAGTCGTGAAAATAAGATCCATAACGAGTGATTCTGAAGTTAATGAAGCTTCGAATGTTACTACAC ATGGAATGACACTTCCTCAGGGAGGAAGTTATCTATCACATCAGCTGAGGTTATTTGGAGTAAACAGTACAAGTTGTCT TAAAGCTCTTGAATTATCACAAATCTTAATGAGGGAAGTTAAAAAAGATAAAGATAGACTCTTTTTAGGAGAAGGAGCA GGAGCTATGTTAGCATGTTATGATGCTACACTCGGTCCTGCAATAAATTATTATAATTCTGGTTTAAATATTACAGATG TAATTGGTCAACGGGAATTAAAAATCTTCCCATCAGAAGTATCATTAGTAGGTAAAAAACTAGGAAATGTAACACAGAT TCTTAATCGGGTGAGGGTGTTATTTAATGGGAATCCCAATTCAACATGGATAGGAAATATGGAATGTGAGAGTTTAATA ^{TGGAGTGAATTAAATGATAAGTCAATTGGTTTAGTACATTGTGACATGGAGGGAGCGATAGGCAAATCAGAAGAAACTG} TTCTACATGAACATTATAGTATTATTAGGATTACATATTTAATCGGGGATGATGATGTTGTCCTAGTATCAAAAATTAT ACCAACTATTACTCCGAATTGGTCTAAAATACTCTATCTATACAAGTTGTATTGGAAGGATGTAAGTGTAGTGTCCCTT ^{4239-112370-02} AAAACATCCAATCCTGCCTCAACAGAGCTTTATTTAATTTCAAAAGATGCTTACTGTACTGTAATGGAACCCAGTAATC TTGTTTTATCAAAACTTAAAAGGATATCATCAATAGAAGAAAATAATCTATTAAAGTGGATAATCTTATCAAAAAGGAA GAATAACGAGTGGTTACAGCATGAAATCAAAGAAGGAGAAAGGGATTATGGGATAATGAGGCCATATCATACAGCACTG CAAATTTTTGGATTCCAAATTAACTTAAATCACTTAGCTAGAGAATTTTTATCAACTCCTGATTTAACCAACATTAATA ATATAATTCAAAGTTTTACAAGAACAATTAAAGATGTTATGTTCGAATGGGTCAATATCACTCATGACAATAAAAGACA TAAATTAGGAGGAAGATATAATCTATTCCCGCTTAAAAATAAGGGGAAATTAAGATTATTATCACGAAGATTAGTACTA AGCTGGATATCATTATCCTTATCAACCAGATTACTGACGGGCCGTTTTCCAGATGAAAAATTTGAAAATAGGGCACAGA CCGGATATGTATCATTGGCTGATATTGATTTAGAATCCTTAAAGTTATTATCAAGAAATATTGTCAAAAATTACAAAGA ACACATAGGATTAATATCATACTGGTTTTTGACCAAAGAGGTCAAAATACTAATGAAGCTTATAGGAGGAGTCAAACTA CTAGGAATTCCTAAACAGTACAAAGAGTTAGAGGATCGATCATCTCAGGGTTATGAATATGATAATGAATTTGATATTG ATTAATACATAAAAACATAAAATAAAACACCTATTCCTCACCCATTCACTTCCAACAAAATGAAAAGTAAGAAAAACAT GTAATATATATATACCAAACAGAGTTTTTCTCTTGTTTGGT SEQ ID NO: 12 is an exemplary nucleic acid sequences of a 3’ leader sequence. ACCAAACAAGAGAAGAGACTGGTTTGGGAATATTAATTCAAATAAAAATTAACTT SEQ ID NO: 13 is an exemplary nucleic acid sequence of a 5’ trailer sequence. ATGTAATATATATATACCAAACAGAGTTTTTCTCTTGTTTGGT SEQ ID NO: 14 is a codon-optimized nucleic acid sequence encoding H7N9 HA protein. ATGAACACCCAGATCCTGGTGTTCGCCCTGATCGCCATCATCCCAACAAATGCCGATAAGATCTGTCTGGGCCACCACGC CGTGTCTAACGGCACCAAAGTGAATACCCTGACAGAGAGGGGAGTGGAGGTGGTGAACGCAACCGAGACAGTGGAGAGAA CCAATACACCCAGGATCTGCTCCAAGGGCAAGCGGACAGTGGACCTGGGACAGTGTGGACTGCTGGGAACCATCACAGGC CCACCTCAGTGCGATCAGTTCCTGGAGTTTAGCGCCGACCTGATCATCGAGCGGAGAGAGGGCTCCGACGTGTGCTACCC ^{CGGCAAGTTCGTGAACGAGGAGGCCCTGAGGCAGATCCTGAGGGAGAGCGGCGGAATCGACAAGGAGCCTATGGGCTTTA} CCTACAACGGCATCCGCACCAATGGCGTGACCAGCGCCTGCCGGCGGAGCGGCAGCTCCTTCTATGCAGAGATGAAGTGG CTGCTGTCCAACACAGACAATGCCGCCTTTCCCCAGATGACCAAGTCCTATAAGAACACAAAGGAGTCTCCTGCCATCAT CGTGTGGGGAATCCACCACAGCGTGTCCACCGCCGAGCAGACAAAGCTGTACGGCAGCGGCAACAAGCTGGTGACAGTGG GCTCTAGCAATTATCAGCAGTCCTTCGTGCCATCTCCCGGCGCCCGCCCTCAGGTGAACGGACAGTCCGGCCGGATCGAT TTTCACTGGCTGATCCTGAACCCTAATGACACCGTGACATTCTCTTTTAATGGAGCCTTCATCGCCCCAGATAGGGCCAG CTTTCTGCGGGGCAAGAGCATGGGCATCCAGTCTCGCGTGCAGGTGGATGCCAACTGCGAGGGCGACTGTTACCACAGCG GCGGCACCATCATCTCCAACCTGCCATTCCAGAATATCGACAGCCGGGCCGTGGGCAAGTGTCCCAGATATGTGAAGCAG AGGTCTCTGCTGCTGGCCACCGGCATGAAGAATGTGCCTGAGGTGCCAAAGCGGAAGAGAACAGCCAGAGGCCTGTTCGG AGCAATCGCAGGCTTTATCGAGAACGGCTGGGAGGGCCTGATCGATGGCTGGTACGGCTTTAGGCACCAGAATGCACAGG GAGAGGGAACCGCCGCCGATTATAAGTCTACACAGAGCGCCATCGACCAGATCACCGGCAAGCTGAACAGACTGATCGCC AAGACAAATCAGCAGTTCAAGCTGATCGATAACGAGTTTAATGAGGTGGAGAAGCAGATCGGCAACGTGATCAATTGGAC CAGGGACTCTATCACAGAAGTGTGGAGCTACAACGCCGAGCTGCTGGTGGCTATGGAGAATCAGCACACCATCGATCTGG CCGACAGCGAGATGGATAAGCTGTATGAGAGGGTGAAGAGGCAGCTGAGGGAGAACGCAGAGGAGGACGGAACCGGCTGC TTCGAGATCTTTCACAAGTGCGACGATGACTGTATGGCCTCCATCAGAAACAATACATACGACCACAGAAAGTATAGGGA GGAGGCCATGCAGAATAGGATCCAGATCGATCCCGTGAAGCTGTCCTCTGGCTACAAGGACGTGATCCTGTGGTTCAGCT TTGGCGCCTCCTGTTTCATCCTGCTGGCCATCGTGATGGGCCTGGTGTTTATCTGCGTGAAGAACGGCAATATGAGGTGC ACCATCTGTATCTGATAG SEQ ID NOs: 15-26 are gene start and gene end sequences for B/HPIV3 N, P, M, F, HN and L genes: Gene Gene start SEQ ID NO Gene end SEQ ID NO ^{4239-112370-02} SEQ ID NO: 27 is a codon-optimized nucleic acid sequence encoding H7N9 NA protein. ATGAATCCCAACCAGAAGATCCTGTGCACCAGCGCCACAGCCATCACCATCGGCGCCATCACCGTGCTGATCGGCATCG CCAACATCGGCCTGAATATCGGCCTGCACCTGAAGTCTGGCTGCAACTGTTCTAGGAGCCAGCCAGAGACCACAAATCC CAGCCAGACCATCATCAACAACTACTACAACGAGACAAACATCACCAACATCCAGATGGGCGAGAGGACATCCCGCAAC TTCAACAATCTGACAAAGGGCCTGTGCACCATCAACTCTTGGCACATCTACGGCAAGGACAATGCCGTGCGGATCGGAG AGAGCTCCGACGTGCTGGTGACACGGGAGCCTTACGTGAGCTGCGACCCAGATGAGTGTAGGTTTTATGCCCTGAGCCA GGGAACCACAATCCGGGGCAAGCACTCCAACGGCACAATCCACGACCGGAGCCAGTACAGAGCCCTGATCAGCTGGCCT CTGTCTAGCCCCCCTACCGTGTATAATTCTAGGGTGGAGTGCATCGGCTGGTCCTCTACAAGCTGTCACGATGGCAAGT ^{CCCGCATGTCTATCTGCATCTCCGGCCCCAACAATAACGCCTCTGCCGTGATCTGGTACAACCGGAGACCTGTGGCCGA} GATCAACACCTGGGCCAGGAATATCCTGCGCACACAGGAGTCCGAGTGCGTGTGCCACAACGGCGTGTGCCCAGTGGTG TTCACAGACGGCCCTGCCACCGGCCCTGCCGATACACGGATCTACTACTTCAAGGAGGGCAAGATCCTGAAGTGGGAGT CCCTGACCGGCACAGCCAAGCACATCGAGGAGTGCTCTTGTTACGGCAAGCGGACCGGCATCACCTGCACCTGTAAGGA CAACTGGCAGGGCTCTAATAGACCCGTGATCCAGATCGATCCTGTGGCCATGACCCACACAAGCCAGTATATCTGCTCC CCTGTGCTGACCGACTCCCCACGGCCCAACGATCCAAATATCGGCAAGTGTAACGACCCTTACCCAGGCAATAACAATA ACGGCGTGAAGGGCTTCAGCTATCTGGACGGCGATAATACCTGGCTGGGCCGGACAATCTCCACCGCCTCCAGATCTGG CTACGAGATGCTGAAGGTGCCAAACGCCCTGACCGACGATAGAAGCAAGCCCATCCAGGGCCAGACAATCGTGCTGAAT GCCGATTGGTCCGGCTACAGCGGCTCCTTCATGGACTATTGGGCCGAGGGCGATTGCTACAGGGCCTGTTTTTATGTGG AGCTGATCCGGGGCAAGCCAAAGGAGGACAAAGTGTGGTGGACCTCTAACAGCATCGTGAGCATGTGCAGCTCCACAGA GTTCCTGGGCCAGTGGAATTGGCCCGATGGCGCCAAGATCGAGTATTTTCTGTGATAGTGA SEQ ID NO: 28 is an exemplary BPIV3 genome sequence (Kansas stain) deposited under GENBANK^TM Accession No. AF178654.1. ACCAAACAAGAGAAGAGACTTGCTTGGGAATATTAATTCAAATAAAAATTAACTTAGGATTAAAGAACTTTACCGAAAGG TAAGGGGAAAGAAATCCTAAGACTGTAATCATGTTGAGTCTATTCGACACATTCAGTGCGCGTAGGCAGGAGAACATAAC GAAATCAGCTGGTGGGGCTGTTATTCCCGGGCAAAAAAACACTGTGTCTATATTTGCTCTTGGACCATCAATAACAGATG ACAATGATAAAATGACATTGGCTCTTCTCTTTTTGTCTCATTCTTTAGACAATGAAAAGCAGCATGCGCAAAGAGCTGGA TTTTTAGTTTCTCTGTTATCAATGGCTTATGCCAACCCAGAATTATATTTAACATCAAATGGTAGTAATGCAGATGTTAA ATATGTTATCTACATGATAGAGAAAGACCCAGGAAGACAGAAATATGGTGGGTTTGTCGTCAAGACTAGAGAGATGGTTT ATGAAAAGACAACTGATTGGATGTTCGGGAGTGATCTTGAGTATGATCAAGACAATATGTTGCAAAATGGTAGAAGCACT TCTACAATCGAGGATCTTGTTCATACTTTTGGATATCCATCGTGTCTTGGAGCCCTTATAATCCAAGTTTGGATAATACT TGTTAAGGCTATAACCAGTATATCAGGATTGAGGAAAGGATTCTTTACTCGGTTAGAAGCATTTCGACAAGATGGAACAG TTAAATCCAGTCTAGTGTTGAGCGGTGATGCAGTAGAACAAATTGGATCAATTATGAGGTCCCAACAGAGCTTGGTAACA CTCATGGTTGAAACACTGATAACAATGAACACAGGCAGGAATGATCTGACAACAATAGAAAAGAATATACAGATTGTAGG ^{AAACTACATCAGAGATGCAGGTCTTGCTTCATTTTTCAACACAATCAGATATGGCATTGAGACTAGAATGGCAGCTCTAA} CTCTGTCTACCCTTAGACCGGATATCAACAGACTCAAGGCACTGATCGAGTTATATCTATCAAAGGGGCCACGTGCTCCT TTTATATGCATTTTGAGAGATCCCGTGCATGGTGAGTTTGCACCAGGCAACTATCCTGCCCTCTGGAGTTATGCGATGGG TGTAGCAGTTGTACAAAACAAGGCCATGCAACAGTATGTAACAGGAAGGTCTTATCTGGATATTGAAATGTTCCAACTTG GTCAAGCAGTGGCACGTGATGCCGAGTCGCAGATGAGTTCAATATTAGAGGATGAACTGGGGGTCACACAAGAAGCCAAG ^{CAAAGCTTGAAGAAACACATGAAGAACATCAGCAGTTCAGATACAACCTTTCATAAGCCTACAGGGGGATCAGCCATAGA} AATGGCGATAGATGAAGAAGCAGGGCAGCCTGAATCCAGAGGAGATCAGGATCAAGGAGATGAGCCTCGGTCATCCATAG TTCCTTATGCATGGGCAGACGAAACCGGGAATGACAATCAAACTGAATCAACTACAGAAATTGACAGCATCAAAACTGAA CAAAGAAACATCAGAGACAGGCTGAACAAAAGACTCAACGAGAAAAGGAAACAGAGTGACCCGAGATCAACTGACATCAC AAACAACACAAATCAAACTGAAATAGATGATTTGTTCAGTGCATTCGGAAGCAACTAGTCACAAAGAGATGACCACTATC ACCAGCAACAAGTAAGAAAAACTTAGGATTAATGGAAATTATCCAATCCAGAGACGGAAGGACAAATCCAGAATCCAACC ACAACTCAATCAACCAAAGATTCATGGAAGACAATGTTCAAAACAATCAAATCATGGATTCTTGGGAAGAGGGATCAGGA GATAAATCATCTGACATCTCATCGGCCCTCGACATCATTGAATTCATACTCAGCACCGACTCCCAAGAGAACACGGCAGA CAGCAATGAAATCAACACAGGAACCACAAGACTTAGCACGACAATCTACCAACCTGAATCCAAAACAACAGAAACAAGCA AGGAAAATAGTGGACCAGCTAACAAAAATCGACAGTTTGGGGCATCACACGAACGTGCCACAGAGACAAAAGATAGAAAT GTTAATCAGGAGACTGTACAGGGAGGATATAGGAGAGGAAGCAGCCCAGATAGTAGAACTGAGACTATGGTCACTCGAAG AATCTCCAGAAGCAGCCCAGATCCTAACAATGGAACCCAAATCCAGGAAGATATTGATTACAATGAAGTTGGAGAGATGG ATAAGGACTCTACTAAGAGGGAAATGCGACAATTTAAAGATGTTCCAGTCAAGGTATCAGGAAGTGATGCCATTCCTCCA ACAAAACAAGATGGAGACGGTGATGATGGAAGAGGCCTGGAATCTATCAGTACATTTGATTCAGGATATACCAGTATAGT GACTGCCGCAACACTAGATGACGAAGAAGAACTCCTTATGAAGAACAACAGGCCAAGAAAGTATCAATCAACACCCCAGA ACAGTGACAAGGGAATTAAAAAAGGGGTTGGAAGGCCAAAAGACACAGACAAACAATCATCAATATTGGACTACGAACTC AACTTCAAAGGATCGAAGAAGAGCCAGAAAATCCTCAAAGCCAGCACGAATACAGGAGAACCAACAAGACCACAGAATGG ATCCCAGGGGAAGAGAATCACATCCTGGAACATCCTCAACAGCGAGAGCGGCAATCGAACAGAATCAACAAACCAAACCC ATCAGACATCAACCTCGGGACAGAACCACACAATGGGACCAAGCAGAACAACCTCCGAACCAAGGATCAAGACACAAAAG ACGGATGGAAAGGAAAGAGAGGACACAGAAGAGAGCACTCGATTTACAGAAAGGGCGATTACATTATTACAGAATCTTGG ^{TGTAATCCAATCTGCAGCAAAATTAGACCTATACCAAGACAAGAGAGTTGTGTGTGTGGCGAATGTCCTAAACAATGCAG 4239-112370-02} ATACTGCATCAAAGATAGACTTCCTAGCAGGTTTGATGATAGGAGTGTCAATGGATCATGATACCAAATTAAATCAGATT CAGAACGAGATATTAAGTTTGAAAACTGATCTTAAAAAGATGGATGAATCACATAGAAGACTAATTGAGAATCAAAAAGA ACAATTATCACTGATCACATCATTAATCTCAAATCTTAAAATTATGACAGAGAGAGGAGGGAAGAAGGACCAACCAGAAC CTAGCGGGAGGACATCCATGATCAAGACAAAAGCAAAAGAAGAGAAAATAAAGAAAGTCAGGTTTGACCCTCTTATGGAA ACACAGGGCATCGAGAAAAACATCCCTGACCTCTATAGATCAATAGAGAAAACACCAGAAAACGACACACAGATCAAATC AGAAATAAACAGATTGAATGATGAATCCAATGCCACTAGATTAGTACCTAGAAGAATAAGCAGTACAATGAGATCATTAA TAATAATCATTAACAACAGCAATTTATCATCAAAAGCAAAGCAATCATACATCAACGAACTCAAGCTCTGCAAGAGTGAC GAGGAAGTGTCTGAGTTGATGGACATGTTCAATGAGGATGTCAGCTCCCAGTAAACCGCCAACCAAGGGTCAACACCAAG AAAACCAATAGCACAAAACAGCCAATCAGAGACCACCCCAATACACCAAACCAATCAACACATAACAAAGATCTCCAGAT CATAGATGATTAAGAAAAACTTAGGATGAAAGGACTAATCAATCCTCCGAAACAATGAGCATCACCAACTCCACAATCTA CACATTCCCAGAATCCTCTTTCTCCGAGAATGGCAACATAGAGCCGTTACCACTCAAGGTCAATGAACAGAGAAAGGCCA TACCTCATATTAGGGTTGTCAAGATAGGAGATCCGCCCAAACATGGATCCAGATATCTGGATGTCTTTTTACTGGGCTTC TTTGAGATGGAAAGGTCAAAAGACAGGTATGGGAGCATAAGTGATCTAGATGATGATCCAAGTTACAAGGTTTGTGGCTC TGGATCATTGCCACTTGGGTTGGCTAGATACACCGGAAATGATCAGGAACTCCTACAGGCTGCAACCAAGCTCGATATAG ^{AAGTAAGAAGAACTGTAAAGGCTACGGAGATGATAGTTTACACTGTACAAAACATCAAACCTGAACTATATCCATGGTCC} AGTAGATTAAGAAAAGGGATGTTATTTGACGCTAATAAGGTTGCACTTGCTCCTCAATGTCTTCCACTAGATAGAGGGAT AAAATTCAGGGTGATATTTGTGAACTGCACAGCAATTGGATCAATAACTCTATTCAAAATCCCTAAGTCCATGGCATTGT TATCATTGCCTAATACAATATCAATAAATCTACAAGTACATATCAAAACAGGAGTTCAGACAGATTCCAAAGGAGTAGTT CAGATTCTAGATGAAAAAGGTGAAAAATCACTAAATTTCATGGTTCATCTCGGGTTGATCAAAAGGAAGATGGGCAGAAT ^{GTACTCAGTTGAATATTGTAAGCAGAAGATCGAGAAGATGAGATTATTATTCTCATTGGGATTAGTTGGAGGGATCAGCT} TCCACGTCAACGCAACTGGCTCTATATCAAAGACATTAGCAAGTCAATTAGCATTCAAAAGAGAAATCTGCTATCCCCTA ATGGATCTGAATCCACACTTAAATTCAGTTATATGGGCATCATCAGTTGAAATTACAAGGGTAGATGCAGTTCTCCAGCC TTCATTACCTGGCGAATTCAGATACTACCCAAACATCATAGCAAAAGGGGTCGGGAAAATCAGACAGTAAAATCAACAAC CCTGATATCCAACATTGCAAATCAGGCTACCCACAGGAGAAAAATCAAAAACTTAGGATCAAAGGGATCACCACGAACCC CGGAAAACAGCCAAACAAACCAACACACAAATCACAGACAAAAAGGAGAAGGCACTGCAAAGACCGAGAAAAAACAGAAC GCACACAACCAAGCAGAGAAAAGCCAAAGCCCGCCATTCACAAACACACCAACAATCCTGCAAACAAGCACCAAAACAGA GGTCAAAAGACAAAGAGCACCAGATATGACCATCACAACCACAATCATAGCCATATTACTAATACCCCCATCATTTTGTC AAATAGACATAACAAAACTGCAACGTGTAGGTGTGTTAGTCAACAATCCTAAAGGCATGAAGATTTCACAAAATTTCGAA ACGAGATACCTGATATTAAGTTTGATACCCAAAATAGAGAATTCACACTCATGTGGGGATCAACAGATAAACCAATACAA GAAGTTATTGGATAGATTGATAATTCCTCTATATGATGGATTAAAATTACAAAAAGATGTAATAGTAGTAAGTCATGAAA CCCACAACAATACTAATCTTAGGACAAAACGATTCTTTGGAGAGATAATTGGGACAATTGCGATAGGGATAGCCACTTCA GCACAAATCACCGCAGCAGTCGCTCTTGTCGAAGCTAAACAGGCAAAGTCAGACATAGAAAAACTCAAAGAGGCTATAAG AGACACAAACAAGGCAGTACAATCGATTCAAAGTTCTGTAGGTAACCTAATTGTTGCAGTTAAATCAGTTCAAGACTATG TCAACAATGAAATTATACCTTCAATCACAAGATTAGGCTGTGAAGCAGCAGGGTTACAATTGGGAATTGCATTGACACAA CATTACTCAGAATTAACAAATATATTTGGTGATAATATAGGAACACTGAAAGAAAAAGGGATAAAATTACAAGGGATAGC ATCATTATATCACACAAACATAACGGAAATATTTACTACTTCAACAGTTGACCAATATGATATTTATGACCTATTATTCA CTGAGTCAATCAAGATGAGAGTGATAGATGTTGATTTGAGTGATTACTCAATTACTCTTCAAGTTAGACTTCCTTTATTA ACTAAACTATCAAATACTCAAATTTATAAAGTAGATTCTATATCATACAACATCCAGGGCAAAGAGTGGTATATTCCTCT TCCCAATCACATCATGACAAAAGGGGCTTTTCTAGGTGGTGCTGATATTAAAGAATGCATAGAGGCATTCAGCAGTTATA ^{TATGTCCTTCTGATCCAGGTTACATATTAAATCACGAGATAGAGAATTGTTTATCAGGGAACATAACACAGTGTCCTAAG} ACTGTTGTTACATCAGATGTGGTACCACGATACGCGTTTGTGAATGGTGGATTAATTGCAAACTGCATAACAACTACATG TACATGCAATGGAATTGACAATAGAATTAATCAATCACCTGATCAAGGAATTAAGATCATAACACATAAAGAATGCCAGG TAATAGGTATAAACGGAATGTTATTCAATACTAATAGAGAAGGGACATTAGCAACTTATACATTTGATGACATCATATTA AATAACTCTGTTGCACTTAATCCAATTGATATATCTATGGAACTCAACAAGGCAAAACTAGAATTAGAAGAATCGAAGGA ATGGATAAAGAAATCAAATCAAAAGTTAGATTCCGTTGGAAGTTGGTATCAATCTAGTGCAACAATCACCATAATCATAG TGATGATAATAATTCTAGTTATAATCAATATAACAATTATTGTAGTCATAATCAAATTCCATAGAATTCAGGGGAAAGAT CAAAACGACAAAAACAGTGAGCCGTATATACTGACAAATAGACAATAAGACTATACACGATCAAATATAAAAAGTACAAA AAACTTAGGAACAAAGTTGTTCAACACAGCAGCACCGAATAGACCAAAAGGCAGCGCAGAGGCGACACCAAACTCAAAAA TGGAATATTGGAAACACACAAACAGCATAAATAACACCAACAATGAAACCGAAACAGCCAGAGGCAAACATAGTAGCAAG GTTACAAATATCATAATGTACACCTTCTGGACAATAACATTAACAATATTATCAGTCATTTTTATAATGATATTGACAAA CTTAATTCAAGAGAACAATCATAATAAATTAATGTTGCAGGAAATAAGAAAAGAATTCGCGGCAATAGACACCAAGATTC AGAGGACTTCGGATGACATTGGAACCTCAATACAGTCAGGAATAAATACAAGACTTCTCACAATTCAGAGTCATGTTCAA AACTATATCCCACTATCATTAACACAACAAATGTCAGATCTCAGAAAATTTATCAATGATCTAACAAATAAAAGAGAACA TCAAGAAGTGCCAATACAGAGAATGACTCATGATAGAGGTATAGAACCCCTAAATCCAAACAAGTTCTGGAGGTGTACAT CTGGTAACCCATCTCTAACAAGTAGTCCTAAGATAAGGTTAATACCAGGACCAGGTTTATTAGCAACATCTACTACAGTA AATGGCTGTATTAGAATTCCATCGTTAGTAATCAATCATCTAATCTATGCTTACACCTCTAATCTTATTACCCAGGGCTG TCAAGATATAGGGAAATCTTACCAAGTACTACAAATAGGGATAATTACTATAAATTCGGACCTAGTACCTGATTTAAACC CCAGAGTCACACATACATTTAATATTGATGATAATAGAAGATCTTGCTCTCTGGCACTATTGAATACAGATGTTTATCAG TTATGCTCAACACCAAAAGTTGATGAAAGATCCGATTATGCATCAACAGGTATTGAGGATATTGTACTTGACATTGTCAC ^{TAATAATGGATTAATTATAACAACAAGGTTTACAAATAATAATATAACTTTTGATAAACCGTATGCAGCATTGTATCCAT} CAGTGGGACCAGGAATCTATTATAAGGATAAAGTTATATTTCTCGGATATGGAGGTCTAGAGCATGAAGAAAACGGAGAC GTAATATGTAATACAACTGGTTGTCCTGGCAAAACACAGAGAGACTGTAATCAGGCTTCTTATAGCCCATGGTTCTCAAA ^{4239-112370-02} TAGGAGAATGGTAAACTCTATTATTGTTGTTGATAAAGGCATAGATGCAACTTTTAGCTTGAGGGTGTGGACTATTCCAA TGAGCCAAAATTATTGGGGATCAGAAGGAAGATTACTTTTATTAGGTGACAGAATATACATATATACTAGATCCACAAGT TGGCACAGTAAATTACAGTTAGGGGTAATTGATATTTCTGATTATACTAATATAAGAATAAATTGGACTTGGCATAATGT ACTATCACGGCCAGGGAATGATGAATGTCCATGGGGTCATTCATGCCCAGACGGATGTATAACAGGAGTTTACACTGATG CATATCCGCTAAACCCATCGGGGAGTGTTGTATCATCAGTAATTCTTGATTCACAAAAGTCTAGAGAAAACCCAATCATT ACTTACTCAACAGCTACAAATAGAATAAATGAATTAGCTATATATAACAGAACACTTCCAGCTGCATATACAACAACAAA TTGTATCACACATTATGATAAAGGGTATTGTTTTCATATAGTAGAAATAAATCACAGAAGTTTGAATACGTTTCAACCTA TGTTATTCAAAACAGAAGTTCCAAAAAACTGCAGCTAAATTGATCATCGCATATCGGATGCAAGATGACATTAAAAGAGA CCACCAGACAGACAACACAGGAGACGATGCAAGATATAAAGAAATAATAAAAAACTTAGGAGAAAAGTGTGCAAGAAAAA TGGACACCGAGTCCCACAGCGGCACAACATCTGACATTCTGTACCCTGAATGTCACCTCAATTCTCCTATAGTTAAAGGA AAGATAGCACAACTGCATACAATAATGAGTTTGCCTCAGCCCTACGATATGGATGATGATTCAATACTGATTATTACTAG ACAAAAAATTAAACTCAATAAATTAGATAAAAGACAACGGTCAATTAGGAAATTAAGATCAGTCTTAATGGAAAGAGTAA GTGATCTAGGTAAATATACCTTTATCAGATATCCAGAGATGTCTAGTGAAATGTTCCAATTATGTATACCCGGAATTAAT AATAAAATAAATGAATTGCTAAGTAAAGCAAGTAAAACATATAATCAAATGACTGATGGATTAAGAGATCTATGGGTTAC ^{TATACTATCGAAGTTAGCATCGAAAAATGATGGAAGTAATTATGATATCAATGAAGATATTAGCAATATATCAAATGTTC} ACATGACTTATCAATCAGACAAATGGTATAATCCATTCAAGACATGGTTTACTATTAAGTATGACATGAGAAGATTACAA AAAGCCAAAAATGAGATTACATTCAATAGGCATAAAGATTATAATCTATTAGAAGACCAAAAGAATATATTGCTGATACA TCCAGAACTCGTCTTAATATTAGATAAACAAAATTACAATGGGTATATAATGACTCCTGAATTGGTACTAATGTATTGTG ATGTAGTTGAAGGGAGGTGGAATATAAGTTCATGTGCAAAATTGGATCCTAAGTTACAATCAATGTATTATAAGGGTAAC ^{AATTTATGGGAAATAATAGATGGACTATTCTCGACCTTAGGAGAAAGAACATTTGACATAATATCACTATTAGAACCACT} TGCATTATCGCTCATTCAAACTTATGACCCGGTTAAACAGCTCAGGGGGGCTTTTTTAAATCACGTGTTATCAGAAATGG AATTAATATTTGCAGCTGAGTGTACAACAGAGGAAATACCTAATGTGGATTATATAGATAAAATTTTAGATGTGTTCAAA GAATCAACAATAGATGAAATAGCAGAAATTTTCTCTTTCTTCCGAACTTTTGGACACCCTCCATTAGAGGCGAGTATAGC AGCAGAGAAAGTTAGAAAGTATATGTATACTGAGAAATGCTTGAAATTTGATACTATCAATAAATGTCATGCTATTTTTT GTACAATAATTATAAATGGATATAGAGAAAGACATGGTGGTCAATGGCCTCCAGTTACATTACCTGTCCATGCACATGAA TTTATCATAAATGCATACGGATCAAATTCTGCCATATCATATGAGAATGCTGTAGATTATTATAAGAGCTTCATAGGAAT AAAATTTGACAAGTTTATAGAGCCTCAATTGGATGAAGACTTAACTATTTATATGAAAGATAAAGCATTATCCCCAAAGA AATCAAACTGGGACACAGTCTATCCAGCTTCAAACCTGTTATACCGCACTAATGTGTCTCATGATTCACGAAGATTGGTT GAAGTATTTATAGCAGATAGTAAATTTGATCCCCACCAAGTATTAGATTACGTAGAATCAGGATATTGGCTGGATGATCC TGAATTTAATATCTCATATAGTTTAAAAGAGAAAGAAATAAAACAAGAAGGTAGACTTTTTGCAAAAATGACATACAAGA TGAGGGCTACACAAGTATTATCAGAAACATTATTGGCGAATAATATAGGGAAATTCTTCCAAGAGAATGGGATGGTTAAA GGAGAAATTGAATTACTCAAGAGACTAACAACAATATCTATGTCTGGAGTTCCGCGGTATAATGAGGTATACAATAATTC AAAAAGTCACACAGAAGAACTTCAAGCTTATAATGCAATTAGCAGTTCCAATTTATCTTCTAATCAGAAGTCAAAGAAGT TTGAATTTAAATCTACAGATATATACAATGATGGATACGAAACCGTAAGCTGCTTCTTAACGACAGATCTTAAAAAATAT TGTTTAAATTGGAGGTATGAATCAACAGCTTTATTCGGTGATACTTGTAATCAGATATTTGGGTTAAAGGAATTATTTAA TTGGCTGCACCCTCGCCTTGAAAAGAGTACAATATATGTTGGAGATCCTTATTGCCCGCCATCAGATATTGAACATTTAC CACTTGATGACCATCCTGATTCAGGATTTTATGTTCATAATCCTAAAGGAGGAATAGAAGGGTTTTGCCAAAAGTTATGG ACACTCATATCTATCAGTGCAATACATTTAGCAGCTGTCAAAATCGGTGTAAGAGTTACTGCAATGGTTCAAGGGGATAA TCAAGCCATAGCTGTTACCACAAGAGTACCTAATAATTATGATTATAAAGTTAAGAAAGAGATTGTTTATAAAGATGTGG ^{TAAGATTTTTTGATTCCTTGAGAGAGGTGATGGATGATCTGGGTCATGAGCTCAAACTAAATGAAACTATAATAAGTAGT} AAAATGTTTATATATAGCAAAAGGATATACTATGACGGAAGAATCCTTCCTCAGGCATTAAAAGCATTGTCTAGATGTGT TTTTTGGTCTGAAACAATCATAGATGAGACAAGATCAGCATCCTCAAATCTGGCTACATCGTTTGCAAAGGCCATTGAGA ATGGCTACTCACCTGTATTGGGATATGTATGCTCAATCTTCAAAAATATCCAACAGTTGTATATAGCGCTTGGAATGAAT ATAAACCCAACTATAACCCAAAATATTAAAGATCAATATTTCAGGAATATTCATTGGATGCAATATGCCTCCTTAATCCC TGCTAGTGTCGGAGGATTTAATTATATGGCCATGTCAAGGTGTTTTGTCAGAAACATTGGAGATCCTACAGTCGCTGCGT TAGCCGATATTAAAAGATTTATAAAAGCAAATTTGTTAGATCGAGGTGTCCTTTACAGAATTATGAATCAAGAACCAGGC GAGTCTTCTTTTTTAGACTGGGCCTCAGATCCCTATTCATGTAACTTACCACAATCTCAAAATATAACCACCATGATAAA GAATATAACTGCAAGAAATGTACTACAGGACTCACCAAACCCATTACTATCTGGATTATTTACAAGTACAATGATAGAAG AGGATGAGGAATTAGCTGAGTTCCTAATGGACAGGAGAATAATCCTCCCAAGAGTTGCACATGACATTTTAGATAATTCT CTTACTGGAATTAGGAATGCTATAGCTGGTATGTTGGATACAACAAAATCACTAATTCGAGTAGGGATAAGCAGAGGAGG ATTAACCTATAACTTATTAAGAAAGATAAGCAACTATGATCTTGTACAATATGAGACACTTAGTAAAACTTTAAGACTAA TAGTCAGTGACAAGATTAAGTATGAAGATATGTGCTCAGTAGACCTAGCCATATCATTAAGACAAAAAATGTGGATGCAT TTATCAGGAGGAAGAATGATAAATGGACTTGAAACTCCAGATCCTTTAGAGTTACTGTCTGGAGTAATAATAACAGGATC TGAACATTGTAGGATATGTTATTCAACTGAAGGTGAAAGCCCATATACATGGATGTATTTACCAGGCAATCTTAATATAG GATCAGCTGAGACAGGAATAGCATCATTAAGGGTCCCTTACTTTGGATCAGTTACAGATGAGAGATCTGAAGCACAATTA GGGTATATCAAAAATCTAAGCAAACCAGCTAAGGCTGCTATAAGAATAGCAATGATATATACTTGGGCATTTGGGAATGA CGAAATATCTTGGATGGAAGCATCACAGATTGCACAAACACGTGCAAACTTTACATTGGATAGCTTAAAGATTTTGACAC CAGTGACAACATCAACAAATCTATCACACAGGTTAAAAGATACTGCTACTCAGATGAAATTTTCTAGTACATCACTTATT AGAGTAAGCAGGTTCATCACAATATCTAATGATAATATGTCTATTAAAGAAGCAAATGAAACTAAAGATACAAATCTTAT ^{TTATCAACAGGTAATGTTAACAGGATTAAGTGTATTTGAATATCTATTTAGGTTAGAGGAGAGTACAGGACATAACCCTA} TGGTCATGCATCTACATATAGAGGATGGATGTTGTATAAAAGAGAGTTACAATGATGAGCATATCAATCCGGAGTCTACA TTAGAGTTAATCAAATACCCTGAGAGTAATGAATTTATATATGATAAGGACCCTTTAAAGGATATAGATCTATCAAAATT ^{4239-112370-02} AATGGTTATAAGAGATCATTCTTATACAATTGACATGAATTACTGGGATGACACAGATATTGTACATGCAATATCAATAT GTACTGCAGTTACAATAGCAGATACAATGTCGCAGCTAGATCGGGATAATCTTAAGGAGCTGGTTGTGATTGCAAATGAT GATGATATTAACAGTCTGATAACTGAATTTCTGACCCTAGATATACTAGTGTTTCTCAAAACATTTGGAGGGTTACTCGT GAATCAATTTGCATATACCCTTTATGGATTGAAAATAGAAGGAAGGGATCCCATTTGGGATTATATAATGAGAACATTAA AAGACACCTCACATTCAGTACTTAAAGTATTATCTAATGCACTATCTCATCCAAAAGTGTTTAAGAGATTTTGGGATTGT GGAGTTTTGAATCCTATTTATGGTCCTAATACTGCTAGTCAAGATCAAGTTAAGCTTGCTCTCTCGATTTGCGAGTACTC CTTGGATCTATTTATGAGAGAATGGTTGAATGGAGCATCACTTGAGATCTATATCTGTGATAGTGACATGGAAATAGCAA ATGACAGAAGACAAGCATTTCTCTCAAGACATCTTGCCTTTGTGTGTTGTTTAGCAGAGATAGCATCTTTTGGACCAAAT TTATTAAATCTAACATATCTAGAGAGACTTGATGAATTAAAACAATACTTAGATCTGAACATCAAAGAAGATCCTACTCT TAAATATGTGCAAGTATCAGGACTGTTAATTAAATCATTCCCCTCAACTGTTACGTATGTAAGGAAAACTGCGATTAAGT ATCTGAGGATTCGTGGTATTAATCCGCCTGAAACGATTGAAGATTGGGATCCCATAGAAGATGAGAATATCTTAGACAAT ATTGTTAAAACTGTAAATGACAATTGCAGTGATAATCAAAAGAGAAATAAAAGTAGTTATTTCTGGGGATTAGCTCTAAA GAATTATCAAGTCGTGAAAATAAGATCCATAACGAGTGATTCTGAAGTTAATGAAGCTTCGAATGTTACTACACATGGAA TGACACTTCCTCAGGGAGGAAGTTATCTATCACATCAGCTGAGGTTATTTGGAGTAAACAGTACAAGTTGTCTTAAAGCT ^{CTTGAATTATCACAAATCTTAATGAGGGAAGTTAAAAAAGATAAAGATAGACTCTTTTTAGGAGAAGGAGCAGGAGCTAT} GTTAGCATGTTATGATGCTACACTCGGTCCTGCAATAAATTATTATAATTCTGGTTTAAATATTACAGATGTAATTGGTC AACGGGAATTAAAAATCTTCCCATCAGAAGTATCATTAGTAGGTAAAAAACTAGGAAATGTAACACAGATTCTTAATCGG GTGAGGGTGTTATTTAATGGGAATCCCAATTCAACATGGATAGGAAATATGGAATGTGAGAGTTTAATATGGAGTGAATT AAATGATAAGTCAATTGGTTTAGTACATTGTGACATGGAGGGAGCGATAGGCAAATCAGAAGAAACTGTTCTACATGAAC ^{ATTATAGTATTATTAGGATTACATATTTAATCGGGGATGATGATGTTGTCCTAGTATCAAAAATTATACCAACTATTACT} CCGAATTGGTCTAAAATACTCTATCTATACAAGTTGTATTGGAAGGATGTAAGTGTAGTGTCCCTTAAAACATCCAATCC TGCCTCAACAGAGCTTTATTTAATTTCAAAAGATGCTTACTGTACTGTAATGGAACCCAGTAATCTTGTTTTATCAAAAC TTAAAAGGATATCATCAATAGAAGAAAATAATCTATTAAAGTGGATAATCTTATCAAAAAGGAAGAATAACGAGTGGTTA CAGCATGAAATCAAAGAAGGAGAAAGGGATTATGGGATAATGAGGCCATATCATACAGCACTGCAAATTTTTGGATTCCA AATTAACTTAAATCACTTAGCTAGAGAATTTTTATCAACTCCTGATTTAACCAACATTAATAATATAATTCAAAGTTTTA CAAGAACAATTAAAGATGTTATGTTCGAATGGGTCAATATCACTCATGACAATAAAAGACATAAATTAGGAGGAAGATAT AATCTATTCCCGCTTAAAAATAAGGGGAAATTAAGATTATTATCACGAAGATTAGTACTAAGCTGGATATCATTATCCTT ATCAACCAGATTACTGACGGGCCGTTTTCCAGATGAAAAATTTGAAAATAGGGCACAGACCGGATATGTATCATTGGCTG ATATTGATTTAGAATCCTTAAAGTTATTATCAAGAAATATTGTCAAAAATTACAAAGAACACATAGGATTAATATCATAC TGGTTTTTGACCAAAGAGGTCAAAATACTAATGAAGCTTATAGGAGGAGTCAAACTACTAGGAATTCCTAAACAGTACAA AGAGTTAGAGGATCGATCATCTCAGGGTTATGAATATGATAATGAATTTGATATTGATTAATACATAAAAACATAAAATA AAACACCTATTCCTCACCCATTCACTTCCAACAAAATGAAAAGTAAGAAAAACATGTAATATATATATACCAAACAGAGT TTTTCTCTTGTTTGGT SEQ ID NO: 29 is exemplary HPIV3 genome sequence (JS strain) deposited under GENBANK^TM Accession No. Z11575.1. ACCAAACAAGAGAAGAAACTTGTCTGGGAATATAAATTTAACTTTAAATTAACTTAGGATTAAAGACATTGACTAGAAGG TCAAGAAAAGGGAACTCTATAATTTCAAAAATGTTGAGCCTATTTGATACATTTAATGCACGTAGGCAAGAAAACATAAC AAAATCAGCCGGTGGAGCTATCATTCCTGGACAGAAAAATACTGTCTCTATATTCGCCCTTGGACCGACAATAACTGATG ATAATGAGAAAATGACATTAGCTCTTCTATTTCTATCTCATTCACTAGATAATGAGAAACAACATGCACAAAGGGCAGGG TTCTTGGTGTCTTTATTGTCAATGGCTTATGCCAATCCAGAGCTCTACCTAACAACAAATGGAAGTAATGCAGATGTCAA GTATGTCATATACATGATTGAGAAAGATCTAAAACGGCAAAAGTATGGAGGATTTGTGGTTAAGACGAGAGAGATGATAT ATGAAAAGACAACTGATTGGATATTTGGAAGTGACCTGGATTATGATCAGGAAACTATGTTGCAGAACGGCAGGAACAAT TCAACAATTGAAGACCTTGTCCACACATTTGGGTATCCATCATGTTTAGGAGCTCTTATAATACAGATCTGGATAGTTCT GGTCAAAGCTATCACTAGTATCTCAGGGTTAAGAAAAGGCTTTTTCACCCGATTGGAAGCTTTCAGACAAGATGGAACAG TGCAGGCAGGGCTGGTATTGAGCGGTGACACAGTGGATCAGATTGGGTCAATCATGCGGTCTCAACAGAGCTTGGTAACT CTTATGGTTGAAACATTAATAACAATGAATACCAGCAGAAATGACCTCACAACCATAGAAAAGAATATACAAATTGTTGG CAACTACATAAGAGATGCAGGTCTCGCTTCATTCTTCAATACAATCAGATATGGAATTGAGACCAGAATGGCAGCTTTGA CTCTATCCACTCTCAGACCAGATATCAATAGATTAAAAGCTTTGATGGAACTGTATTTATCAAAGGGACCACGCGCTCCT TTCATCTGTATCCTCAGAGATCCTATACATGGTGAGTTCGCACCAGGCAACTATCCTGCCATATGGAGCTATGCAATGGG GGTGGCAGTTGTACAAAATAGAGCCATGCAACAGTATGTGACGGGAAGATCATATCTAGACATTGATATGTTCCAGCTAG GACAAGCAGTAGCACGTGATGCCGAAGCTCAAATGAGCTCAACACTGGAAGATGAACTTGGAGTGACACACGAATCTAAA GAAAGCTTGAAGAGACATATAAGGAACATAAACAGTTCAGAGACATCTTTCCACAAACCGACAGGTGGATCAGCCATAGA GATGGCAATAGATGAAGAGCCAGAACAATTCGAACATAGAGCAGATCAAGAACAAAATGGAGAACCTCAATCATCCATAA TTCAATATGCCTGGGCAGAAGGAAATAGAAGCGATGATCAGACTGAGCAAGCTACAGAATCTGACAATATCAAGACCGAA CAACAAAACATCAGAGACAGACTAAACAAGAGACTCAACGACAAGAAGAAACAAAGCAGTCAACCACCCACTAATCCCAC AAACAGAACAAACCAGGACGAAATAGATGATCTGTTTAACGCATTTGGAAGCAACTAATCGAATCAACATTTTAATCTAA ATCAATAATAAATAAGAAAAACTTAGGATTAAAGAATCCTATCATACCGGAATATAGGGTGGTAAATTTAGAGTCTGCTT GAAACTCAATCAATAGAGAGTTGATGGAAAGCGATGCTAAAAACTATCAAATCATGGATTCTTGGGAAGAGGAATCAAGA GATAAATCAACTAATATCTCCTCGGCCCTCAACATCATTGAATTCATACTCAGCACCGACCCCCAAGAAGACTTATCGGA AAACGACACAATCAACACAAGAACCCAGCAACTCAGTGCCACCATCTGTCAACCAGAAATCAAACCAACAGAAACAAGTG ^{4239-112370-02} AGAAAGATAGTGGATCAACTGACAAAAATAGACAGTCCGGGTCATCACACGAATGTACAACAGAAGCAAAAGATAGAAAT ATTGATCAGGAAACTGTACAGAGAGGACCTGGGAGAAGAAGCAGCTCAGATAGTAGAGCTGAGACTGTGGTCTCTGGAGG AATCCCCAGAAGCATCACAGATTCTAAAAATGGAACCCAAAACACGGAGGATATTGATCTCAATGAAATTAGAAAGATGG ATAAGGACTCTATTGAGGGGAAAATGCGACAATCTGCAAATGTTCCAAGCGAGATATCAGGAAGTGATGACATATTTACA ACAGAACAAAGTAGAAACAGTGATCATGGAAGAAGCCTGGAATCTATCAGTACACCTGATACAAGATCAATAAGTGTTGT TACTGCTGCAACACCAGATGATGAAGAAGAAATACTAATGAAAAATAGTAGGACAAAGAAAAGTTCTTCAACACATCAAG AAGATGACAAAAGAATTAAAAAAGGGGGAAAAGGGAAAGACTGGTTTAAGAAATCAAAAGATACCGACAACCAGATACCA ACATCAGACTACAGATCCACATCAAAAGGGCAGAAGAAAATCTCAAAGACAACAACCACCAACACCGACACAAAGGGGCA AACAGAAATACAGACAGAATCATCAGAAACACAATCCTCATCATGGAATCTCATCATCGACAACAACACCGACCGGAACG AACAGACAAGCACAACTCCTCCAACAACAACTTCCAGATCAACTTATACAAAAGAATCGATCCGAACAAACTCTGAATCC AAACCCAAGACACAAAAGACAAATGGAAAGGAAAGGAAGGATACAGAAGAGAGCAATCGATTTACAGAGAGGGCAATTAC TCTATTGCAGAATCTTGGTGTAATTCAATCCACATCAAAACTAGATTTATATCAAGACAAACGAGTTGTATGTGTAGCAA ATGTACTAAACAATGTAGATACTGCATCAAAGATAGATTTCCTGGCAGGATTAGTCATAGGGGTTTCAATGGACAACGAC ACAAAATTAACACAGATACAAAATGAAATGCTAAACCTCAAAGCAGATCTAAAGAAAATGGACGAATCACATAGAAGATT ^{GATAGAAAATCAAAGAGAACAACTGTCATTGATCACGTCACTAATTTCAAATCTCAAAATTATGACTGAGAGAGGAGGAA} AGAAAGACCAAAATGAATCCAATGAGAGAGTATCCATGATCAAAACAAAATTGAAAGAAGAAAAGATCAAGAAGACCAGG TTTGACCCACTTATGGAGGCACAAGGCATTGACAAGAATATACCCGATCTATATCGACATGCAGGAGATACACTAGAGAA CGATGTACAAGTTAAATCAGAGATATTAAGTTCATACAATGAGTCAAATGCAACAAGACTAATACCCAAAAAAGTGAGCA GTACAATGAGATCACTAGTTGCAGTCATCAACAACAGCAATCTCTCACAAAGCACAAAACAATCATACATAAACGAACTC ^{AAACGTTGCAAAAATGATGAAGAAGTATCTGAATTAATGGACATGTTCAATGAAGATGTCAACAATTGCCAATGATCCAA} CAAAGAAACGACACCGAACAAACAGACAAGAAACAACAGTAGATCAAAACCTGTCAACACACACAAAATCAAGCAGAATG AAACAACAGATATCAATCAATATACAAATAAGAAAAACTTAGGATTAAAGAATAAATTAATCCTTGTCCAAAATGAGTAT AACTAACTCTGCAATATACACATTCCCAGAATCATCATTCTCTGAAAATGGTCATATAGAACCATTACCACTCAAAGTCA ATGAACAGAGGAAAGCAGTACCCCACATTAGAGTTGCCAAGATCGGAAATCCACCAAAACACGGATCCCGGTATTTAGAT GTCTTCTTACTCGGCTTCTTCGAGATGGAACGAATCAAAGACAAATACGGGAGTGTGAATGATCTCGACAGTGACCCGAG TTACAAAGTTTGTGGCTCTGGATCATTACCAATCGGATTGGCTAAGTACACTGGGAATGACCAGGAATTGTTACAAGCCG CAACCAAACTGGATATAGAAGTGAGAAGAACAGTCAAAGCGAAAGAGATGGTTGTTTACACGGTACAAAATATAAAACCA GAACTGTACCCATGGTCCAATAGACTAAGAAAAGGAATGCTGTTCGATGCCAACAAAGTTGCTCTTGCTCCTCAATGTCT TCCACTAGATAGGAGCATAAAATTTAGAGTAATCTTCGTGAATTGTACGGCAATTGGATCAATAACCTTGTTCAAAATTC CTAAGTCAATGGCATCACTATCTCTACCCAACACAATATCAATCAATCTGCAGGTACACATAAAAACAGGGGTTCAGACT GATTCTAAAGGGATAGTTCAAATTTTGGATGAGAAAGGCGAAAAATCACTGAATTTCATGGTCCATCTCGGATTGATCAA AAGAAAAGTAGGCAGAATGTACTCTGTTGAATACTGTAAACAGAAAATCGAGAAAATGAGATTGATATTTTCTTTAGGAC TAGTTGGAGGAATCAGTCTTCATGTCAATGCAACTGGGTCCATATCAAAAACACTAGCAAGTCAGCTGGTATTCAAAAGA GAGATTTGTTATCCTTTAATGGATCTAAATCCGCATCTCAATCTAGTTATCTGGGCTTCATCAGTAGAGATTACAAGAGT GGATGCAATTTTCCAACCTTCTTTACCTGGCGAGTTCAGATACTATCCTAATATTATTGCAAAAGGAGTTGGGAAAATCA AACAATGGAACTAGTAATCTCTATTTTAGTCCGGACGTATCTATTAAGCCGAAGCAAATAAAGGATAATCAAAAACTTAG GACAAAAGAGGTCAATACCAACAACTATTAGCAGTCACACTCGCAAGAATAAGAGAGAAGGGACCAAAAAAGTCAAATAG GAGAAATCAAAACAAAAGGTACAGAACACCAGAACAACAAAATCAAAACATCCAACTCACTCAAAACAAAAATTCCAAAA GAGACCGGCAACACAACAAGCACTGAACACAATGCCAACTTCAATACTGCTAATTATTACAACCATGATCATGGCATCTT ^{TCTGCCAAATAGATATCACAAAACTACAGCACGTAGGTGTATTGGTCAACAGTCCCAAAGGGATGAAGATATCACAAAAC} TTTGAAACAAGATATCTAATTTTGAGCCTCATACCAAAAATAGAAGACTCTAACTCTTGTGGTGACCAACAGATCAAGCA ATACAAGAAGTTATTGGATAGACTGATCATCCCTTTATATGATGGATTAAGATTACAGAAAGATGTGATAGTAACCAATC AAGAATCCAATGAAAACACTGATCCCAGAACAAAACGATTCTTTGGAGGGGTAATTGGAACCATTGCTCTGGGAGTAGCA ACCTCAGCACAAATTACAGCGGCAGTTGCTCTGGTTGAAGCCAAGCAGGCAAGATCAGACATCGAAAAACTCAAAGAAGC AATTAGGGACACAAACAAAGCAGTGCAGTCAGTTCAGAGCTCCATAGGAAATTTAATAGTAGCAATTAAATCAGTCCAGG ATTATGTTAACAAAGAAATCGTGCCATCGATTGCGAGGCTAGGTTGTGAAGCAGCAGGACTTCAATTAGGAATTGCATTA ACACAGCATTACTCAGAATTAACAAACATATTTGGTGATAACATAGGATCGTTACAAGAAAAAGGAATAAAATTACAAGG TATAGCATCATTATACCGCACAAATATCACAGAAATATTCACAACATCAACAGTTGATAAATATGATATCTATGATCTGT TATTTACAGAATCAATAAAGGTGAGAGTTATAGATGTTGACTTGAATGATTACTCAATCACCCTCCAAGTCAGACTCCCT TTATTAACTAGGCTGCTGAACACTCAGATCTACAAAGTAGATTCCATATCATATAACATCCAAAACAGAGAATGGTATAT CCCTCTTCCCAGCCATATCATGACGAAAGGGGCATTTCTAGGTGGAGCAGACGTCAAAGAATGTATAGAAGCATTCAGCA GCTATATATGCCCTTCTGATCCAGGATTTGTATTAAACCATGAAATAGAGAGCTGCTTATCAGGAAACATATCCCAATGT CCAAGAACAACGGTCACATCAGACATTGTTCCAAGATATGCATTTGTCAATGGAGGAGTGGTTGCAAACTGTATAACAAC CACCTGTACATGCAACGGAATTGGTAATAGAATCAATCAACCACCTGATCAAGGAGTAAAAATTATAACACATAAAGAAT GTAGTACAATAGGTATCAACGGAATGCTGTTCAATACAAATAAAGAAGGAACTCTTGCATTCTATACACCAAATGATATA ACACTAAACAATTCTGTTGCACTTGATCCAATTGACATATCAATCGAGCTCAACAAGGCCAAATCAGATCTAGAAGAATC AAAAGAATGGATAAGAAGGTCAAATCAAAAACTAGATTCTATTGGAAATTGGCATCAATCTAGCACTACAATCATAATTA TTTTGATAATGATCATTATATTGTTTATAATTAATATAACGATAATTACAATTGCAATTAAGTATTACAGAATTCAAAAG AGAAATCGAGTGGATCAAAATGACAAGCCATATGTACTAACAAACAAATAACATATCTACAGATCATTAGATATTAAAAT ^{TATAAAAAACTTAGGAGTAAAGTTACGCAATCCAACTCTACTCATATAATTGAGGAAGGACCCAATAGACAAATCCAAAT} TCGAGATGGAATACTGGAAGCATACCAATCACGGAAAGGATGCTGGTAATGAGCTGGAGACGTCTATGGCTACTCATGGC AACAAGCTCACTAATAAGATAATATACATATTATGGACAATAATCCTGGTGTTATTATCAATAGTCTTCATCATAGTGCT ^{4239-112370-02} AATTAATTCCATCAAAAGTGAAAAGGCCCACGAATCATTGCTGCAAGACATAAATAATGAGTTTATGGAAATTACAGAAA AGATCCAAATGGCATCGGATAATACCAATGATCTAATACAGTCAGGAGTGAATACAAGGCTTCTTACAATTCAGAGTCAT GTCCAGAATTACATACCAATATCATTGACACAACAGATGTCAGATCTTAGGAAATTCATTAGTGAAATTACAATTAGAAA TGATAATCAAGAAGTGCTGCCACAAAGAATAACACATGATGTAGGTATAAAACCTTTAAATCCAGATGATTTTTGGAGAT GCACGTCTGGTCTTCCATCTTTAATGAAAACTCCAAAAATAAGGTTAATGCCAGGGCCGGGATTATTAGCTATGCCAACG ACTGTTGATGGCTGTGTTAGAACTCCGTCTTTAGTTATAAATGATCTGATTTATGCTTATACCTCAAATCTAATTACTCG AGGTTGTCAGGATATAGGAAAATCATATCAAGTCTTACAGATAGGGATAATAACTGTAAACTCAGACTTGGTACCTGACT TAAATCCTAGGATCTCTCATACCTTTAACATAAATGACAATAGGAAGTCATGTTCTCTAGCACTCCTAAATACAGATGTA TATCAACTGTGTTCAACTCCCAAAGTTGATGAAAGATCAGATTATGCATCATCAGGCATAGAAGATATTGTACTTGATAT TGTCAATTATGATGGTTCAATCTCAACAACAAGATTTAAGAATAATAACATAAGCTTTGATCAACCATATGCTGCACTAT ACCCATCTGTTGGACCAGGGATATACTACAAAGGCAAAATAATATTTCTCGGGTATGGAGGTCTTGAACATCCAATAAAT GAGAATGTAATCTGCAACACAACTGGGTGCCCCGGGAAAACACAGAGAGACTGTAATCAAGCGTCTCATAGTCCATGGTT TTCAGATAGGAGGATGGTCAACTCCATCATTGTTGTTGACAAAGGCTTAAACTCAATTCCAAAATTGAAAGTATGGACGA TATCTATGCGACAAAATTACTGGGGGTCAGAAGGAAGGTTACTTCTACTAGGTAACAAGATCTATATATATACAAGATCT ^{ACAAGTTGGCATAGCAAGTTACAATTAGGAATAATTGATATTACTGATTACAGTGATATAAGGATAAAATGGACATGGCA} TAATGTGCTATCAAGACCAGGAAACAATGAATGTCCATGGGGACATTCATGTCCAGATGGATGTATAACAGGAGTATATA CTGATGCATATCCACTCAATCCCACAGGGAGCATTGTGTCATCTGTCATATTAGACTCACAAAAATCGAGAGTGAACCCA GTCATAACTTACTCAACAGCAACCGAAAGAGTAAACGAGCTGGCCATCCTAAACAGAACACTCTCAGCTGGATATACAAC AACAAGCTGCATTACACACTATAACAAAGGATATTGTTTTCATATAGTAGAAATAAATCATAAAAGCTTAAACACATTTC ^{AACCCATGTTGTTCAAAACAGAGATTCCAAAAAGCTGCAGTTAATCATAATTAACCATAATATGCATCAATCTATCTATA} ATACAAGTATATGATAAGTAATCAGCAATCAGACAATAGACAAAAGGGAAATATAAAAAACTTAGGAGCAAAGCGTGCTC GGGAAATGGACACTGAATCTAACAATGGCACTGTATCTGACATACTCTATCCTGAGTGTCACCTTAACTCTCCTATCGTT AAAGGTAAAATAGCACAATTACACACTATTATGAGTCTACCTCAGCCTTATGATATGGATGACGACTCAATACTAGTTAT CACTAGACAGAAAATAAAACTTAATAAATTGGATAAAAGACAACGATCTATTAGAAGATTAAAATTAATATTAACTGAAA AAGTGAATGACTTAGGAAAATACACATTTATCAGATATCCAGAAATGTCAAAAGAAATGTTCAAATTATATATACCTGGT ATTAACAGTAAAGTGACTGAATTATTACTTAAAGCAGATAGAACATATAGTCAAATGACTGATGGATTAAGAGATCTATG GATTAATGTGCTATCAAAATTAGCCTCAAAAAATGATGGAAGCAATTATGATCTTAATGAAGAAATTAATAATATATCGA AAGTTCACACAACCTATAAATCAGATAAATGGTATAATCCATTCAAAACATGGTTTACTATCAAGTATGATATGAGAAGA TTACAAAAAGCTCGAAATGAGATCACTTTTAATGTTGGGAAGGATTATAACTTGTTAGAAGACCAGAAGAATTTCTTATT GATACATCCAGAATTGGTTTTGATATTAGATAAACAAAACTATAATGGTTATCTAATTACTCCTGAATTAGTATTGATGT ATTGTGACGTAGTCGAAGGCCGATGGAATATAAGTGCATGTGCTAAGTTAGATCCAAAATTACAATCTATGTATCAGAAA GGTAATAACCTGTGGGAAGTGATAGATAAATTGTTTCCAATTATGGGAGAAAAGACATTTGATGTGATATCGTTATTAGA ACCACTTGCATTATCCTTAATTCAAACTCATGATCCTGTTAAACAACTAAGAGGAGCTTTTTTAAATCATGTGTTATCCG AGATGGAATTAATATTTGAATCTAGAGAATCGATTAAGGAATTTCTGAGTGTAGATTACATTGATAAAATTTTAGATATA TTTAATAAGTCTACAATAGATGAAATAGCAGAGATTTTCTCTTTTTTTAGAACATTTGGGCATCCTCCATTAGAAGCTAG TATTGCAGCAGAAAAGGTTAGAAAATATATGTATATTGGAAAACAATTAAAATTTGACACTATTAATAAATGTCATGCTA TCTTCTGTACAATAATAATTAACGGATATAGAGAGAGGCATGGTGGACAGTGGCCTCCTGTGACATTACCTGATCATGCA CACGAATTCATCATAAATGCTTACGGTTCAAACTCTGCGATATCATATGAAAATGCTGTTGATTATTACCAGAGCTTTAT AGGAATAAAATTCAATAAATTCATAGAGCCTCAGTTAGATGAGGATTTGACAATTTATATGAAAGATAAAGCATTATCTC ^{CAAAAAAATCAAATTGGGACACAGTTTATCCTGCATCTAATTTACTGTACCGTACTAACGCATCCAACGAATCACGAAGA} TTAGTTGAAGTATTTATAGCAGATAGTAAATTTGATCCTCATCAGATATTGGATTATGTAGAATCTGGGGACTGGTTAGA TGATCCAGAATTTAATATTTCTTATAGTCTTAAAGAAAAAGAGATCAAACAGGAAGGTAGACTCTTTGCAAAAATGACAT ACAAAATGAGAGCTACACAAGTTTTATCAGAGACACTACTTGCAAATAACATAGGAAAATTCTTTCAAGAAAATGGGATG GTGAAGGGAGAGATTGAATTACTTAAGAGATTAACAACCATATCAATATCAGGAGTTCCACGGTATAATGAAGTGTACAA TAATTCTAAAAGCCATACAGATGACCTTAAAACCTACAATAAAATAAGTAATCTTAATTTGTCTTCTAATCAGAAATCAA AGAAATTTGAATTCAAGTCAACGGATATCTACAATGATGGATACGAGACTGTGAGCTGTTTCCTAACAACAGATCTCAAA AAATACTGTCTTAATTGGAGATATGAATCAACAGCTCTATTTGGAGAAACTTGCAACCAAATATTTGGATTAAATAAATT GTTTAATTGGTTACACCCTCGTCTTGAAGGAAGTACAATCTATGTAGGTGATCCTTACTGTCCTCCATCAGATAAAGAAC ATATATCATTAGAGGATCACCCTGATTCTGGTTTTTACGTTCATAACCCAAGAGGGGGTATAGAAGGATTTTGTCAAAAA TTATGGACACTCATATCTATAAGTGCAATACATCTAGCAGCTGTTAGAATAGGCGTGAGGGTGACTGCAATGGTTCAAGG AGACAATCAAGCTATAGCTGTAACCACAAGAGTACCCAACAATTATGACTACAGAGTTAAGAAGGAGATAGTTTATAAAG ATGTAGTGAGATTTTTTGATTCATTAAGAGAAGTGATGGATGATCTAGGTCATGAACTTAAATTAAATGAAACGATTATA AGTAGCAAGATGTTCATATATAGCAAAAGAATCTATTATGATGGGAGAATTCTTCCTCAAGCTCTAAAAGCATTATCTAG ATGTGTCTTCTGGTCAGAGACAGTAATAGACGAAACAAGATCAGCATCTTCAAATTTGGCAACATCATTTGCAAAAGCAA TTGAGAATGGTTATTCACCTGTTCTAGGATATGCATGCTCAATTTTTAAGAACATTCAACAACTATATATTGCCCTTGGG ATGAATATCAATCCAACTATAACACAGAATATCAGAGATCAGTATTTTAGGAATCCAAATTGGATGCAATATGCCTCTTT AATACCTGCTAGTGTTGGGGGATTCAATTACATGGCCATGTCAAGATGTTTTGTAAGGAATATTGGTGATCCATCAGTTG CCGCATTGGCTGATATTAAAAGATTTATTAAGGCGAATCTATTAGACCGAAGTGTTCTTTATAGGATTATGAATCAAGAA CCAGGTGAGTCATCTTTTTTGGACTGGGCTTCAGATCCATATTCATGCAATTTACCACAATCTCAAAATATAACCACCAT ^{GATAAAAAATATAACAGCAAGGAATGTATTACAAGATTCACCAAATCCATTATTATCTGGATTATTCACAAATACAATGA} TAGAAGAAGATGAAGAATTAGCTGAGTTCCTGATGGACAGGAAGGTAATTCTCCCTAGAGTTGCACATGATATTCTAGAT AATTCTCTCACAGGAATTAGAAATGCCATAGCTGGAATGTTAGATACGACAAAATCACTAATTCGGGTTGGCATAAATAG ^{4239-112370-02} AGGAGGACTGACATATAGTTTGTTGAGGAAAATCAGTAATTACGATCTAGTACAATATGAAACACTAAGTAGGACTTTGC GACTAATTGTAAGTGATAAAATCAAGTATGAAGATATGTGTTCGGTAGACCTTGCCATAGCATTGCGACAAAAGATGTGG ATTCATTTATCAGGAGGAAGGATGATAAGTGGACTTGAAACGCCTGACCCATTAGAATTACTATCTGGGGTAGTAATAAC AGGATCAGAACATTGTAAAATATGTTATTCTTCAGATGGCACAAACCCATATACTTGGATGTATTTACCCGGTAATATCA AAATAGGATCAGCAGAAACAGGTATATCGTCATTAAGAGTTCCTTATTTTGGATCAGTCACTGATGAAAGATCTGAAGCA CAATTAGGATATATCAAGAATCTTAGTAAACCTGCAAAAGCCGCAATAAGAATAGCAATGATATATACATGGGCATTTGG TAATGATGAGATATCTTGGATGGAAGCCTCACAGATAGCACAAACACGTGCAAATTTTACACTAGATAGTCTCAAAATTT TAACACCGGTAGCTACATCAACAAATTTATCACACAGATTAAAGGATACTGCAACTCAGATGAAATTCTCCAGTACATCA TTGATCAGAGTCAGCAGATTCATAACAATGTCCAATGATAACATGTCTATCAAAGAAGCTAATGAAACCAAAGATACTAA TCTTATTTATCAACAAATAATGTTAACAGGATTAAGTGTTTTCGAATATTTATTTAGATTAAAAGAAACCACAGGACACA ACCCTATAGTTATGCATCTGCACATAGAAGATGAGTGTTGTATTAAAGAAAGTTTTAATGATGAACATATTAATCCAGAG TCTACATTAGAATTAATTCGATATCCTGAAAGTAATGAATTTATTTATGATAAAGACCCACTCAAAGATGTGGACTTATC AAAACTTATGGTTATTAAAGACCATTCTTACACAATTGATATGAATTATTGGGATGATACTGACATCATACATGCAATTT CAATATGTACTGCAATTACAATAGCAGATACTATGTCACAATTAGATCGAGATAATTTAAAAGAGATAATAGTTATTGCA ^{AATGATGATGATATTAATAGCTTAATCACTGAATTTTTGACTCTTGACATACTTGTATTTCTCAAGACATTTGGTGGATT} ATTAGTAAATCAATTTGCATACACTCTTTATAGTCTAAAAATAGAAGGTAGGGATCTCATTTGGGATTATATAATGAGAA CACTGAGAGATACTTCCCATTCAATATTAAAAGTATTATCTAATGCATTATCTCATCCTAAAGTATTCAAGAGGTTCTGG GATTGTGGAGTTTTAAACCCTATTTATGGTCCTAATACTGCTAGTCAAGACCAGATAAAACTTGCCCTATCTATATGTGA ATATTCACTAGATCTATTTATGAGAGAATGGTTGAATGGTGTATCACTTGAAATATACATTTGTGACAGCGATATGGAAG ^{TTGCAAATGATAGGAAACAAGCCTTTATTTCTAGACACCTTTCATTTGTTTGTTGTTTAGCAGAAATTGCATCTTTCGGA} CCTAACCTGTTAAACTTAACATACTTGGAGAGACTTGATCTATTGAAACAATATCTTGAATTAAATATTAAAGAAGACCC TACTCTTAAATATGTACAAATATCTGGATTATTAATTAAATCGTTCCCATCAACTGTAACATACGTAAGAAAGACTGCAA TCAAATATCTAAGGATTCGCGGTATTAGTCCACCTGAGGTAATTGATGATTGGGATCCGGTAGAAGATGAAAATATGCTG GATAACATTGTCAAAACTATAAATGATAACTGTAATAAAGATAATAAAGGGAATAAAATTAACAATTTCTGGGGACTAGC ACTTAAGAACTATCAAGTCCTTAAAATCAGATCTATAACAAGTGATTCTGATGATAATGATAGACTAGATGCTAATACAA GTGGTTTGACACTTCCTCAAGGAGGGAATTATCTATCGCATCAATTGAGATTATTCGGAATCAACAGCACTAGTTGTCTG AAAGCTCTTGAGTTATCACAAATTTTAATGAAGGAAGTCAATAAAGACAAGGACAGGCTCTTCCTGGGAGAAGGAGCAGG AGCTATGCTAGCATGTTATGATGCCACATTAGGACCTGCAGTTAATTATTATAATTCAGGTTTGAATATAACAGATGTAA TTGGTCAACGAGAATTGAAAATATTTCCTTCAGAGGTATCATTAGTAGGTAAAAAATTAGGAAATGTGACACAGATTCTT AACAGGGTAAAAGTACTGTTCAATGGGAATCCTAATTCAACATGGATAGGAAATATGGAATGTGAGAGCTTAATATGGAG TGAATTAAATGATAAGTCCATTGGATTAGTACATTGTGATATGGAAGGAGCTATCGGTAAATCAGAAGAAACTGTTCTAC ATGAACATTATAGTGTTATAAGAATTACATACTTGATTGGGGATGATGATGTTGTTTTAGTTTCCAAAATTATACCTACA ATCACTCCGAATTGGTCTAGAATACTTTATCTATATAAATTATATTGGAAAGATGTAAGTATAATATCACTCAAAACTTC TAATCCTGCATCAACAGAATTATATCTAATTTCGAAAGATGCATATTGTACTATAATGGAACCTAGTGAAATTGTTTTAT CAAAACTTAAAAGATTGTCACTCTTGGAAGAAAATAATCTATTAAAATGGATCATTTTATCAAAGAAGAGGAATAATGAA TGGTTACATCATGAAATCAAAGAAGGAGAAAGAGATTATGGAATCATGAGACCATATCATATGGCACTACAAATCTTTGG ATTTCAAATCAATTTAAATCATCTGGCGAAAGAATTTTTATCAACCCCAGATCTGACTAATATCAACAATATAATCCAAA GTTTTCAGCGAACAATAAAGGATGTTTTATTTGAATGGATTAATATAACTCATGATGATAAGAGACATAAATTAGGCGGA AGATATAACATATTCCCACTGAAAAATAAGGGAAAGTTAAGACTGCTATCGAGAAGACTAGTATTAAGTTGGATTTCATT ^{ATCATTATCGACTCGATTACTTACAGGTCGCTTTCCTGATGAAAAATTTGAACATAGAGCACAGACTGGATATGTATCAT} TAGCTGATACTGATTTAGAATCATTAAAGTTATTGTCGAAAAACATCATTAAGAATTACAGAGAGTGTATAGGATCAATA TCATATTGGTTTCTAACCAAAGAAGTTAAAATACTTATGAAATTGATTGGTGGTGCTAAATTATTAGGAATTCCCAGACA ATATAAAGAACCCGAAGACCAGTTATTAGAAAACTACAATCAACATGATGAATTTGATATCGATTAAAACATAAATACAA TGAAGATATATCCTAACCTTTATCTTTAAGCCTAGGAATAGACAAAAAGTAAGAAAAACATGTAATATATATATACCAAA CAGAGTTCTTCTCTTGTTTGGT SEQ ID NO: 30 is an exemplary amino acid sequence of the BPIV3 C protein (encoded by nucleotide 1794-2399 of GENBANK^TM Accession No. AF178654). MFKTIKSWILGKRDQEINHLTSHRPSTSLNSYSAPTPKRTRQTAMKSTQEPQDLARQSTNLNPKQQKQARKIVDQLTKID SLGHHTNVPQRQKIEMLIRRLYREDIGEEAAQIVELRLWSLEESPEAAQILTMEPKSRKILITMKLERWIRTLLRGKCDN LKMFQSRYQEVMPFLQQNKMETVMMEEAWNLSVHLIQDIPV SEQ ID NO: 31 is an exemplary amino acid sequence of the BPIV3 V protein (encoded by nucleotide 1784-3018 of GENBANK^TM Accession No. AF178654 with an inserted nucleotide g between nucleotide 2505-2506 at a gene editing site located at nucleotide 2500-2507). MEDNVQNNQIMDSWEEGSGDKSSDISSALDIIEFILSTDSQENTADSNEINTGTTRLSTTIYQPESKTTETSKENSGPAN KNRQFGASHERATETKDRNVNQETVQGGYRRGSSPDSRTETMVTRRISRSSPDPNNGTQIQEDIDYNEVGEMDKDSTKRE MRQFKDVPVKVSGSDAIPPTKQDGDGDDGRGLESISTFDSGYTSIVTAATLDDEEELLMKNNRPRKYQSTPQNSDKGIKK ^{4239-112370-02} GGWKAKRHRQTIINIGLRTQLQRIEEEPENPQSQHEYRRTNKTTEWIPGEENHILEHPQQRERQSNRINKPNPSDINLGT EPHNGTKQNNLRTKDQDTKDGWKGKRGHRREHSIYRKGDYIITESWCNPICSKIRPIPRQESCVCGECPKQCRYCIKDRL PSRFDDRSVNGS SEQ ID NO: 32 is an exemplary rB/HPIV3/NA antigenomic cDNA sequence. ACCAAACAAGAGAAGAGACTGGTTTGGGAATATTAATTCAAATAAAAATTAACTTAGGATTAAAGAACTTTACCGAAAG GTAAGGGGAAAGAAATCCTAAGAGCTTAGCCATGTTGAGTCTATTCGACACATTCAGTGCGCGTAGGCAGGAGAACATA ACGAAATCAGCTGGTGGGGCTGTTATTCCCGGGCAAAAAAACACTGTGTCTATATTTGCTCTTGGACCATCAATAACAG ATGACAATGATAAAATGACATTGGCTCTTCTCTTTTTGTCTCATTCTTTAGACAATGAAAAGCAGCATGCGCAAAGAGC TGGATTTTTAGTTTCTCTGTTATCAATGGCTTATGCCAACCCAGAATTATATTTAACATCAAATGGTAGTAATGCAGAT GTTAAATATGTTATCTACATGATAGAGAAAGACCCAGGAAGACAGAAATATGGTGGGTTTGTCGTCAAGACTAGAGAGA TGGTTTATGAAAAGACAACTGATTGGATGTTCGGGAGTGATCTTGAGTATGATCAAGACAATATGTTGCAAAATGGTAG AAGCACTTCTACAATCGAGGATCTTGTTCATACTTTTGGATATCCATCGTGTCTTGGAGCCCTTATAATCCAAGTTTGG ATAATACTTGTTAAGGCTATAACCAGTATATCAGGATTGAGGAAAGGATTCTTTACTCGGTTAGAAGCATTTCGACAAG ATGGAACAGTTAAATCCAGTCTAGTGTTGAGCGGTGATGCAGTAGAACAAATTGGATCAATTATGAGGTCCCAACAGAG CTTGGTAACACTCATGGTTGAAACACTGATAACAATGAACACAGGCAGGAATGATCTGACAACAATAGAAAAGAATATA CAGATTGTAGGAAACTACATCAGAGATGCAGGTCTTGCTTCATTTTTCAACACAATCAGATATGGCATTGAGACTAGAA TGGCAGCTCTAACTCTGTCTACCCTTAGACCGGATATCAACAGACTCAAGGCACTGATCGAGTTATATCTATCAAAGGG GCCACGTGCTCCTTTTATATGCATTTTGAGAGATCCCGTGCATGGTGAGTTTGCACCAGGCAACTATCCTGCCCTCTGG AGTTATGCGATGGGTGTAGCAGTTGTACAAAACAAGGCCATGCAACAGTATGTAACAGGAAGGTCTTATCTGGATATTG AAATGTTCCAACTTGGTCAAGCAGTGGCACGTGATGCCGAGTCGCAGATGAGTTCAATATTAGAGGATGAACTGGGGGT CACACAAGAAGCCAAGCAAAGCTTGAAGAAACACATGAAGAACATCAGCAGTTCAGATACAACCTTTCATAAGCCTACA GGGGGATCAGCCATAGAAATGGCGATAGATGAAGAAGCAGGGCAGCCTGAATCCAGAGGAGATCAGGATCAAGGAGATG AGCCTCGGTCATCCATAGTTCCTTATGCATGGGCAGACGAAACCGGGAATGACAATCAAACTGAATCAACTACAGAAAT TGACAGCATCAAAACTGAACAAAGAAACATCAGAGACAGGCTGAACAAAAGACTCAACGAGAAAAGGAAACAGAGTGAC CCGAGATCAACTGACATCACAAACAACACAAATCAAACTGAAATAGATGATTTGTTCAGTGCATTCGGAAGCAACTAGT CACAAAGAGATGACCAGGCGCGCCAAGTAAGAAAAACTTAGGATTAATGGACCTGCAGGATGAATCCCAACCAGAAGAT CCTGTGCACCAGCGCCACAGCCATCACCATCGGCGCCATCACCGTGCTGATCGGCATCGCCAACATCGGCCTGAATATC GGCCTGCACCTGAAGTCTGGCTGCAACTGTTCTAGGAGCCAGCCAGAGACCACAAATCCCAGCCAGACCATCATCAACA ACTACTACAACGAGACAAACATCACCAACATCCAGATGGGCGAGAGGACATCCCGCAACTTCAACAATCTGACAAAGGG CCTGTGCACCATCAACTCTTGGCACATCTACGGCAAGGACAATGCCGTGCGGATCGGAGAGAGCTCCGACGTGCTGGTG ACACGGGAGCCTTACGTGAGCTGCGACCCAGATGAGTGTAGGTTTTATGCCCTGAGCCAGGGAACCACAATCCGGGGCA AGCACTCCAACGGCACAATCCACGACCGGAGCCAGTACAGAGCCCTGATCAGCTGGCCTCTGTCTAGCCCCCCTACCGT GTATAATTCTAGGGTGGAGTGCATCGGCTGGTCCTCTACAAGCTGTCACGATGGCAAGTCCCGCATGTCTATCTGCATC TCCGGCCCCAACAATAACGCCTCTGCCGTGATCTGGTACAACCGGAGACCTGTGGCCGAGATCAACACCTGGGCCAGGA ATATCCTGCGCACACAGGAGTCCGAGTGCGTGTGCCACAACGGCGTGTGCCCAGTGGTGTTCACAGACGGCCCTGCCAC CGGCCCTGCCGATACACGGATCTACTACTTCAAGGAGGGCAAGATCCTGAAGTGGGAGTCCCTGACCGGCACAGCCAAG CACATCGAGGAGTGCTCTTGTTACGGCAAGCGGACCGGCATCACCTGCACCTGTAAGGACAACTGGCAGGGCTCTAATA GACCCGTGATCCAGATCGATCCTGTGGCCATGACCCACACAAGCCAGTATATCTGCTCCCCTGTGCTGACCGACTCCCC ACGGCCCAACGATCCAAATATCGGCAAGTGTAACGACCCTTACCCAGGCAATAACAATAACGGCGTGAAGGGCTTCAGC TATCTGGACGGCGATAATACCTGGCTGGGCCGGACAATCTCCACCGCCTCCAGATCTGGCTACGAGATGCTGAAGGTGC CAAACGCCCTGACCGACGATAGAAGCAAGCCCATCCAGGGCCAGACAATCGTGCTGAATGCCGATTGGTCCGGCTACAG CGGCTCCTTCATGGACTATTGGGCCGAGGGCGATTGCTACAGGGCCTGTTTTTATGTGGAGCTGATCCGGGGCAAGCCA AAGGAGGACAAAGTGTGGTGGACCTCTAACAGCATCGTGAGCATGTGCAGCTCCACAGAGTTCCTGGGCCAGTGGAATT GGCCCGATGGCGCCAAGATCGAGTATTTTCTGTGATAGTGACTAGCGGCGCGCCAGCAACAAGTAAGAAAAACTTAGGA TTAATGGAAATTATCCAATCCAGAGACGGAAGGACAAATCCAGAATCCAACCACAACTCAATCAACCAAAGATTCATGG AAGACAATGTTCAAAACAATCAAATCATGGATTCTTGGGAAGAGGGATCAGGAGATAAATCATCTGACATCTCATCGGC CCTCGACATCATTGAATTCATACTCAGCACCGACTCCCAAGAGAACACGGCAGACAGCAATGAAATCAACACAGGAACC ^{ACAAGACTTAGCACGACAATCTACCAACCTGAATCCAAAACAACAGAAACAAGCAAGGAAAATAGTGGACCAGCTAACA} AAAATCGACAGTTTGGGGCATCACACGAACGTGCCACAGAGACAAAAGATAGAAATGTTAATCAGGAGACTGTACAGGG AGGATATAGGAGAGGAAGCAGCCCAGATAGTAGAACTGAGACTATGGTCACTCGAAGAATCTCCAGAAGCAGCCCAGAT CCTAACAATGGAACCCAAATCCAGGAAGATATTGATTACAATGAAGTTGGAGAGATGGATAAGGACTCTACTAAGAGGG AAATGCGACAATTTAAAGATGTTCCAGTCAAGGTATCAGGAAGTGATGCCATTCCTCCAACAAAACAAGATGGAGACGG TGATGATGGAAGAGGCCTGGAATCTATCAGTACATTTGATTCAGGATATACCAGTATAGTGACTGCCGCAACACTAGAT GACGAAGAAGAACTCCTTATGAAGAACAACAGGCCAAGAAAGTATCAATCAACACCCCAGAACAGTGACAAGGGAATTA AAAAAGGGGTTGGAAGGCCAAAAGACACAGACAAACAATCATCAATATTGGACTACGAACTCAACTTCAAAGGATCGAA GAAGAGCCAGAAAATCCTCAAAGCCAGCACGAATACAGGAGAACCAACAAGACCACAGAATGGATCCCAGGGGAAGAGA ATCACATCCTGGAACATCCTCAACAGCGAGAGCGGCAATCGAACAGAATCAACAAACCAAACCCATCAGACATCAACCT CGGGACAGAACCACACAATGGGACCAAGCAGAACAACCTCCGAACCAAGGATCAAGACACAAAAGACGGATGGAAAGGA AAGAGAGGACACAGAAGAGAGCACTCGATTTACAGAAAGGGCGATTACATTATTACAGAATCTTGGTGTAATCCAATCT ^{4239-112370-02} GCAGCAAAATTAGACCTATACCAAGACAAGAGAGTTGTGTGTGTGGCGAATGTCCTAAACAATGCAGATACTGCATCAA AGATAGACTTCCTAGCAGGTTTGATGATAGGAGTGTCAATGGATCATGATACCAAATTAAATCAGATTCAGAACGAGAT ATTAAGTTTGAAAACTGATCTTAAAAAGATGGATGAATCACATAGAAGACTAATTGAGAATCAAAAAGAACAATTATCA CTGATCACATCATTAATCTCAAATCTTAAAATTATGACAGAGAGAGGAGGGAAGAAGGACCAACCAGAACCTAGCGGGA GGACATCCATGATCAAGACAAAAGCAAAAGAAGAGAAAATAAAGAAAGTCAGGTTTGACCCTCTTATGGAAACACAGGG CATCGAGAAAAACATCCCTGACCTCTATAGATCAATAGAGAAAACACCAGAAAACGACACACAGATCAAATCAGAAATA AACAGATTGAATGATGAATCCAATGCCACTAGATTAGTACCTAGAAGAATAAGCAGTACAATGAGATCATTAATAATAA TCATTAACAACAGCAATTTATCATCAAAAGCAAAGCAATCATACATCAACGAACTCAAGCTCTGCAAGAGTGACGAGGA AGTGTCTGAGTTGATGGACATGTTCAATGAGGATGTCAGCTCCCAGTAAACCGCCAACCAAGGGTCAACACCAAGAAAA CCAATAGCACAAAACAGCCAATCAGAGACCACCCCAATACACCAAACCAATCAACACATAACAAAGATCGCGGCCGCAT AGATGATTAAGAAAAACTTAGGATGAAAGGACTAATCAATCCTCCGAAACAATGAGCATCACCAACTCCACAATCTACA CATTCCCAGAATCCTCTTTCTCCGAGAATGGCAACATAGAGCCGTTACCACTCAAGGTCAATGAACAGAGAAAGGCCAT ACCTCATATTAGGGTTGTCAAGATAGGAGATCCGCCCAAACATGGATCCAGATATCTGGATGTCTTTTTACTGGGCTTC TTTGAGATGGAAAGGTCAAAAGACAGGTATGGGAGCATAAGTGATCTAGATGATGATCCAAGTTACAAGGTTTGTGGCT ^{CTGGATCATTGCCACTTGGGTTGGCTAGATACACCGGAAATGATCAGGAACTCCTACAGGCTGCAACCAAGCTCGATAT} AGAAGTAAGAAGAACTGTAAAGGCTACGGAGATGATAGTTTACACTGTACAAAACATCAAACCTGAACTATATCCATGG TCCAGTAGATTAAGAAAAGGGATGTTATTTGACGCTAATAAGGTTGCACTTGCTCCTCAATGTCTTCCACTAGATAGAG GGATAAAATTCAGGGTGATATTTGTGAACTGCACAGCAATTGGATCAATAACTCTATTCAAAATCCCTAAGTCCATGGC ATTGTTATCATTGCCTAATACAATATCAATAAATCTACAAGTACATATCAAAACAGGAGTTCAGACAGATTCCAAAGGA ^{GTAGTTCAGATTCTAGATGAAAAAGGTGAAAAATCACTAAATTTCATGGTTCATCTCGGGTTGATCAAAAGGAAGATGG} GCAGAATGTACTCAGTTGAATATTGTAAGCAGAAGATCGAGAAGATGAGATTATTATTCTCATTGGGATTAGTTGGAGG GATCAGCTTCCACGTCAACGCAACTGGCTCTATATCAAAGACATTAGCAAGTCAATTAGCATTCAAAAGAGAAATCTGC TATCCCCTAATGGATCTGAATCCACACTTAAATTCAGTTATATGGGCATCATCAGTTGAAATTACAAGGGTAGATGCAG TTCTCCAGCCTTCATTACCTGGCGAATTCAGATACTACCCAAACATCATAGCAAAAGGGGTCGGGAAAATCAGACAGTA AAATCAACAACCCTGATATCCACCGGTGTATTAAGCCGAAGCAAATAAAGGATAATCAAAAACTTAGGACAAAAGAGGT CAATACCAACAACTATTAGCAGTCACACTCGCAAGAATAAGAGAGAAGGGACCAAAAAAGTCAAATAGGAGAAATCAAA ACAAAAGGTACAGAACACCAGAACAACAAAATCAAAACATCCAACTCACTCAAAACAAAAATTCCAAAAGAGACCGGCA ACACAACAAGCACTGAACACAATGCCAACTTCAATACTGCTAATTATTACAACCATGATCATGGCATCTTTCTGCCAAA TAGATATCACAAAACTACAGCACGTAGGTGTATTGGTCAACAGTCCCAAAGGGATGAAGATATCACAAAACTTTGAAAC AAGATATCTAATTTTGAGCCTCATACCAAAAATAGAAGACTCTAACTCTTGTGGTGACCAACAGATCAAGCAATACAAG AAGTTATTGGATAGACTGATCATCCCTTTATATGATGGATTAAGATTACAGAAAGATGTGATAGTAACCAATCAAGAAT CCAATGAAAACACTGATCCCAGAACAAAACGATTCTTTGGAGGGGTAATTGGAACCATTGCTCTGGGAGTAGCAACCTC AGCACAAATTACAGCGGCAGTTGCTCTGGTTGAAGCCAAGCAGGCAAGATCAGACATCGAAAAACTCAAAGAAGCAATT AGGGACACAAACAAAGCAGTGCAGTCAGTTCAGAGCTCCATAGGAAATTTAATAGTAGCAATTAAATCAGTCCAGGATT ATGTTAACAAAGAAATCGTGCCATCGATTGCGAGGCTAGGTTGTGAAGCAGCAGGACTTCAATTAGGAATTGCATTAAC ACAGCATTACTCAGAATTAACAAACATATTTGGTGATAACATAGGATCGTTACAAGAAAAAGGAATAAAATTACAAGGT ATAGCATCATTATACCGCACAAATATCACAGAAATATTCACAACATCAACAGTTGATAAATATGATATCTATGATCTGT TATTTACAGAATCAATAAAGGTGAGAGTTATAGATGTTGACTTGAATGATTACTCAATCACCCTCCAAGTCAGACTCCC TTTATTAACTAGGCTGCTGAACACTCAGATCTACAAAGTAGATTCCATATCATATAACATCCAAAACAGAGAATGGTAT ^{ATCCCTCTTCCCAGCCATATCATGACGAAAGGGGCATTTCTAGGTGGAGCAGACGTCAAAGAATGTATAGAAGCATTCA} GCAGCTATATATGCCCTTCTGATCCAGGATTTGTATTAAACCATGAAATAGAGAGCTGCTTATCAGGAAACATATCCCA ATGTCCAAGAACAACGGTCACATCAGACATTGTTCCAAGATATGCATTTGTCAATGGAGGAGTGGTTGCAAACTGTATA ACAACCACCTGTACATGCAACGGAATTGGTAATAGAATCAATCAACCACCTGATCAAGGAGTAAAAATTATAACACATA AAGAATGTAGTACAATAGGTATCAACGGAATGCTGTTCAATACAAATAAAGAAGGAACTCTTGCATTCTATACACCAAA TGATATAACACTAAACAATTCTGTTGCACTTGATCCAATTGACATATCAATCGAGCTCAACAAGGCCAAATCAGATCTA GAAGAATCAAAAGAATGGATAAGAAGGTCAAATCAAAAACTAGATTCTATTGGAAATTGGCATCAATCTAGCACTACAA TCATAATTATTTTGATAATGATCATTATATTGTTTATAATTAATATAACGATAATTACAATTGCAATTAAGTATTACAG AATTCAAAAGAGAAATCGAGTGGATCAAAATGACAAGCCATATGTACTAACAAACAAATAACATATCTACAGATCATTA GATATTAAAATTATAAAAAACTTAGGAGTAAAGTTACGCAATCCAACTCTACTCATATAATTGAGGAAGGACCCAATAG ACAAATCCAAATTCGAGATGGAATACTGGAAGCATACCAATCACGGAAAGGATGCTGGTAATGAGCTGGAGACGTCTAT GGCTACTCATGGCAACAAGCTCACTAATAAGATAATATACATATTATGGACAATAATCCTGGTGTTATTATCAATAGTC TTCATCATAGTGCTAATTAATTCCATCAAAAGTGAAAAGGCCCACGAATCATTGCTGCAAGACATAAATAATGAGTTTA TGGAAATTACAGAAAAGATCCAAATGGCATCGGATAATACCAATGATCTAATACAGTCAGGAGTGAATACAAGGCTTCT TACAATTCAGAGTCATGTCCAGAATTACATACCAATATCATTGACACAACAGATGTCAGATCTTAGGAAATTCATTAGT GAAATTACAATTAGAAATGATAATCAAGAAGTGCTGCCACAAAGAATAACACATGATGTAGGTATAAAACCTTTAAATC CAGATGATTTTTGGAGATGCACGTCTGGTCTTCCATCTTTAATGAAAACTCCAAAAATAAGGTTAATGCCAGGGCCGGG ATTATTAGCTATGCCAACGACTGTTGATGGCTGTGTTAGAACTCCGTCTTTAGTTATAAATGATCTGATTTATGCTTAT ACCTCAAATCTAATTACTCGAGGTTGTCAGGATATAGGAAAATCATATCAAGTCTTACAGATAGGGATAATAACTGTAA ACTCAGACTTGGTACCTGACTTAAATCCTAGGATCTCTCATACCTTTAACATAAATGACAATAGGAAGTCATGTTCTCT ^{AGCACTCCTAAATATAGATGTATATCAACTGTGTTCAACTCCCAAAGTTGATGAAAGATCAGATTATGCATCATCAGGC} ATAGAAGATATTGTACTTGATATTGTCAATTATGATGGTTCAATCTCAACAACAAGATTTAAGAATAATAACATAAGCT TTGATCAACCATATGCTGCACTATACCCATCTGTTGGACCAGGGATATACTACAAAGGCAAAATAATATTTCTCGGGTA ^{4239-112370-02} TGGAGGTCTTGAACATCCAATAAATGAGAATGTAATCTGCAACACAACTGGGTGCCCCGGGAAAACACAGAGAGACTGT AATCAAGCATCTCATAGTACTTGGTTTTCAGATAGGAGGATGGTCAACTCCATCATTGTTGTTGACAAAGGCTTAAACT CAATTCCAAAATTGAAAGTATGGACGATATCTATGCGACAAAATTACTGGGGGTCAGAAGGAAGGTTACTTCTACTAGG TAACAAGATCTATATATATACAAGATCTACAAGTTGGCATAGCAAGTTACAATTAGGAATAATTGATATTACTGATTAC AGTGATATAAGGATAAAATGGACATGGCATAATGTGCTATCAAGACCAGGAAACAATGAATGTCCATGGGGACATTCAT GTCCAGATGGATGTATAACAGGAGTATATACTGATGCATATCCACTCAATCCCACAGGGAGCATTGTGTCATCTGTCAT ATTAGACTCACAAAAATCGAGAGTGAACCCAGTCATAACTTACTCAACAGCAACCGAAAGAGTAAACGAGCTGGCCATC CTAAACAGAACACTCTCAGCTGGATATACAACAACAAGCTGCATTACACACTATAACAAAGGATATTGTTTTCATATAG TAGAAATAAATCATAAAAGCTTAAACACATTTCAACCCATGTTGTTCAAAACAGAGATTCCAAAAAGCTGCAGTTAATC ATAATTAACCATAATATGCATCAATCTATCTATAATACAAGTATATGATAAGTAATCAGCAATCAGACAATAGACGTAC GGAAATAATAAAAAACTTAGGAGAAAAGTGTGCAAGAAAAATGGACACCGAGTCCCACAGCGGCACAACATCTGACATT CTGTACCCTGAATGTCACCTCAATTCTCCTATAGTTAAAGGAAAGATAGCACAACTGCATACAATAATGAGTTTGCCTC AGCCCTACGATATGGATGATGATTCAATACTGATTATTACTAGACAAAAAATTAAACTCAATAAATTAGATAAAAGACA ACGGTCAATTAGGAAATTAAGATCAGTCTTAATGGAAAGAGTAAGTGATCTAGGTAAATATACCTTTATCAGATATCCA ^{GAGATGTCTAGTGAAATGTTCCAATTATGTATACCCGGAATTAATAATAAAATAAATGAATTGCTAAGTAAAGCAAGTA} AAACATATAATCAAATGACTGATGGATTAAGAGATCTATGGGTTACTATACTATCGAAGTTAGCATCGAAAAATGATGG AAGTAATTATGATATCAATGAAGATATTAGCAATATATCAAATGTTCACATGACTTATCAATCAGACAAATGGTATAAT CCATTCAAGACATGGTTTACTATTAAGTATGACATGAGAAGATTACAAAAAGCCAAAAATGAGATTACATTCAATAGGC ATAAAGATTATAATCTATTAGAAGACCAAAAGAATATATTGCTGATACATCCAGAACTCGTCTTAATATTAGATAAACA ^{AAATTACAATGGGTATATAATGACTCCTGAATTGGTACTAATGTATTGTGATGTAGTTGAAGGGAGGTGGAATATAAGT} TCATGTGCAAAATTGGATCCTAAGTTACAATCAATGTATTATAAGGGTAACAATTTATGGGAAATAATAGATGGACTAT TCTCGACCTTAGGAGAAAGAACATTTGACATAATATCACTATTAGAACCACTTGCATTATCGCTCATTCAAACTTATGA CCCGGTTAAACAGCTCAGGGGGGCTTTTTTAAATCACGTGTTATCAGAAATGGAATTAATATTTGCAGCTGAGTGTACA ACAGAGGAAATACCTAATGTGGATTATATAGATAAAATTTTAGATGTGTTCAAAGAATCAACAATAGATGAAATAGCAG AAATTTTCTCTTTCTTCCGAACTTTTGGACACCCTCCATTAGAGGCGAGTATAGCAGCAGAGAAAGTTAGAAAGTATAT GTATACTGAGAAATGCTTGAAATTTGATACTATCAATAAATGTCATGCTATTTTTTGTACAATAATTATAAATGGATAT AGAGAAAGACATGGTGGTCAATGGCCTCCAGTTACATTACCTGTCCATGCACATGAATTTATCATAAATGCATACGGAT CAAATTCTGCCATATCATATGAGAATGCTGTAGATTATTATAAGAGCTTCATAGGAATAAAATTTGACAAGTTTATAGA GCCTCAATTGGATGAAGACTTAACTATTTATATGAAAGATAAAGCATTATCCCCAAAGAAATCAAACTGGGACACAGTC TATCCAGCTTCAAACCTGTTATACCGCACTAATGTGTCTCATGATTCACGAAGATTGGTTGAAGTATTTATAGCAGATA GTAAATTTGATCCCCACCAAGTATTAGATTACGTAGAATCAGGATATTGGCTGGATGATCCTGAATTTAATATCTCATA TAGTTTAAAAGAGAAAGAAATAAAACAAGAAGGTAGACTTTTTGCAAAAATGACATACAAGATGAGGGCTACACAAGTA TTATCAGAAACATTATTGGCGAATAATATAGGGAAATTCTTCCAAGAGAATGGGATGGTTAAAGGAGAAATTGAATTAC TCAAGAGACTAACAACAATATCTATGTCTGGAGTTCCGCGGTATAATGAGGTATACAATAATTCAAAAAGTCACACAGA AGAACTTCAAGCTTATAATGCAATTAGCAGTTCCAATTTATCTTCTAATCAGAAGTCAAAGAAGTTTGAATTTAAATCT ACAGATATATACAATGATGGATACGAAACCGTAAGCTGCTTCTTAACGACAGATCTTAAAAAATATTGTTTAAATTGGA GGTATGAATCAACAGCTTTATTCGGTGATACTTGTAATCAGATATTTGGGTTAAAGGAATTATTTAATTGGCTGCACCC TCGCCTTGAAAAGAGTACAATATATGTTGGAGATCCTTATTGCCCGCCATCAGATATTGAACATTTACCACTTGATGAC CATCCTGATTCAGGATTTTATGTTCATAATCCTAAAGGAGGAATAGAAGGGTTTTGCCAAAAGTTATGGACACTCATAT ^{CTATCAGTGCAATACATTTAGCAGCTGTCAAAATCGGTGTAAGAGTTACTGCAATGGTTCAAGGGGATAATCAAGCCAT} AGCTGTTACCACAAGAGTACCTAATAATTATGATTATAAAGTTAAGAAAGAGATTGTTTATAAAGATGTGGTAAGATTT TTTGATTCCTTGAGAGAGGTGATGGATGATCTGGGTCATGAGCTCAAACTAAATGAAACTATAATAAGTAGTAAAATGT TTATATATAGCAAAAGGATATACTATGACGGAAGAATCCTTCCTCAGGCATTAAAAGCATTGTCTAGATGTGTTTTTTG GTCTGAAACAATCATAGATGAGACAAGATCAGCATCCTCAAATCTGGCTACATCGTTTGCAAAGGCCATTGAGAATGGC TACTCACCTGTATTGGGATATGTATGCTCAATCTTCAAAAATATCCAACAGTTGTATATAGCGCTTGGAATGAATATAA ACCCAACTATAACCCAAAATATTAAAGATCAATATTTCAGGAATATTCATTGGATGCAATATGCCTCCTTAATCCCTGC TAGTGTCGGAGGATTTAATTATATGGCCATGTCAAGGTGTTTTGTCAGAAACATTGGAGATCCTACAGTCGCTGCGTTA GCCGATATTAAAAGATTTATAAAAGCAAATTTGTTAGATCGAGGTGTCCTTTACAGAATTATGAATCAAGAACCAGGCG AGTCTTCTTTTTTAGACTGGGCCTCAGATCCCTATTCATGTAACTTACCACAATCTCAAAATATAACCACCATGATAAA GAATATAACTGCAAGAAATGTACTACAGGACTCACCAAACCCATTACTATCTGGATTATTTACAAGTACAATGATAGAA GAGGATGAGGAATTAGCTGAGTTCCTAATGGACAGGAGAATAATCCTCCCAAGAGTTGCACATGACATTTTAGATAATT CTCTTACTGGAATTAGGAATGCTATAGCTGGTATGTTGGATACAACAAAATCACTAATTCGAGTAGGGATAAGCAGAGG AGGATTAACCTATAACTTATTAAGAAAGATAAGCAACTATGATCTTGTACAATATGAGACACTTAGTAAAACTTTAAGA CTAATAGTCAGTGACAAGATTAAGTATGAAGATATGTGCTCAGTAGACCTAGCCATATCATTAAGACAAAAAATGTGGA TGCATTTATCAGGAGGAAGAATGATAAATGGACTTGAAACTCCAGATCCTTTAGAGTTACTGTCTGGAGTAATAATAAC AGGATCTGAACATTGTAGGATATGTTATTCAACTGAAGGTGAAAGCCCATATACATGGATGTATTTACCAGGCAATCTT AATATAGGATCAGCTGAGACAGGAATAGCATCATTAAGGGTCCCTTACTTTGGATCAGTTACAGATGAGAGATCTGAAG CACAATTAGGGTATATCAAAAATCTAAGCAAACCAGCTAAGGCTGCTATAAGAATAGCAATGATATATACTTGGGCATT TGGGAATGACGAAATATCTTGGATGGAAGCATCACAGATTGCACAAACACGTGCAAACTTTACATTGGATAGCTTAAAG ^{ATTTTGACACCAGTGACAACATCAACAAATCTATCACACAGGTTAAAAGATACTGCTACTCAGATGAAATTTTCTAGTA} CATCACTTATTAGAGTAAGCAGGTTCATCACAATATCTAATGATAATATGTCTATTAAAGAAGCAAATGAAACTAAAGA TACAAATCTTATTTATCAACAGGTAATGTTAACAGGATTAAGTGTATTTGAATATCTATTTAGGTTAGAGGAGAGTACA ^{4239-112370-02} GGACATAACCCTATGGTCATGCATCTACATATAGAGGATGGATGTTGTATAAAAGAGAGTTACAATGATGAGCATATCA ATCCGGAGTCTACATTAGAGTTAATCAAATACCCTGAGAGTAATGAATTTATATATGATAAGGACCCTTTAAAGGATAT AGATCTATCAAAATTAATGGTTATAAGAGATCATTCTTATACAATTGACATGAATTACTGGGATGACACAGATATTGTA CATGCAATATCAATATGTACTGCAGTTACAATAGCAGATACAATGTCGCAGCTAGATCGGGATAATCTTAAGGAGCTGG TTGTGATTGCAAATGATGATGATATTAACAGTCTGATAACTGAATTTCTGACCCTAGATATACTAGTGTTTCTCAAAAC ATTTGGAGGGTTACTCGTGAATCAATTTGCATATACCCTTTATGGATTGAAAATAGAAGGAAGGGATCCCATTTGGGAT TATATAATGAGAACATTAAAAGACACCTCACATTCAGTACTTAAAGTATTATCTAATGCACTATCTCATCCAAAAGTGT TTAAGAGATTTTGGGATTGTGGAGTTTTGAATCCTATTTATGGTCCTAATACTGCTAGTCAAGATCAAGTTAAGCTTGC TCTCTCGATTTGCGAGTACTCCTTGGATCTATTTATGAGAGAATGGTTGAATGGAGCATCACTTGAGATCTATATCTGT GATAGTGACATGGAAATAGCAAATGACAGAAGACAAGCATTTCTCTCAAGACATCTTGCCTTTGTGTGTTGTTTAGCAG AGATAGCATCTTTTGGACCAAATTTATTAAATCTAACATATCTAGAGAGACTTGATGAATTAAAACAATACTTAGATCT GAACATCAAAGAAGATCCTACTCTTAAATATGTGCAAGTATCAGGACTGTTAATTAAATCATTCCCCTCAACTGTTACG TATGTAAGGAAAACTGCGATTAAGTATCTGAGGATTCGTGGTATTAATCCGCCTGAAACGATTGAAGATTGGGATCCCA TAGAAGATGAGAATATCTTAGACAATATTGTTAAAACTGTAAATGACAATTGCAGTGATAATCAAAAGAGAAATAAAAG ^{TAGTTATTTCTGGGGATTAGCTCTAAAGAATTATCAAGTCGTGAAAATAAGATCCATAACGAGTGATTCTGAAGTTAAT} GAAGCTTCGAATGTTACTACACATGGAATGACACTTCCTCAGGGAGGAAGTTATCTATCACATCAGCTGAGGTTATTTG GAGTAAACAGTACAAGTTGTCTTAAAGCTCTTGAATTATCACAAATCTTAATGAGGGAAGTTAAAAAAGATAAAGATAG ACTCTTTTTAGGAGAAGGAGCAGGAGCTATGTTAGCATGTTATGATGCTACACTCGGTCCTGCAATAAATTATTATAAT TCTGGTTTAAATATTACAGATGTAATTGGTCAACGGGAATTAAAAATCTTCCCATCAGAAGTATCATTAGTAGGTAAAA ^{AACTAGGAAATGTAACACAGATTCTTAATCGGGTGAGGGTGTTATTTAATGGGAATCCCAATTCAACATGGATAGGAAA} TATGGAATGTGAGAGTTTAATATGGAGTGAATTAAATGATAAGTCAATTGGTTTAGTACATTGTGACATGGAGGGAGCG ATAGGCAAATCAGAAGAAACTGTTCTACATGAACATTATAGTATTATTAGGATTACATATTTAATCGGGGATGATGATG TTGTCCTAGTATCAAAAATTATACCAACTATTACTCCGAATTGGTCTAAAATACTCTATCTATACAAGTTGTATTGGAA GGATGTAAGTGTAGTGTCCCTTAAAACATCCAATCCTGCCTCAACAGAGCTTTATTTAATTTCAAAAGATGCTTACTGT ACTGTAATGGAACCCAGTAATCTTGTTTTATCAAAACTTAAAAGGATATCATCAATAGAAGAAAATAATCTATTAAAGT GGATAATCTTATCAAAAAGGAAGAATAACGAGTGGTTACAGCATGAAATCAAAGAAGGAGAAAGGGATTATGGGATAAT GAGGCCATATCATACAGCACTGCAAATTTTTGGATTCCAAATTAACTTAAATCACTTAGCTAGAGAATTTTTATCAACT CCTGATTTAACCAACATTAATAATATAATTCAAAGTTTTACAAGAACAATTAAAGATGTTATGTTCGAATGGGTCAATA TCACTCATGACAATAAAAGACATAAATTAGGAGGAAGATATAATCTATTCCCGCTTAAAAATAAGGGGAAATTAAGATT ATTATCACGAAGATTAGTACTAAGCTGGATATCATTATCCTTATCAACCAGATTACTGACGGGCCGTTTTCCAGATGAA AAATTTGAAAATAGGGCACAGACCGGATATGTATCATTGGCTGATATTGATTTAGAATCCTTAAAGTTATTATCAAGAA ATATTGTCAAAAATTACAAAGAACACATAGGATTAATATCATACTGGTTTTTGACCAAAGAGGTCAAAATACTAATGAA GCTTATAGGAGGAGTCAAACTACTAGGAATTCCTAAACAGTACAAAGAGTTAGAGGATCGATCATCTCAGGGTTATGAA TATGATAATGAATTTGATATTGATTAATACATAAAAACATAAAATAAAACACCTATTCCTCACCCATTCACTTCCAACA AAATGAAAAGTAAGAAAAACATGTAATATATATATACCAAACAGAGTTTTTCTCTTGTTTGGT SEQ ID NO: 33 is an exemplary rB/HPIV3/HA-TMCT antigenomic cDNA sequence. ACCAAACAAGAGAAGAGACTGGTTTGGGAATATTAATTCAAATAAAAATTAACTTAGGATTAAAGAACTTTACCGAAAG GTAAGGGGAAAGAAATCCTAAGAGCTTAGCCATGTTGAGTCTATTCGACACATTCAGTGCGCGTAGGCAGGAGAACATA ACGAAATCAGCTGGTGGGGCTGTTATTCCCGGGCAAAAAAACACTGTGTCTATATTTGCTCTTGGACCATCAATAACAG ATGACAATGATAAAATGACATTGGCTCTTCTCTTTTTGTCTCATTCTTTAGACAATGAAAAGCAGCATGCGCAAAGAGC TGGATTTTTAGTTTCTCTGTTATCAATGGCTTATGCCAACCCAGAATTATATTTAACATCAAATGGTAGTAATGCAGAT GTTAAATATGTTATCTACATGATAGAGAAAGACCCAGGAAGACAGAAATATGGTGGGTTTGTCGTCAAGACTAGAGAGA TGGTTTATGAAAAGACAACTGATTGGATGTTCGGGAGTGATCTTGAGTATGATCAAGACAATATGTTGCAAAATGGTAG AAGCACTTCTACAATCGAGGATCTTGTTCATACTTTTGGATATCCATCGTGTCTTGGAGCCCTTATAATCCAAGTTTGG ATAATACTTGTTAAGGCTATAACCAGTATATCAGGATTGAGGAAAGGATTCTTTACTCGGTTAGAAGCATTTCGACAAG ATGGAACAGTTAAATCCAGTCTAGTGTTGAGCGGTGATGCAGTAGAACAAATTGGATCAATTATGAGGTCCCAACAGAG CTTGGTAACACTCATGGTTGAAACACTGATAACAATGAACACAGGCAGGAATGATCTGACAACAATAGAAAAGAATATA CAGATTGTAGGAAACTACATCAGAGATGCAGGTCTTGCTTCATTTTTCAACACAATCAGATATGGCATTGAGACTAGAA ^{TGGCAGCTCTAACTCTGTCTACCCTTAGACCGGATATCAACAGACTCAAGGCACTGATCGAGTTATATCTATCAAAGGG} GCCACGTGCTCCTTTTATATGCATTTTGAGAGATCCCGTGCATGGTGAGTTTGCACCAGGCAACTATCCTGCCCTCTGG AGTTATGCGATGGGTGTAGCAGTTGTACAAAACAAGGCCATGCAACAGTATGTAACAGGAAGGTCTTATCTGGATATTG AAATGTTCCAACTTGGTCAAGCAGTGGCACGTGATGCCGAGTCGCAGATGAGTTCAATATTAGAGGATGAACTGGGGGT CACACAAGAAGCCAAGCAAAGCTTGAAGAAACACATGAAGAACATCAGCAGTTCAGATACAACCTTTCATAAGCCTACA GGGGGATCAGCCATAGAAATGGCGATAGATGAAGAAGCAGGGCAGCCTGAATCCAGAGGAGATCAGGATCAAGGAGATG AGCCTCGGTCATCCATAGTTCCTTATGCATGGGCAGACGAAACCGGGAATGACAATCAAACTGAATCAACTACAGAAAT TGACAGCATCAAAACTGAACAAAGAAACATCAGAGACAGGCTGAACAAAAGACTCAACGAGAAAAGGAAACAGAGTGAC CCGAGATCAACTGACATCACAAACAACACAAATCAAACTGAAATAGATGATTTGTTCAGTGCATTCGGAAGCAACTAGT CACAAAGAGATGACCAGGCGCGCCAAGTAAGAAAAACTTAGGATTAATGGACCTGCAGGATGAACACCCAGATCCTGGT GTTCGCCCTGATCGCCATCATCCCAACAAATGCCGATAAGATCTGTCTGGGCCACCACGCCGTGTCTAACGGCACCAAA GTGAATACCCTGACAGAGAGGGGAGTGGAGGTGGTGAACGCAACCGAGACAGTGGAGAGAACCAATACACCCAGGATCT GCTCCAAGGGCAAGCGGACAGTGGACCTGGGACAGTGTGGACTGCTGGGAACCATCACAGGCCCACCTCAGTGCGATCA ^{4239-112370-02} GTTCCTGGAGTTTAGCGCCGACCTGATCATCGAGCGGAGAGAGGGCTCCGACGTGTGCTACCCCGGCAAGTTCGTGAAC GAGGAGGCCCTGAGGCAGATCCTGAGGGAGAGCGGCGGAATCGACAAGGAGCCTATGGGCTTTACCTACAACGGCATCC GCACCAATGGCGTGACCAGCGCCTGCCGGCGGAGCGGCAGCTCCTTCTATGCAGAGATGAAGTGGCTGCTGTCCAACAC AGACAATGCCGCCTTTCCCCAGATGACCAAGTCCTATAAGAACACAAAGGAGTCTCCTGCCATCATCGTGTGGGGAATC CACCACAGCGTGTCCACCGCCGAGCAGACAAAGCTGTACGGCAGCGGCAACAAGCTGGTGACAGTGGGCTCTAGCAATT ATCAGCAGTCCTTCGTGCCATCTCCCGGCGCCCGCCCTCAGGTGAACGGACAGTCCGGCCGGATCGATTTTCACTGGCT GATCCTGAACCCTAATGACACCGTGACATTCTCTTTTAATGGAGCCTTCATCGCCCCAGATAGGGCCAGCTTTCTGCGG GGCAAGAGCATGGGCATCCAGTCTCGCGTGCAGGTGGATGCCAACTGCGAGGGCGACTGTTACCACAGCGGCGGCACCA TCATCTCCAACCTGCCATTCCAGAATATCGACAGCCGGGCCGTGGGCAAGTGTCCCAGATATGTGAAGCAGAGGTCTCT GCTGCTGGCCACCGGCATGAAGAATGTGCCTGAGGTGCCAAAGCGGAAGAGAACAGCCAGAGGCCTGTTCGGAGCAATC GCAGGCTTTATCGAGAACGGCTGGGAGGGCCTGATCGATGGCTGGTACGGCTTTAGGCACCAGAATGCACAGGGAGAGG GAACCGCCGCCGATTATAAGTCTACACAGAGCGCCATCGACCAGATCACCGGCAAGCTGAACAGACTGATCGCCAAGAC AAATCAGCAGTTCAAGCTGATCGATAACGAGTTTAATGAGGTGGAGAAGCAGATCGGCAACGTGATCAATTGGACCAGG GACTCTATCACAGAAGTGTGGAGCTACAACGCCGAGCTGCTGGTGGCTATGGAGAATCAGCACACCATCGATCTGGCCG ^{ACAGCGAGATGGATAAGCTGTATGAGAGGGTGAAGAGGCAGCTGAGGGAGAACGCAGAGGAGGACGGAACCGGCTGCTT} CGAGATCTTTCACAAGTGCGACGATGACTGTATGGCCTCCATCAGAAACAATACATACGACCACAGAAAGTATAGGGAG GAGGCCATGCAGAATAGGATCCAGATCGATCCCGTGAAGCTGTCCTCTGGCTACAAGGACATCACCATCATTATCGTGA TGATTATCATTCTGGTCATCATTAACATCACAATCATTGTGGTCATCATTAAGTTCCACCGGATTCAGGGCAAGGACCA GAACGATAAAAATAGCGAGCCCTACATCCTGACCAATAGACAGTGATAGCTAGCGGCGCGCCAGCAACAAGTAAGAAAA ^{ACTTAGGATTAATGGAAATTATCCAATCCAGAGACGGAAGGACAAATCCAGAATCCAACCACAACTCAATCAACCAAAG} ATTCATGGAAGACAATGTTCAAAACAATCAAATCATGGATTCTTGGGAAGAGGGATCAGGAGATAAATCATCTGACATC TCATCGGCCCTCGACATCATTGAATTCATACTCAGCACCGACTCCCAAGAGAACACGGCAGACAGCAATGAAATCAACA CAGGAACCACAAGACTTAGCACGACAATCTACCAACCTGAATCCAAAACAACAGAAACAAGCAAGGAAAATAGTGGACC AGCTAACAAAAATCGACAGTTTGGGGCATCACACGAACGTGCCACAGAGACAAAAGATAGAAATGTTAATCAGGAGACT GTACAGGGAGGATATAGGAGAGGAAGCAGCCCAGATAGTAGAACTGAGACTATGGTCACTCGAAGAATCTCCAGAAGCA GCCCAGATCCTAACAATGGAACCCAAATCCAGGAAGATATTGATTACAATGAAGTTGGAGAGATGGATAAGGACTCTAC TAAGAGGGAAATGCGACAATTTAAAGATGTTCCAGTCAAGGTATCAGGAAGTGATGCCATTCCTCCAACAAAACAAGAT GGAGACGGTGATGATGGAAGAGGCCTGGAATCTATCAGTACATTTGATTCAGGATATACCAGTATAGTGACTGCCGCAA CACTAGATGACGAAGAAGAACTCCTTATGAAGAACAACAGGCCAAGAAAGTATCAATCAACACCCCAGAACAGTGACAA GGGAATTAAAAAAGGGGTTGGAAGGCCAAAAGACACAGACAAACAATCATCAATATTGGACTACGAACTCAACTTCAAA GGATCGAAGAAGAGCCAGAAAATCCTCAAAGCCAGCACGAATACAGGAGAACCAACAAGACCACAGAATGGATCCCAGG GGAAGAGAATCACATCCTGGAACATCCTCAACAGCGAGAGCGGCAATCGAACAGAATCAACAAACCAAACCCATCAGAC ATCAACCTCGGGACAGAACCACACAATGGGACCAAGCAGAACAACCTCCGAACCAAGGATCAAGACACAAAAGACGGAT GGAAAGGAAAGAGAGGACACAGAAGAGAGCACTCGATTTACAGAAAGGGCGATTACATTATTACAGAATCTTGGTGTAA TCCAATCTGCAGCAAAATTAGACCTATACCAAGACAAGAGAGTTGTGTGTGTGGCGAATGTCCTAAACAATGCAGATAC TGCATCAAAGATAGACTTCCTAGCAGGTTTGATGATAGGAGTGTCAATGGATCATGATACCAAATTAAATCAGATTCAG AACGAGATATTAAGTTTGAAAACTGATCTTAAAAAGATGGATGAATCACATAGAAGACTAATTGAGAATCAAAAAGAAC AATTATCACTGATCACATCATTAATCTCAAATCTTAAAATTATGACAGAGAGAGGAGGGAAGAAGGACCAACCAGAACC TAGCGGGAGGACATCCATGATCAAGACAAAAGCAAAAGAAGAGAAAATAAAGAAAGTCAGGTTTGACCCTCTTATGGAA ^{ACACAGGGCATCGAGAAAAACATCCCTGACCTCTATAGATCAATAGAGAAAACACCAGAAAACGACACACAGATCAAAT} CAGAAATAAACAGATTGAATGATGAATCCAATGCCACTAGATTAGTACCTAGAAGAATAAGCAGTACAATGAGATCATT AATAATAATCATTAACAACAGCAATTTATCATCAAAAGCAAAGCAATCATACATCAACGAACTCAAGCTCTGCAAGAGT GACGAGGAAGTGTCTGAGTTGATGGACATGTTCAATGAGGATGTCAGCTCCCAGTAAACCGCCAACCAAGGGTCAACAC CAAGAAAACCAATAGCACAAAACAGCCAATCAGAGACCACCCCAATACACCAAACCAATCAACACATAACAAAGATCGC GGCCGCATAGATGATTAAGAAAAACTTAGGATGAAAGGACTAATCAATCCTCCGAAACAATGAGCATCACCAACTCCAC AATCTACACATTCCCAGAATCCTCTTTCTCCGAGAATGGCAACATAGAGCCGTTACCACTCAAGGTCAATGAACAGAGA AAGGCCATACCTCATATTAGGGTTGTCAAGATAGGAGATCCGCCCAAACATGGATCCAGATATCTGGATGTCTTTTTAC TGGGCTTCTTTGAGATGGAAAGGTCAAAAGACAGGTATGGGAGCATAAGTGATCTAGATGATGATCCAAGTTACAAGGT TTGTGGCTCTGGATCATTGCCACTTGGGTTGGCTAGATACACCGGAAATGATCAGGAACTCCTACAGGCTGCAACCAAG CTCGATATAGAAGTAAGAAGAACTGTAAAGGCTACGGAGATGATAGTTTACACTGTACAAAACATCAAACCTGAACTAT ATCCATGGTCCAGTAGATTAAGAAAAGGGATGTTATTTGACGCTAATAAGGTTGCACTTGCTCCTCAATGTCTTCCACT AGATAGAGGGATAAAATTCAGGGTGATATTTGTGAACTGCACAGCAATTGGATCAATAACTCTATTCAAAATCCCTAAG TCCATGGCATTGTTATCATTGCCTAATACAATATCAATAAATCTACAAGTACATATCAAAACAGGAGTTCAGACAGATT CCAAAGGAGTAGTTCAGATTCTAGATGAAAAAGGTGAAAAATCACTAAATTTCATGGTTCATCTCGGGTTGATCAAAAG GAAGATGGGCAGAATGTACTCAGTTGAATATTGTAAGCAGAAGATCGAGAAGATGAGATTATTATTCTCATTGGGATTA GTTGGAGGGATCAGCTTCCACGTCAACGCAACTGGCTCTATATCAAAGACATTAGCAAGTCAATTAGCATTCAAAAGAG AAATCTGCTATCCCCTAATGGATCTGAATCCACACTTAAATTCAGTTATATGGGCATCATCAGTTGAAATTACAAGGGT AGATGCAGTTCTCCAGCCTTCATTACCTGGCGAATTCAGATACTACCCAAACATCATAGCAAAAGGGGTCGGGAAAATC AGACAGTAAAATCAACAACCCTGATATCCACCGGTGTATTAAGCCGAAGCAAATAAAGGATAATCAAAAACTTAGGACA ^{AAAGAGGTCAATACCAACAACTATTAGCAGTCACACTCGCAAGAATAAGAGAGAAGGGACCAAAAAAGTCAAATAGGAG} AAATCAAAACAAAAGGTACAGAACACCAGAACAACAAAATCAAAACATCCAACTCACTCAAAACAAAAATTCCAAAAGA GACCGGCAACACAACAAGCACTGAACACAATGCCAACTTCAATACTGCTAATTATTACAACCATGATCATGGCATCTTT ^{4239-112370-02} CTGCCAAATAGATATCACAAAACTACAGCACGTAGGTGTATTGGTCAACAGTCCCAAAGGGATGAAGATATCACAAAAC TTTGAAACAAGATATCTAATTTTGAGCCTCATACCAAAAATAGAAGACTCTAACTCTTGTGGTGACCAACAGATCAAGC AATACAAGAAGTTATTGGATAGACTGATCATCCCTTTATATGATGGATTAAGATTACAGAAAGATGTGATAGTAACCAA TCAAGAATCCAATGAAAACACTGATCCCAGAACAAAACGATTCTTTGGAGGGGTAATTGGAACCATTGCTCTGGGAGTA GCAACCTCAGCACAAATTACAGCGGCAGTTGCTCTGGTTGAAGCCAAGCAGGCAAGATCAGACATCGAAAAACTCAAAG AAGCAATTAGGGACACAAACAAAGCAGTGCAGTCAGTTCAGAGCTCCATAGGAAATTTAATAGTAGCAATTAAATCAGT CCAGGATTATGTTAACAAAGAAATCGTGCCATCGATTGCGAGGCTAGGTTGTGAAGCAGCAGGACTTCAATTAGGAATT GCATTAACACAGCATTACTCAGAATTAACAAACATATTTGGTGATAACATAGGATCGTTACAAGAAAAAGGAATAAAAT TACAAGGTATAGCATCATTATACCGCACAAATATCACAGAAATATTCACAACATCAACAGTTGATAAATATGATATCTA TGATCTGTTATTTACAGAATCAATAAAGGTGAGAGTTATAGATGTTGACTTGAATGATTACTCAATCACCCTCCAAGTC AGACTCCCTTTATTAACTAGGCTGCTGAACACTCAGATCTACAAAGTAGATTCCATATCATATAACATCCAAAACAGAG AATGGTATATCCCTCTTCCCAGCCATATCATGACGAAAGGGGCATTTCTAGGTGGAGCAGACGTCAAAGAATGTATAGA AGCATTCAGCAGCTATATATGCCCTTCTGATCCAGGATTTGTATTAAACCATGAAATAGAGAGCTGCTTATCAGGAAAC ATATCCCAATGTCCAAGAACAACGGTCACATCAGACATTGTTCCAAGATATGCATTTGTCAATGGAGGAGTGGTTGCAA ^{ACTGTATAACAACCACCTGTACATGCAACGGAATTGGTAATAGAATCAATCAACCACCTGATCAAGGAGTAAAAATTAT} AACACATAAAGAATGTAGTACAATAGGTATCAACGGAATGCTGTTCAATACAAATAAAGAAGGAACTCTTGCATTCTAT ACACCAAATGATATAACACTAAACAATTCTGTTGCACTTGATCCAATTGACATATCAATCGAGCTCAACAAGGCCAAAT CAGATCTAGAAGAATCAAAAGAATGGATAAGAAGGTCAAATCAAAAACTAGATTCTATTGGAAATTGGCATCAATCTAG CACTACAATCATAATTATTTTGATAATGATCATTATATTGTTTATAATTAATATAACGATAATTACAATTGCAATTAAG ^{TATTACAGAATTCAAAAGAGAAATCGAGTGGATCAAAATGACAAGCCATATGTACTAACAAACAAATAACATATCTACA} GATCATTAGATATTAAAATTATAAAAAACTTAGGAGTAAAGTTACGCAATCCAACTCTACTCATATAATTGAGGAAGGA CCCAATAGACAAATCCAAATTCGAGATGGAATACTGGAAGCATACCAATCACGGAAAGGATGCTGGTAATGAGCTGGAG ACGTCTATGGCTACTCATGGCAACAAGCTCACTAATAAGATAATATACATATTATGGACAATAATCCTGGTGTTATTAT CAATAGTCTTCATCATAGTGCTAATTAATTCCATCAAAAGTGAAAAGGCCCACGAATCATTGCTGCAAGACATAAATAA TGAGTTTATGGAAATTACAGAAAAGATCCAAATGGCATCGGATAATACCAATGATCTAATACAGTCAGGAGTGAATACA AGGCTTCTTACAATTCAGAGTCATGTCCAGAATTACATACCAATATCATTGACACAACAGATGTCAGATCTTAGGAAAT TCATTAGTGAAATTACAATTAGAAATGATAATCAAGAAGTGCTGCCACAAAGAATAACACATGATGTAGGTATAAAACC TTTAAATCCAGATGATTTTTGGAGATGCACGTCTGGTCTTCCATCTTTAATGAAAACTCCAAAAATAAGGTTAATGCCA GGGCCGGGATTATTAGCTATGCCAACGACTGTTGATGGCTGTGTTAGAACTCCGTCTTTAGTTATAAATGATCTGATTT ATGCTTATACCTCAAATCTAATTACTCGAGGTTGTCAGGATATAGGAAAATCATATCAAGTCTTACAGATAGGGATAAT AACTGTAAACTCAGACTTGGTACCTGACTTAAATCCTAGGATCTCTCATACCTTTAACATAAATGACAATAGGAAGTCA TGTTCTCTAGCACTCCTAAATATAGATGTATATCAACTGTGTTCAACTCCCAAAGTTGATGAAAGATCAGATTATGCAT CATCAGGCATAGAAGATATTGTACTTGATATTGTCAATTATGATGGTTCAATCTCAACAACAAGATTTAAGAATAATAA CATAAGCTTTGATCAACCATATGCTGCACTATACCCATCTGTTGGACCAGGGATATACTACAAAGGCAAAATAATATTT CTCGGGTATGGAGGTCTTGAACATCCAATAAATGAGAATGTAATCTGCAACACAACTGGGTGCCCCGGGAAAACACAGA GAGACTGTAATCAAGCATCTCATAGTACTTGGTTTTCAGATAGGAGGATGGTCAACTCCATCATTGTTGTTGACAAAGG CTTAAACTCAATTCCAAAATTGAAAGTATGGACGATATCTATGCGACAAAATTACTGGGGGTCAGAAGGAAGGTTACTT CTACTAGGTAACAAGATCTATATATATACAAGATCTACAAGTTGGCATAGCAAGTTACAATTAGGAATAATTGATATTA CTGATTACAGTGATATAAGGATAAAATGGACATGGCATAATGTGCTATCAAGACCAGGAAACAATGAATGTCCATGGGG ^{ACATTCATGTCCAGATGGATGTATAACAGGAGTATATACTGATGCATATCCACTCAATCCCACAGGGAGCATTGTGTCA} TCTGTCATATTAGACTCACAAAAATCGAGAGTGAACCCAGTCATAACTTACTCAACAGCAACCGAAAGAGTAAACGAGC TGGCCATCCTAAACAGAACACTCTCAGCTGGATATACAACAACAAGCTGCATTACACACTATAACAAAGGATATTGTTT TCATATAGTAGAAATAAATCATAAAAGCTTAAACACATTTCAACCCATGTTGTTCAAAACAGAGATTCCAAAAAGCTGC AGTTAATCATAATTAACCATAATATGCATCAATCTATCTATAATACAAGTATATGATAAGTAATCAGCAATCAGACAAT AGACGTACGGAAATAATAAAAAACTTAGGAGAAAAGTGTGCAAGAAAAATGGACACCGAGTCCCACAGCGGCACAACAT CTGACATTCTGTACCCTGAATGTCACCTCAATTCTCCTATAGTTAAAGGAAAGATAGCACAACTGCATACAATAATGAG TTTGCCTCAGCCCTACGATATGGATGATGATTCAATACTGATTATTACTAGACAAAAAATTAAACTCAATAAATTAGAT AAAAGACAACGGTCAATTAGGAAATTAAGATCAGTCTTAATGGAAAGAGTAAGTGATCTAGGTAAATATACCTTTATCA GATATCCAGAGATGTCTAGTGAAATGTTCCAATTATGTATACCCGGAATTAATAATAAAATAAATGAATTGCTAAGTAA AGCAAGTAAAACATATAATCAAATGACTGATGGATTAAGAGATCTATGGGTTACTATACTATCGAAGTTAGCATCGAAA AATGATGGAAGTAATTATGATATCAATGAAGATATTAGCAATATATCAAATGTTCACATGACTTATCAATCAGACAAAT GGTATAATCCATTCAAGACATGGTTTACTATTAAGTATGACATGAGAAGATTACAAAAAGCCAAAAATGAGATTACATT CAATAGGCATAAAGATTATAATCTATTAGAAGACCAAAAGAATATATTGCTGATACATCCAGAACTCGTCTTAATATTA GATAAACAAAATTACAATGGGTATATAATGACTCCTGAATTGGTACTAATGTATTGTGATGTAGTTGAAGGGAGGTGGA ATATAAGTTCATGTGCAAAATTGGATCCTAAGTTACAATCAATGTATTATAAGGGTAACAATTTATGGGAAATAATAGA TGGACTATTCTCGACCTTAGGAGAAAGAACATTTGACATAATATCACTATTAGAACCACTTGCATTATCGCTCATTCAA ACTTATGACCCGGTTAAACAGCTCAGGGGGGCTTTTTTAAATCACGTGTTATCAGAAATGGAATTAATATTTGCAGCTG AGTGTACAACAGAGGAAATACCTAATGTGGATTATATAGATAAAATTTTAGATGTGTTCAAAGAATCAACAATAGATGA AATAGCAGAAATTTTCTCTTTCTTCCGAACTTTTGGACACCCTCCATTAGAGGCGAGTATAGCAGCAGAGAAAGTTAGA ^{AAGTATATGTATACTGAGAAATGCTTGAAATTTGATACTATCAATAAATGTCATGCTATTTTTTGTACAATAATTATAA} ATGGATATAGAGAAAGACATGGTGGTCAATGGCCTCCAGTTACATTACCTGTCCATGCACATGAATTTATCATAAATGC ATACGGATCAAATTCTGCCATATCATATGAGAATGCTGTAGATTATTATAAGAGCTTCATAGGAATAAAATTTGACAAG ^{4239-112370-02} TTTATAGAGCCTCAATTGGATGAAGACTTAACTATTTATATGAAAGATAAAGCATTATCCCCAAAGAAATCAAACTGGG ACACAGTCTATCCAGCTTCAAACCTGTTATACCGCACTAATGTGTCTCATGATTCACGAAGATTGGTTGAAGTATTTAT AGCAGATAGTAAATTTGATCCCCACCAAGTATTAGATTACGTAGAATCAGGATATTGGCTGGATGATCCTGAATTTAAT ATCTCATATAGTTTAAAAGAGAAAGAAATAAAACAAGAAGGTAGACTTTTTGCAAAAATGACATACAAGATGAGGGCTA CACAAGTATTATCAGAAACATTATTGGCGAATAATATAGGGAAATTCTTCCAAGAGAATGGGATGGTTAAAGGAGAAAT TGAATTACTCAAGAGACTAACAACAATATCTATGTCTGGAGTTCCGCGGTATAATGAGGTATACAATAATTCAAAAAGT CACACAGAAGAACTTCAAGCTTATAATGCAATTAGCAGTTCCAATTTATCTTCTAATCAGAAGTCAAAGAAGTTTGAAT TTAAATCTACAGATATATACAATGATGGATACGAAACCGTAAGCTGCTTCTTAACGACAGATCTTAAAAAATATTGTTT AAATTGGAGGTATGAATCAACAGCTTTATTCGGTGATACTTGTAATCAGATATTTGGGTTAAAGGAATTATTTAATTGG CTGCACCCTCGCCTTGAAAAGAGTACAATATATGTTGGAGATCCTTATTGCCCGCCATCAGATATTGAACATTTACCAC TTGATGACCATCCTGATTCAGGATTTTATGTTCATAATCCTAAAGGAGGAATAGAAGGGTTTTGCCAAAAGTTATGGAC ACTCATATCTATCAGTGCAATACATTTAGCAGCTGTCAAAATCGGTGTAAGAGTTACTGCAATGGTTCAAGGGGATAAT CAAGCCATAGCTGTTACCACAAGAGTACCTAATAATTATGATTATAAAGTTAAGAAAGAGATTGTTTATAAAGATGTGG TAAGATTTTTTGATTCCTTGAGAGAGGTGATGGATGATCTGGGTCATGAGCTCAAACTAAATGAAACTATAATAAGTAG ^{TAAAATGTTTATATATAGCAAAAGGATATACTATGACGGAAGAATCCTTCCTCAGGCATTAAAAGCATTGTCTAGATGT} GTTTTTTGGTCTGAAACAATCATAGATGAGACAAGATCAGCATCCTCAAATCTGGCTACATCGTTTGCAAAGGCCATTG AGAATGGCTACTCACCTGTATTGGGATATGTATGCTCAATCTTCAAAAATATCCAACAGTTGTATATAGCGCTTGGAAT GAATATAAACCCAACTATAACCCAAAATATTAAAGATCAATATTTCAGGAATATTCATTGGATGCAATATGCCTCCTTA ATCCCTGCTAGTGTCGGAGGATTTAATTATATGGCCATGTCAAGGTGTTTTGTCAGAAACATTGGAGATCCTACAGTCG ^{CTGCGTTAGCCGATATTAAAAGATTTATAAAAGCAAATTTGTTAGATCGAGGTGTCCTTTACAGAATTATGAATCAAGA} ACCAGGCGAGTCTTCTTTTTTAGACTGGGCCTCAGATCCCTATTCATGTAACTTACCACAATCTCAAAATATAACCACC ATGATAAAGAATATAACTGCAAGAAATGTACTACAGGACTCACCAAACCCATTACTATCTGGATTATTTACAAGTACAA TGATAGAAGAGGATGAGGAATTAGCTGAGTTCCTAATGGACAGGAGAATAATCCTCCCAAGAGTTGCACATGACATTTT AGATAATTCTCTTACTGGAATTAGGAATGCTATAGCTGGTATGTTGGATACAACAAAATCACTAATTCGAGTAGGGATA AGCAGAGGAGGATTAACCTATAACTTATTAAGAAAGATAAGCAACTATGATCTTGTACAATATGAGACACTTAGTAAAA CTTTAAGACTAATAGTCAGTGACAAGATTAAGTATGAAGATATGTGCTCAGTAGACCTAGCCATATCATTAAGACAAAA AATGTGGATGCATTTATCAGGAGGAAGAATGATAAATGGACTTGAAACTCCAGATCCTTTAGAGTTACTGTCTGGAGTA ATAATAACAGGATCTGAACATTGTAGGATATGTTATTCAACTGAAGGTGAAAGCCCATATACATGGATGTATTTACCAG GCAATCTTAATATAGGATCAGCTGAGACAGGAATAGCATCATTAAGGGTCCCTTACTTTGGATCAGTTACAGATGAGAG ATCTGAAGCACAATTAGGGTATATCAAAAATCTAAGCAAACCAGCTAAGGCTGCTATAAGAATAGCAATGATATATACT TGGGCATTTGGGAATGACGAAATATCTTGGATGGAAGCATCACAGATTGCACAAACACGTGCAAACTTTACATTGGATA GCTTAAAGATTTTGACACCAGTGACAACATCAACAAATCTATCACACAGGTTAAAAGATACTGCTACTCAGATGAAATT TTCTAGTACATCACTTATTAGAGTAAGCAGGTTCATCACAATATCTAATGATAATATGTCTATTAAAGAAGCAAATGAA ACTAAAGATACAAATCTTATTTATCAACAGGTAATGTTAACAGGATTAAGTGTATTTGAATATCTATTTAGGTTAGAGG AGAGTACAGGACATAACCCTATGGTCATGCATCTACATATAGAGGATGGATGTTGTATAAAAGAGAGTTACAATGATGA GCATATCAATCCGGAGTCTACATTAGAGTTAATCAAATACCCTGAGAGTAATGAATTTATATATGATAAGGACCCTTTA AAGGATATAGATCTATCAAAATTAATGGTTATAAGAGATCATTCTTATACAATTGACATGAATTACTGGGATGACACAG ATATTGTACATGCAATATCAATATGTACTGCAGTTACAATAGCAGATACAATGTCGCAGCTAGATCGGGATAATCTTAA GGAGCTGGTTGTGATTGCAAATGATGATGATATTAACAGTCTGATAACTGAATTTCTGACCCTAGATATACTAGTGTTT ^{CTCAAAACATTTGGAGGGTTACTCGTGAATCAATTTGCATATACCCTTTATGGATTGAAAATAGAAGGAAGGGATCCCA} TTTGGGATTATATAATGAGAACATTAAAAGACACCTCACATTCAGTACTTAAAGTATTATCTAATGCACTATCTCATCC AAAAGTGTTTAAGAGATTTTGGGATTGTGGAGTTTTGAATCCTATTTATGGTCCTAATACTGCTAGTCAAGATCAAGTT AAGCTTGCTCTCTCGATTTGCGAGTACTCCTTGGATCTATTTATGAGAGAATGGTTGAATGGAGCATCACTTGAGATCT ATATCTGTGATAGTGACATGGAAATAGCAAATGACAGAAGACAAGCATTTCTCTCAAGACATCTTGCCTTTGTGTGTTG TTTAGCAGAGATAGCATCTTTTGGACCAAATTTATTAAATCTAACATATCTAGAGAGACTTGATGAATTAAAACAATAC TTAGATCTGAACATCAAAGAAGATCCTACTCTTAAATATGTGCAAGTATCAGGACTGTTAATTAAATCATTCCCCTCAA CTGTTACGTATGTAAGGAAAACTGCGATTAAGTATCTGAGGATTCGTGGTATTAATCCGCCTGAAACGATTGAAGATTG GGATCCCATAGAAGATGAGAATATCTTAGACAATATTGTTAAAACTGTAAATGACAATTGCAGTGATAATCAAAAGAGA AATAAAAGTAGTTATTTCTGGGGATTAGCTCTAAAGAATTATCAAGTCGTGAAAATAAGATCCATAACGAGTGATTCTG AAGTTAATGAAGCTTCGAATGTTACTACACATGGAATGACACTTCCTCAGGGAGGAAGTTATCTATCACATCAGCTGAG GTTATTTGGAGTAAACAGTACAAGTTGTCTTAAAGCTCTTGAATTATCACAAATCTTAATGAGGGAAGTTAAAAAAGAT AAAGATAGACTCTTTTTAGGAGAAGGAGCAGGAGCTATGTTAGCATGTTATGATGCTACACTCGGTCCTGCAATAAATT ATTATAATTCTGGTTTAAATATTACAGATGTAATTGGTCAACGGGAATTAAAAATCTTCCCATCAGAAGTATCATTAGT AGGTAAAAAACTAGGAAATGTAACACAGATTCTTAATCGGGTGAGGGTGTTATTTAATGGGAATCCCAATTCAACATGG ATAGGAAATATGGAATGTGAGAGTTTAATATGGAGTGAATTAAATGATAAGTCAATTGGTTTAGTACATTGTGACATGG AGGGAGCGATAGGCAAATCAGAAGAAACTGTTCTACATGAACATTATAGTATTATTAGGATTACATATTTAATCGGGGA TGATGATGTTGTCCTAGTATCAAAAATTATACCAACTATTACTCCGAATTGGTCTAAAATACTCTATCTATACAAGTTG TATTGGAAGGATGTAAGTGTAGTGTCCCTTAAAACATCCAATCCTGCCTCAACAGAGCTTTATTTAATTTCAAAAGATG CTTACTGTACTGTAATGGAACCCAGTAATCTTGTTTTATCAAAACTTAAAAGGATATCATCAATAGAAGAAAATAATCT ^{ATTAAAGTGGATAATCTTATCAAAAAGGAAGAATAACGAGTGGTTACAGCATGAAATCAAAGAAGGAGAAAGGGATTAT} GGGATAATGAGGCCATATCATACAGCACTGCAAATTTTTGGATTCCAAATTAACTTAAATCACTTAGCTAGAGAATTTT TATCAACTCCTGATTTAACCAACATTAATAATATAATTCAAAGTTTTACAAGAACAATTAAAGATGTTATGTTCGAATG ^{4239-112370-02} GGTCAATATCACTCATGACAATAAAAGACATAAATTAGGAGGAAGATATAATCTATTCCCGCTTAAAAATAAGGGGAAA TTAAGATTATTATCACGAAGATTAGTACTAAGCTGGATATCATTATCCTTATCAACCAGATTACTGACGGGCCGTTTTC CAGATGAAAAATTTGAAAATAGGGCACAGACCGGATATGTATCATTGGCTGATATTGATTTAGAATCCTTAAAGTTATT ATCAAGAAATATTGTCAAAAATTACAAAGAACACATAGGATTAATATCATACTGGTTTTTGACCAAAGAGGTCAAAATA CTAATGAAGCTTATAGGAGGAGTCAAACTACTAGGAATTCCTAAACAGTACAAAGAGTTAGAGGATCGATCATCTCAGG GTTATGAATATGATAATGAATTTGATATTGATTAATACATAAAAACATAAAATAAAACACCTATTCCTCACCCATTCAC TTCCAACAAAATGAAAAGTAAGAAAAACATGTAATATATATATACCAAACAGAGTTTTTCTCTTGTTTGGT SEQ ID NO: 34 is an exemplary rB/HPIV3/NA-TMCT antigenomic cDNA sequence. ^{ACCAAACAAGAGAAGAGACTGGTTTGGGAATATTAATTCAAATAAAAATTAACTTAGGATTAAAGAACTTTACCGAAAGG} TAAGGGGAAAGAAATCCTAAGAGCTTAGCCATGTTGAGTCTATTCGACACATTCAGTGCGCGTAGGCAGGAGAACATAAC GAAATCAGCTGGTGGGGCTGTTATTCCCGGGCAAAAAAACACTGTGTCTATATTTGCTCTTGGACCATCAATAACAGATG ACAATGATAAAATGACATTGGCTCTTCTCTTTTTGTCTCATTCTTTAGACAATGAAAAGCAGCATGCGCAAAGAGCTGGA TTTTTAGTTTCTCTGTTATCAATGGCTTATGCCAACCCAGAATTATATTTAACATCAAATGGTAGTAATGCAGATGTTAA ATATGTTATCTACATGATAGAGAAAGACCCAGGAAGACAGAAATATGGTGGGTTTGTCGTCAAGACTAGAGAGATGGTTT ATGAAAAGACAACTGATTGGATGTTCGGGAGTGATCTTGAGTATGATCAAGACAATATGTTGCAAAATGGTAGAAGCACT TCTACAATCGAGGATCTTGTTCATACTTTTGGATATCCATCGTGTCTTGGAGCCCTTATAATCCAAGTTTGGATAATACT TGTTAAGGCTATAACCAGTATATCAGGATTGAGGAAAGGATTCTTTACTCGGTTAGAAGCATTTCGACAAGATGGAACAG TTAAATCCAGTCTAGTGTTGAGCGGTGATGCAGTAGAACAAATTGGATCAATTATGAGGTCCCAACAGAGCTTGGTAACA CTCATGGTTGAAACACTGATAACAATGAACACAGGCAGGAATGATCTGACAACAATAGAAAAGAATATACAGATTGTAGG AAACTACATCAGAGATGCAGGTCTTGCTTCATTTTTCAACACAATCAGATATGGCATTGAGACTAGAATGGCAGCTCTAA CTCTGTCTACCCTTAGACCGGATATCAACAGACTCAAGGCACTGATCGAGTTATATCTATCAAAGGGGCCACGTGCTCCT TTTATATGCATTTTGAGAGATCCCGTGCATGGTGAGTTTGCACCAGGCAACTATCCTGCCCTCTGGAGTTATGCGATGGG TGTAGCAGTTGTACAAAACAAGGCCATGCAACAGTATGTAACAGGAAGGTCTTATCTGGATATTGAAATGTTCCAACTTG GTCAAGCAGTGGCACGTGATGCCGAGTCGCAGATGAGTTCAATATTAGAGGATGAACTGGGGGTCACACAAGAAGCCAAG CAAAGCTTGAAGAAACACATGAAGAACATCAGCAGTTCAGATACAACCTTTCATAAGCCTACAGGGGGATCAGCCATAGA AATGGCGATAGATGAAGAAGCAGGGCAGCCTGAATCCAGAGGAGATCAGGATCAAGGAGATGAGCCTCGGTCATCCATAG TTCCTTATGCATGGGCAGACGAAACCGGGAATGACAATCAAACTGAATCAACTACAGAAATTGACAGCATCAAAACTGAA CAAAGAAACATCAGAGACAGGCTGAACAAAAGACTCAACGAGAAAAGGAAACAGAGTGACCCGAGATCAACTGACATCAC ^{AAACAACACAAATCAAACTGAAATAGATGATTTGTTCAGTGCATTCGGAAGCAACTAGTCACAAAGAGATGACCAGGCGC} GCCAAGTAAGAAAAACTTAGGATTAATGGACCTGCAGGATGGAATATTGGAAACACACAAACAGCATAAATAACACCAAC AATGAAACCGAAACAGCCAGAGGCAAACATAGTAGCAAGGTTACAAATATCATAATGTACACCTTCTGGACAATAACATT AACAATATTATCAGTCATTTTTATAATGATATTGACAAACTTAATTAATATCGGCCTGCACCTGAAGTCTGGCTGCAACT GTTCTAGGAGCCAGCCAGAGACCACAAATCCCAGCCAGACCATCATCAACAACTACTACAACGAGACAAACATCACCAAC ATCCAGATGGGCGAGAGGACATCCCGCAACTTCAACAATCTGACAAAGGGCCTGTGCACCATCAACTCTTGGCACATCTA CGGCAAGGACAATGCCGTGCGGATCGGAGAGAGCTCCGACGTGCTGGTGACACGGGAGCCTTACGTGAGCTGCGACCCAG ATGAGTGTAGGTTTTATGCCCTGAGCCAGGGAACCACAATCCGGGGCAAGCACTCCAACGGCACAATCCACGACCGGAGC CAGTACAGAGCCCTGATCAGCTGGCCTCTGTCTAGCCCCCCTACCGTGTATAATTCTAGGGTGGAGTGCATCGGCTGGTC CTCTACAAGCTGTCACGATGGCAAGTCCCGCATGTCTATCTGCATCTCCGGCCCCAACAATAACGCCTCTGCCGTGATCT GGTACAACCGGAGACCTGTGGCCGAGATCAACACCTGGGCCAGGAATATCCTGCGCACACAGGAGTCCGAGTGCGTGTGC CACAACGGCGTGTGCCCAGTGGTGTTCACAGACGGCCCTGCCACCGGCCCTGCCGATACACGGATCTACTACTTCAAGGA GGGCAAGATCCTGAAGTGGGAGTCCCTGACCGGCACAGCCAAGCACATCGAGGAGTGCTCTTGTTACGGCAAGCGGACCG GCATCACCTGCACCTGTAAGGACAACTGGCAGGGCTCTAATAGACCCGTGATCCAGATCGATCCTGTGGCCATGACCCAC ACAAGCCAGTATATCTGCTCCCCTGTGCTGACCGACTCCCCACGGCCCAACGATCCAAATATCGGCAAGTGTAACGACCC TTACCCAGGCAATAACAATAACGGCGTGAAGGGCTTCAGCTATCTGGACGGCGATAATACCTGGCTGGGCCGGACAATCT CCACCGCCTCCAGATCTGGCTACGAGATGCTGAAGGTGCCAAACGCCCTGACCGACGATAGAAGCAAGCCCATCCAGGGC CAGACAATCGTGCTGAATGCCGATTGGTCCGGCTACAGCGGCTCCTTCATGGACTATTGGGCCGAGGGCGATTGCTACAG GGCCTGTTTTTATGTGGAGCTGATCCGGGGCAAGCCAAAGGAGGACAAAGTGTGGTGGACCTCTAACAGCATCGTGAGCA TGTGCAGCTCCACAGAGTTCCTGGGCCAGTGGAATTGGCCCGATGGCGCCAAGATCGAGTATTTTCTGTGATAGCTAGCG ^{GCGCGCCAGCAACAAGTAAGAAAAACTTAGGATTAATGGAAATTATCCAATCCAGAGACGGAAGGACAAATCCAGAATCC} AACCACAACTCAATCAACCAAAGATTCATGGAAGACAATGTTCAAAACAATCAAATCATGGATTCTTGGGAAGAGGGATC AGGAGATAAATCATCTGACATCTCATCGGCCCTCGACATCATTGAATTCATACTCAGCACCGACTCCCAAGAGAACACGG CAGACAGCAATGAAATCAACACAGGAACCACAAGACTTAGCACGACAATCTACCAACCTGAATCCAAAACAACAGAAACA AGCAAGGAAAATAGTGGACCAGCTAACAAAAATCGACAGTTTGGGGCATCACACGAACGTGCCACAGAGACAAAAGATAG AAATGTTAATCAGGAGACTGTACAGGGAGGATATAGGAGAGGAAGCAGCCCAGATAGTAGAACTGAGACTATGGTCACTC GAAGAATCTCCAGAAGCAGCCCAGATCCTAACAATGGAACCCAAATCCAGGAAGATATTGATTACAATGAAGTTGGAGAG ATGGATAAGGACTCTACTAAGAGGGAAATGCGACAATTTAAAGATGTTCCAGTCAAGGTATCAGGAAGTGATGCCATTCC TCCAACAAAACAAGATGGAGACGGTGATGATGGAAGAGGCCTGGAATCTATCAGTACATTTGATTCAGGATATACCAGTA TAGTGACTGCCGCAACACTAGATGACGAAGAAGAACTCCTTATGAAGAACAACAGGCCAAGAAAGTATCAATCAACACCC CAGAACAGTGACAAGGGAATTAAAAAAGGGGTTGGAAGGCCAAAAGACACAGACAAACAATCATCAATATTGGACTACGA ACTCAACTTCAAAGGATCGAAGAAGAGCCAGAAAATCCTCAAAGCCAGCACGAATACAGGAGAACCAACAAGACCACAGA ATGGATCCCAGGGGAAGAGAATCACATCCTGGAACATCCTCAACAGCGAGAGCGGCAATCGAACAGAATCAACAAACCAA ^{4239-112370-02} ACCCATCAGACATCAACCTCGGGACAGAACCACACAATGGGACCAAGCAGAACAACCTCCGAACCAAGGATCAAGACACA AAAGACGGATGGAAAGGAAAGAGAGGACACAGAAGAGAGCACTCGATTTACAGAAAGGGCGATTACATTATTACAGAATC TTGGTGTAATCCAATCTGCAGCAAAATTAGACCTATACCAAGACAAGAGAGTTGTGTGTGTGGCGAATGTCCTAAACAAT GCAGATACTGCATCAAAGATAGACTTCCTAGCAGGTTTGATGATAGGAGTGTCAATGGATCATGATACCAAATTAAATCA GATTCAGAACGAGATATTAAGTTTGAAAACTGATCTTAAAAAGATGGATGAATCACATAGAAGACTAATTGAGAATCAAA AAGAACAATTATCACTGATCACATCATTAATCTCAAATCTTAAAATTATGACAGAGAGAGGAGGGAAGAAGGACCAACCA GAACCTAGCGGGAGGACATCCATGATCAAGACAAAAGCAAAAGAAGAGAAAATAAAGAAAGTCAGGTTTGACCCTCTTAT GGAAACACAGGGCATCGAGAAAAACATCCCTGACCTCTATAGATCAATAGAGAAAACACCAGAAAACGACACACAGATCA AATCAGAAATAAACAGATTGAATGATGAATCCAATGCCACTAGATTAGTACCTAGAAGAATAAGCAGTACAATGAGATCA TTAATAATAATCATTAACAACAGCAATTTATCATCAAAAGCAAAGCAATCATACATCAACGAACTCAAGCTCTGCAAGAG TGACGAGGAAGTGTCTGAGTTGATGGACATGTTCAATGAGGATGTCAGCTCCCAGTAAACCGCCAACCAAGGGTCAACAC CAAGAAAACCAATAGCACAAAACAGCCAATCAGAGACCACCCCAATACACCAAACCAATCAACACATAACAAAGATCGCG GCCGCATAGATGATTAAGAAAAACTTAGGATGAAAGGACTAATCAATCCTCCGAAACAATGAGCATCACCAACTCCACAA TCTACACATTCCCAGAATCCTCTTTCTCCGAGAATGGCAACATAGAGCCGTTACCACTCAAGGTCAATGAACAGAGAAAG ^{GCCATACCTCATATTAGGGTTGTCAAGATAGGAGATCCGCCCAAACATGGATCCAGATATCTGGATGTCTTTTTACTGGG} CTTCTTTGAGATGGAAAGGTCAAAAGACAGGTATGGGAGCATAAGTGATCTAGATGATGATCCAAGTTACAAGGTTTGTG GCTCTGGATCATTGCCACTTGGGTTGGCTAGATACACCGGAAATGATCAGGAACTCCTACAGGCTGCAACCAAGCTCGAT ATAGAAGTAAGAAGAACTGTAAAGGCTACGGAGATGATAGTTTACACTGTACAAAACATCAAACCTGAACTATATCCATG GTCCAGTAGATTAAGAAAAGGGATGTTATTTGACGCTAATAAGGTTGCACTTGCTCCTCAATGTCTTCCACTAGATAGAG ^{GGATAAAATTCAGGGTGATATTTGTGAACTGCACAGCAATTGGATCAATAACTCTATTCAAAATCCCTAAGTCCATGGCA} TTGTTATCATTGCCTAATACAATATCAATAAATCTACAAGTACATATCAAAACAGGAGTTCAGACAGATTCCAAAGGAGT AGTTCAGATTCTAGATGAAAAAGGTGAAAAATCACTAAATTTCATGGTTCATCTCGGGTTGATCAAAAGGAAGATGGGCA GAATGTACTCAGTTGAATATTGTAAGCAGAAGATCGAGAAGATGAGATTATTATTCTCATTGGGATTAGTTGGAGGGATC AGCTTCCACGTCAACGCAACTGGCTCTATATCAAAGACATTAGCAAGTCAATTAGCATTCAAAAGAGAAATCTGCTATCC CCTAATGGATCTGAATCCACACTTAAATTCAGTTATATGGGCATCATCAGTTGAAATTACAAGGGTAGATGCAGTTCTCC AGCCTTCATTACCTGGCGAATTCAGATACTACCCAAACATCATAGCAAAAGGGGTCGGGAAAATCAGACAGTAAAATCAA CAACCCTGATATCCACCGGTGTATTAAGCCGAAGCAAATAAAGGATAATCAAAAACTTAGGACAAAAGAGGTCAATACCA ACAACTATTAGCAGTCACACTCGCAAGAATAAGAGAGAAGGGACCAAAAAAGTCAAATAGGAGAAATCAAAACAAAAGGT ACAGAACACCAGAACAACAAAATCAAAACATCCAACTCACTCAAAACAAAAATTCCAAAAGAGACCGGCAACACAACAAG CACTGAACACAATGCCAACTTCAATACTGCTAATTATTACAACCATGATCATGGCATCTTTCTGCCAAATAGATATCACA AAACTACAGCACGTAGGTGTATTGGTCAACAGTCCCAAAGGGATGAAGATATCACAAAACTTTGAAACAAGATATCTAAT TTTGAGCCTCATACCAAAAATAGAAGACTCTAACTCTTGTGGTGACCAACAGATCAAGCAATACAAGAAGTTATTGGATA GACTGATCATCCCTTTATATGATGGATTAAGATTACAGAAAGATGTGATAGTAACCAATCAAGAATCCAATGAAAACACT GATCCCAGAACAAAACGATTCTTTGGAGGGGTAATTGGAACCATTGCTCTGGGAGTAGCAACCTCAGCACAAATTACAGC GGCAGTTGCTCTGGTTGAAGCCAAGCAGGCAAGATCAGACATCGAAAAACTCAAAGAAGCAATTAGGGACACAAACAAAG CAGTGCAGTCAGTTCAGAGCTCCATAGGAAATTTAATAGTAGCAATTAAATCAGTCCAGGATTATGTTAACAAAGAAATC GTGCCATCGATTGCGAGGCTAGGTTGTGAAGCAGCAGGACTTCAATTAGGAATTGCATTAACACAGCATTACTCAGAATT AACAAACATATTTGGTGATAACATAGGATCGTTACAAGAAAAAGGAATAAAATTACAAGGTATAGCATCATTATACCGCA CAAATATCACAGAAATATTCACAACATCAACAGTTGATAAATATGATATCTATGATCTGTTATTTACAGAATCAATAAAG ^{GTGAGAGTTATAGATGTTGACTTGAATGATTACTCAATCACCCTCCAAGTCAGACTCCCTTTATTAACTAGGCTGCTGAA} CACTCAGATCTACAAAGTAGATTCCATATCATATAACATCCAAAACAGAGAATGGTATATCCCTCTTCCCAGCCATATCA TGACGAAAGGGGCATTTCTAGGTGGAGCAGACGTCAAAGAATGTATAGAAGCATTCAGCAGCTATATATGCCCTTCTGAT CCAGGATTTGTATTAAACCATGAAATAGAGAGCTGCTTATCAGGAAACATATCCCAATGTCCAAGAACAACGGTCACATC AGACATTGTTCCAAGATATGCATTTGTCAATGGAGGAGTGGTTGCAAACTGTATAACAACCACCTGTACATGCAACGGAA TTGGTAATAGAATCAATCAACCACCTGATCAAGGAGTAAAAATTATAACACATAAAGAATGTAGTACAATAGGTATCAAC GGAATGCTGTTCAATACAAATAAAGAAGGAACTCTTGCATTCTATACACCAAATGATATAACACTAAACAATTCTGTTGC ACTTGATCCAATTGACATATCAATCGAGCTCAACAAGGCCAAATCAGATCTAGAAGAATCAAAAGAATGGATAAGAAGGT CAAATCAAAAACTAGATTCTATTGGAAATTGGCATCAATCTAGCACTACAATCATAATTATTTTGATAATGATCATTATA TTGTTTATAATTAATATAACGATAATTACAATTGCAATTAAGTATTACAGAATTCAAAAGAGAAATCGAGTGGATCAAAA TGACAAGCCATATGTACTAACAAACAAATAACATATCTACAGATCATTAGATATTAAAATTATAAAAAACTTAGGAGTAA AGTTACGCAATCCAACTCTACTCATATAATTGAGGAAGGACCCAATAGACAAATCCAAATTCGAGATGGAATACTGGAAG CATACCAATCACGGAAAGGATGCTGGTAATGAGCTGGAGACGTCTATGGCTACTCATGGCAACAAGCTCACTAATAAGAT AATATACATATTATGGACAATAATCCTGGTGTTATTATCAATAGTCTTCATCATAGTGCTAATTAATTCCATCAAAAGTG AAAAGGCCCACGAATCATTGCTGCAAGACATAAATAATGAGTTTATGGAAATTACAGAAAAGATCCAAATGGCATCGGAT AATACCAATGATCTAATACAGTCAGGAGTGAATACAAGGCTTCTTACAATTCAGAGTCATGTCCAGAATTACATACCAAT ATCATTGACACAACAGATGTCAGATCTTAGGAAATTCATTAGTGAAATTACAATTAGAAATGATAATCAAGAAGTGCTGC CACAAAGAATAACACATGATGTAGGTATAAAACCTTTAAATCCAGATGATTTTTGGAGATGCACGTCTGGTCTTCCATCT TTAATGAAAACTCCAAAAATAAGGTTAATGCCAGGGCCGGGATTATTAGCTATGCCAACGACTGTTGATGGCTGTGTTAG AACTCCGTCTTTAGTTATAAATGATCTGATTTATGCTTATACCTCAAATCTAATTACTCGAGGTTGTCAGGATATAGGAA ^{AATCATATCAAGTCTTACAGATAGGGATAATAACTGTAAACTCAGACTTGGTACCTGACTTAAATCCTAGGATCTCTCAT} ACCTTTAACATAAATGACAATAGGAAGTCATGTTCTCTAGCACTCCTAAATATAGATGTATATCAACTGTGTTCAACTCC CAAAGTTGATGAAAGATCAGATTATGCATCATCAGGCATAGAAGATATTGTACTTGATATTGTCAATTATGATGGTTCAA ^{4239-112370-02} TCTCAACAACAAGATTTAAGAATAATAACATAAGCTTTGATCAACCATATGCTGCACTATACCCATCTGTTGGACCAGGG ATATACTACAAAGGCAAAATAATATTTCTCGGGTATGGAGGTCTTGAACATCCAATAAATGAGAATGTAATCTGCAACAC AACTGGGTGCCCCGGGAAAACACAGAGAGACTGTAATCAAGCATCTCATAGTACTTGGTTTTCAGATAGGAGGATGGTCA ACTCCATCATTGTTGTTGACAAAGGCTTAAACTCAATTCCAAAATTGAAAGTATGGACGATATCTATGCGACAAAATTAC TGGGGGTCAGAAGGAAGGTTACTTCTACTAGGTAACAAGATCTATATATATACAAGATCTACAAGTTGGCATAGCAAGTT ACAATTAGGAATAATTGATATTACTGATTACAGTGATATAAGGATAAAATGGACATGGCATAATGTGCTATCAAGACCAG GAAACAATGAATGTCCATGGGGACATTCATGTCCAGATGGATGTATAACAGGAGTATATACTGATGCATATCCACTCAAT CCCACAGGGAGCATTGTGTCATCTGTCATATTAGACTCACAAAAATCGAGAGTGAACCCAGTCATAACTTACTCAACAGC AACCGAAAGAGTAAACGAGCTGGCCATCCTAAACAGAACACTCTCAGCTGGATATACAACAACAAGCTGCATTACACACT ATAACAAAGGATATTGTTTTCATATAGTAGAAATAAATCATAAAAGCTTAAACACATTTCAACCCATGTTGTTCAAAACA GAGATTCCAAAAAGCTGCAGTTAATCATAATTAACCATAATATGCATCAATCTATCTATAATACAAGTATATGATAAGTA ATCAGCAATCAGACAATAGACGTACGGAAATAATAAAAAACTTAGGAGAAAAGTGTGCAAGAAAAATGGACACCGAGTCC CACAGCGGCACAACATCTGACATTCTGTACCCTGAATGTCACCTCAATTCTCCTATAGTTAAAGGAAAGATAGCACAACT GCATACAATAATGAGTTTGCCTCAGCCCTACGATATGGATGATGATTCAATACTGATTATTACTAGACAAAAAATTAAAC ^{TCAATAAATTAGATAAAAGACAACGGTCAATTAGGAAATTAAGATCAGTCTTAATGGAAAGAGTAAGTGATCTAGGTAAA} TATACCTTTATCAGATATCCAGAGATGTCTAGTGAAATGTTCCAATTATGTATACCCGGAATTAATAATAAAATAAATGA ATTGCTAAGTAAAGCAAGTAAAACATATAATCAAATGACTGATGGATTAAGAGATCTATGGGTTACTATACTATCGAAGT TAGCATCGAAAAATGATGGAAGTAATTATGATATCAATGAAGATATTAGCAATATATCAAATGTTCACATGACTTATCAA TCAGACAAATGGTATAATCCATTCAAGACATGGTTTACTATTAAGTATGACATGAGAAGATTACAAAAAGCCAAAAATGA ^{GATTACATTCAATAGGCATAAAGATTATAATCTATTAGAAGACCAAAAGAATATATTGCTGATACATCCAGAACTCGTCT} TAATATTAGATAAACAAAATTACAATGGGTATATAATGACTCCTGAATTGGTACTAATGTATTGTGATGTAGTTGAAGGG AGGTGGAATATAAGTTCATGTGCAAAATTGGATCCTAAGTTACAATCAATGTATTATAAGGGTAACAATTTATGGGAAAT AATAGATGGACTATTCTCGACCTTAGGAGAAAGAACATTTGACATAATATCACTATTAGAACCACTTGCATTATCGCTCA TTCAAACTTATGACCCGGTTAAACAGCTCAGGGGGGCTTTTTTAAATCACGTGTTATCAGAAATGGAATTAATATTTGCA GCTGAGTGTACAACAGAGGAAATACCTAATGTGGATTATATAGATAAAATTTTAGATGTGTTCAAAGAATCAACAATAGA TGAAATAGCAGAAATTTTCTCTTTCTTCCGAACTTTTGGACACCCTCCATTAGAGGCGAGTATAGCAGCAGAGAAAGTTA GAAAGTATATGTATACTGAGAAATGCTTGAAATTTGATACTATCAATAAATGTCATGCTATTTTTTGTACAATAATTATA AATGGATATAGAGAAAGACATGGTGGTCAATGGCCTCCAGTTACATTACCTGTCCATGCACATGAATTTATCATAAATGC ATACGGATCAAATTCTGCCATATCATATGAGAATGCTGTAGATTATTATAAGAGCTTCATAGGAATAAAATTTGACAAGT TTATAGAGCCTCAATTGGATGAAGACTTAACTATTTATATGAAAGATAAAGCATTATCCCCAAAGAAATCAAACTGGGAC ACAGTCTATCCAGCTTCAAACCTGTTATACCGCACTAATGTGTCTCATGATTCACGAAGATTGGTTGAAGTATTTATAGC AGATAGTAAATTTGATCCCCACCAAGTATTAGATTACGTAGAATCAGGATATTGGCTGGATGATCCTGAATTTAATATCT CATATAGTTTAAAAGAGAAAGAAATAAAACAAGAAGGTAGACTTTTTGCAAAAATGACATACAAGATGAGGGCTACACAA GTATTATCAGAAACATTATTGGCGAATAATATAGGGAAATTCTTCCAAGAGAATGGGATGGTTAAAGGAGAAATTGAATT ACTCAAGAGACTAACAACAATATCTATGTCTGGAGTTCCGCGGTATAATGAGGTATACAATAATTCAAAAAGTCACACAG AAGAACTTCAAGCTTATAATGCAATTAGCAGTTCCAATTTATCTTCTAATCAGAAGTCAAAGAAGTTTGAATTTAAATCT ACAGATATATACAATGATGGATACGAAACCGTAAGCTGCTTCTTAACGACAGATCTTAAAAAATATTGTTTAAATTGGAG GTATGAATCAACAGCTTTATTCGGTGATACTTGTAATCAGATATTTGGGTTAAAGGAATTATTTAATTGGCTGCACCCTC GCCTTGAAAAGAGTACAATATATGTTGGAGATCCTTATTGCCCGCCATCAGATATTGAACATTTACCACTTGATGACCAT ^{CCTGATTCAGGATTTTATGTTCATAATCCTAAAGGAGGAATAGAAGGGTTTTGCCAAAAGTTATGGACACTCATATCTAT} CAGTGCAATACATTTAGCAGCTGTCAAAATCGGTGTAAGAGTTACTGCAATGGTTCAAGGGGATAATCAAGCCATAGCTG TTACCACAAGAGTACCTAATAATTATGATTATAAAGTTAAGAAAGAGATTGTTTATAAAGATGTGGTAAGATTTTTTGAT TCCTTGAGAGAGGTGATGGATGATCTGGGTCATGAGCTCAAACTAAATGAAACTATAATAAGTAGTAAAATGTTTATATA TAGCAAAAGGATATACTATGACGGAAGAATCCTTCCTCAGGCATTAAAAGCATTGTCTAGATGTGTTTTTTGGTCTGAAA CAATCATAGATGAGACAAGATCAGCATCCTCAAATCTGGCTACATCGTTTGCAAAGGCCATTGAGAATGGCTACTCACCT GTATTGGGATATGTATGCTCAATCTTCAAAAATATCCAACAGTTGTATATAGCGCTTGGAATGAATATAAACCCAACTAT AACCCAAAATATTAAAGATCAATATTTCAGGAATATTCATTGGATGCAATATGCCTCCTTAATCCCTGCTAGTGTCGGAG GATTTAATTATATGGCCATGTCAAGGTGTTTTGTCAGAAACATTGGAGATCCTACAGTCGCTGCGTTAGCCGATATTAAA AGATTTATAAAAGCAAATTTGTTAGATCGAGGTGTCCTTTACAGAATTATGAATCAAGAACCAGGCGAGTCTTCTTTTTT AGACTGGGCCTCAGATCCCTATTCATGTAACTTACCACAATCTCAAAATATAACCACCATGATAAAGAATATAACTGCAA GAAATGTACTACAGGACTCACCAAACCCATTACTATCTGGATTATTTACAAGTACAATGATAGAAGAGGATGAGGAATTA GCTGAGTTCCTAATGGACAGGAGAATAATCCTCCCAAGAGTTGCACATGACATTTTAGATAATTCTCTTACTGGAATTAG GAATGCTATAGCTGGTATGTTGGATACAACAAAATCACTAATTCGAGTAGGGATAAGCAGAGGAGGATTAACCTATAACT TATTAAGAAAGATAAGCAACTATGATCTTGTACAATATGAGACACTTAGTAAAACTTTAAGACTAATAGTCAGTGACAAG ATTAAGTATGAAGATATGTGCTCAGTAGACCTAGCCATATCATTAAGACAAAAAATGTGGATGCATTTATCAGGAGGAAG AATGATAAATGGACTTGAAACTCCAGATCCTTTAGAGTTACTGTCTGGAGTAATAATAACAGGATCTGAACATTGTAGGA TATGTTATTCAACTGAAGGTGAAAGCCCATATACATGGATGTATTTACCAGGCAATCTTAATATAGGATCAGCTGAGACA GGAATAGCATCATTAAGGGTCCCTTACTTTGGATCAGTTACAGATGAGAGATCTGAAGCACAATTAGGGTATATCAAAAA TCTAAGCAAACCAGCTAAGGCTGCTATAAGAATAGCAATGATATATACTTGGGCATTTGGGAATGACGAAATATCTTGGA ^{TGGAAGCATCACAGATTGCACAAACACGTGCAAACTTTACATTGGATAGCTTAAAGATTTTGACACCAGTGACAACATCA} ACAAATCTATCACACAGGTTAAAAGATACTGCTACTCAGATGAAATTTTCTAGTACATCACTTATTAGAGTAAGCAGGTT CATCACAATATCTAATGATAATATGTCTATTAAAGAAGCAAATGAAACTAAAGATACAAATCTTATTTATCAACAGGTAA ^{4239-112370-02} TGTTAACAGGATTAAGTGTATTTGAATATCTATTTAGGTTAGAGGAGAGTACAGGACATAACCCTATGGTCATGCATCTA CATATAGAGGATGGATGTTGTATAAAAGAGAGTTACAATGATGAGCATATCAATCCGGAGTCTACATTAGAGTTAATCAA ATACCCTGAGAGTAATGAATTTATATATGATAAGGACCCTTTAAAGGATATAGATCTATCAAAATTAATGGTTATAAGAG ATCATTCTTATACAATTGACATGAATTACTGGGATGACACAGATATTGTACATGCAATATCAATATGTACTGCAGTTACA ATAGCAGATACAATGTCGCAGCTAGATCGGGATAATCTTAAGGAGCTGGTTGTGATTGCAAATGATGATGATATTAACAG TCTGATAACTGAATTTCTGACCCTAGATATACTAGTGTTTCTCAAAACATTTGGAGGGTTACTCGTGAATCAATTTGCAT ATACCCTTTATGGATTGAAAATAGAAGGAAGGGATCCCATTTGGGATTATATAATGAGAACATTAAAAGACACCTCACAT TCAGTACTTAAAGTATTATCTAATGCACTATCTCATCCAAAAGTGTTTAAGAGATTTTGGGATTGTGGAGTTTTGAATCC TATTTATGGTCCTAATACTGCTAGTCAAGATCAAGTTAAGCTTGCTCTCTCGATTTGCGAGTACTCCTTGGATCTATTTA TGAGAGAATGGTTGAATGGAGCATCACTTGAGATCTATATCTGTGATAGTGACATGGAAATAGCAAATGACAGAAGACAA GCATTTCTCTCAAGACATCTTGCCTTTGTGTGTTGTTTAGCAGAGATAGCATCTTTTGGACCAAATTTATTAAATCTAAC ATATCTAGAGAGACTTGATGAATTAAAACAATACTTAGATCTGAACATCAAAGAAGATCCTACTCTTAAATATGTGCAAG TATCAGGACTGTTAATTAAATCATTCCCCTCAACTGTTACGTATGTAAGGAAAACTGCGATTAAGTATCTGAGGATTCGT GGTATTAATCCGCCTGAAACGATTGAAGATTGGGATCCCATAGAAGATGAGAATATCTTAGACAATATTGTTAAAACTGT ^{AAATGACAATTGCAGTGATAATCAAAAGAGAAATAAAAGTAGTTATTTCTGGGGATTAGCTCTAAAGAATTATCAAGTCG} TGAAAATAAGATCCATAACGAGTGATTCTGAAGTTAATGAAGCTTCGAATGTTACTACACATGGAATGACACTTCCTCAG GGAGGAAGTTATCTATCACATCAGCTGAGGTTATTTGGAGTAAACAGTACAAGTTGTCTTAAAGCTCTTGAATTATCACA AATCTTAATGAGGGAAGTTAAAAAAGATAAAGATAGACTCTTTTTAGGAGAAGGAGCAGGAGCTATGTTAGCATGTTATG ATGCTACACTCGGTCCTGCAATAAATTATTATAATTCTGGTTTAAATATTACAGATGTAATTGGTCAACGGGAATTAAAA ^{ATCTTCCCATCAGAAGTATCATTAGTAGGTAAAAAACTAGGAAATGTAACACAGATTCTTAATCGGGTGAGGGTGTTATT} TAATGGGAATCCCAATTCAACATGGATAGGAAATATGGAATGTGAGAGTTTAATATGGAGTGAATTAAATGATAAGTCAA TTGGTTTAGTACATTGTGACATGGAGGGAGCGATAGGCAAATCAGAAGAAACTGTTCTACATGAACATTATAGTATTATT AGGATTACATATTTAATCGGGGATGATGATGTTGTCCTAGTATCAAAAATTATACCAACTATTACTCCGAATTGGTCTAA AATACTCTATCTATACAAGTTGTATTGGAAGGATGTAAGTGTAGTGTCCCTTAAAACATCCAATCCTGCCTCAACAGAGC TTTATTTAATTTCAAAAGATGCTTACTGTACTGTAATGGAACCCAGTAATCTTGTTTTATCAAAACTTAAAAGGATATCA TCAATAGAAGAAAATAATCTATTAAAGTGGATAATCTTATCAAAAAGGAAGAATAACGAGTGGTTACAGCATGAAATCAA AGAAGGAGAAAGGGATTATGGGATAATGAGGCCATATCATACAGCACTGCAAATTTTTGGATTCCAAATTAACTTAAATC ACTTAGCTAGAGAATTTTTATCAACTCCTGATTTAACCAACATTAATAATATAATTCAAAGTTTTACAAGAACAATTAAA GATGTTATGTTCGAATGGGTCAATATCACTCATGACAATAAAAGACATAAATTAGGAGGAAGATATAATCTATTCCCGCT TAAAAATAAGGGGAAATTAAGATTATTATCACGAAGATTAGTACTAAGCTGGATATCATTATCCTTATCAACCAGATTAC TGACGGGCCGTTTTCCAGATGAAAAATTTGAAAATAGGGCACAGACCGGATATGTATCATTGGCTGATATTGATTTAGAA TCCTTAAAGTTATTATCAAGAAATATTGTCAAAAATTACAAAGAACACATAGGATTAATATCATACTGGTTTTTGACCAA AGAGGTCAAAATACTAATGAAGCTTATAGGAGGAGTCAAACTACTAGGAATTCCTAAACAGTACAAAGAGTTAGAGGATC GATCATCTCAGGGTTATGAATATGATAATGAATTTGATATTGATTAATACATAAAAACATAAAATAAAACACCTATTCCT CACCCATTCACTTCCAACAAAATGAAAAGTAAGAAAAACATGTAATATATATATACCAAACAGAGTTTTTCTCTTGTTTG GT SEQ ID NOS: 35-37 are sequences shown in FIGS.1A and 1B. SEQ ID NOS: 38 and 39 are sequences shown in FIG.6D. DETAILED DESCRIPTION I. Introduction The IAV genome is composed of eight separate single stranded, negative sense, RNA segments that collectively express 10 essential proteins including the non-structural proteins (NS1 and NS2), nucleoprotein (NP), matrix (M1 and M2), polymerase subunits (PA, PB1, and PB2), hemagglutinin (HA), and neuraminidase (NA). Several additional strain-dependent accessory proteins can also be expressed. HA and NA are virion surface glycoproteins; HA mediates attachment and fusion; NA possesses neuraminidase activity and cleaves the cell surface sialic acid residues for virus release from the infected cells. HA and NA are the virus neutralization and major protective antigens and are the primary vaccine targets; the former is immunodominant and more protective (Krammer, “The human antibody response to influenza A virus infection and vaccination.” Nat Rev Immunol 19:383-397, 2019). HA and NA proteins also are the most variable. To date, 18 HA and 11 NA subtypes of IAVs have been identified (Han et al., “Co-evolution of ^{4239-112370-02} immunity and seasonal influenza viruses.” Nat Rev Microbiol 21:805-817, 2023) that are antigenically distinct, provide little or no cross protection, and thus present a challenge for vaccine development. Influenza viruses generate antigenic diversity by antigenic drift and antigenic shift. The former involves acquiring amino acid substitutions in the HA and NA genes. The latter involves substitution of HA and/or NA gene segments by reassortment between influenza strains. These mechanisms enable evasion of immunity induced by prior infections or vaccination. Reassortment can result in viruses that carry novel HA and/or NA proteins against which humans lack protective immunity, and could potentially trigger a pandemic. For example, an avian influenza virus (AIV), or a reassortant human virus bearing one or both AIV HA and NA genes, might infect humans lacking immunity against the AIV HA and NA proteins, and could initiate a pandemic if the virus adapts to acquire efficient human-to-human transmission. The vast and ever-evolving reservoir of avian influenza viruses in wild birds makes it difficult to predict or prevent a potential pandemic. However, sometimes, warning signs are evident. One such warning is a recently described reassortant H7N9 AIV that bears gene segments of several wild bird origin AIVs. The first transmission of H7N9 from infected poultry to humans occurred in China in 2013. Since then, H7N9 was transmitted from birds to humans on numerous occasions, causing five epidemic waves in mainland China that involved 1,568 laboratory confirmed human infections with a 40% mortality rate. Clinical symptoms in humans include fever, cough, and dyspnea and in severe cases acute respiratory distress syndrome and multiorgan failure leading to death. The virus remains inefficient in human-to-human transmission and primarily infects those in direct contact with infected poultry. However, the virus has evolved to harbor multiple basic amino acids at the HA protein cleavage site, a determinant of greater pathogenicity in poultry, and was classified as a highly pathogenic AIV (HPAIV). The World Health Organization declared this new version to have a high potential of causing a pandemic. Vaccination campaigns in China have reduced the incidence of H7N9 in poultry. However, the ongoing risk of infection of humans, especially the potential for the emergence of a version of an H7N9 virus that is efficiently transmitted in humans, continues to exist and H7N9 remains a “bird flu” virus with the greatest pandemic potential. Candidate vaccine viruses (CVVs) for H7N9 have been developed by the United States Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), and other international health agencies. These particular CVVs are inactivated virus vaccines for intramuscular administration and are based on a recombinant PR8 laboratory strain backbone that had been subjected to reassortment in order to contain the surface HA and NA proteins of AIV H7N9 in place of the PR8 HA and NA (H1N1) genes. Vaccines based on HA protein and mRNA are also under development (Arevalo et al., “A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes.” Science 378:899-904 (2022); Uno et al., “Multivalent next generation influenza virus vaccines protect against seasonal and pre- pandemic viruses.” Sci Rep 14:1440, 2024). The immunogenicity of the H7 and N9 proteins in humans is extremely low, making vaccine development challenging (see, e.g., Couch et al., “Evaluations for in vitro correlates of immunogenicity of inactivated influenza a H5, H7 and H9 vaccines in humans.” PLoS One ^{4239-112370-02} 7:e50830, 2012; Jackson et al., “Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial.” JAMA 314:237-246, 2015; Couch et al., “A randomized clinical trial of an inactivated avian influenza (H7N7) vaccine.” PLoS One 7: e49704, 2012). In addition, parenterally injected influenza vaccines are not efficient in protecting the respiratory mucosal sites against virus infection and replication. Human parainfluenza virus 3 (HPIV3) is another important viral pathogen that infects infants and young children worldwide and can cause severe lower respiratory illness. Re-infections are common throughout life suggesting lifelong susceptibility, albeit the severity of disease decreases with repeat exposure. HPIV3 is an enveloped virus of the family Paramyxoviridae, contains a single-stranded negative sense RNA genome, and codes for 6 structural proteins including nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), hemagglutinin neuraminidase (HN) and large polymerase (L). F and HN are the virus neutralization and major protective antigens. HPIV3 can be produced de novo in cell culture from transfected cDNAs encoding a positive-sense copy of the HPIV3 genome (the antigenome) together with the N, P, and L proteins, providing a means for manipulating the RNA genome through the cDNA intermediate (Durbin et al., “Recovery of infectious human parainfluenza virus type 3 from cDNA,” Virology 1;235(2):323-32, 1997). There is no licensed vaccine or effective therapeutic currently available for HPIV3, but there are some live-attenuated HPIV3 vaccines in clinical trials (see, ClinicalTrials.gov; ID NCT06546423, NCT06026514). Described herein is the development of live-attenuated vectored vaccines against highly pathogenic avian influenza virus (HPAIV) H7N9. A chimera of bovine and human parainfluenza virus 3 (B/HPIV3) was used as a vector backbone. Bovine PIV3 (BPIV3) is a viral agent of bovine respiratory disease that is a close relative of HPIV3. B/HPIV3 consists of BPIV3 in which the F and HN genes have been replaced by their HPIV3 counterparts. The BPIV3 backbone confers attenuation in humans due to host-range restriction, and the HPIV3 F and HN proteins provide protection against HPIV3. B/HPIV3 was developed as a Jennerian pediatric IN vaccine and was safe and immunogenic against HPIV3 in children as young as 6 months of age (Karron et al., “Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children.” Vaccine 30:3975-3981, 2012). In this disclosure, B/HPIV3 was modified to express H7 HA or N9 NA as a wild type protein or a chimera containing the transmembrane-cytoplasmic tail (TMCT) domains of BPIV3 F or HN, respectively, to promote packaging in the vector virion, which has been previously been shown to enhance the quality and magnitude of the immune response against respiratory syncytial virus (RSV) F protein (Liang et al., “Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate.” J Virol 91, 2017). This provides live attenuated candidate bivalent vaccines against both HPAIV H7N9 and HPIV3. Without being bound to any particular theory, since older children and adults typically have immunity to HPIV3 from natural exposure that would reduce the infectivity and immunogenicity of the B/HPIV3 vector, a vaccine based on this vector may be most effective for immunization of infants and young children who ^{4239-112370-02} generally have no or low pre-existing immunity against HPIV3. This B/HPIV3 vaccine could be delivered by the IN route, stimulating both systemic and mucosal immunity, the latter being particularly important for restricting respiratory pathogens. Six constructs were designed (see, FIG.1). Four containing H7N9 HA, HA-TMCT, NA, or NA- TMCT gene were successfully recovered (B/HPIV3/HA, B/HPIV3/HA-TMCT, B/HPIV3/NA, and B/HPIV3/NA-TMCT). Infectious virus was not recovered for two constructs, which contained the H7N9 HA and NA inserted into B/HPIV3 lacking the HPIV3 F and HN genes. In vitro characterization of B/HPIV3/HA, B/HPIV3/HA-TMCT, B/HPIV3/NA and B/HPIV3/NA-TMCT virions showed that HA and NA were efficiently incorporated into B/HPIV3 particles. Since B/HPIV3 carrying the HA and NA as the sole surface glycoproteins were not recovered, likely due to lack of functionality, the incorporation of HA or NA as individual glycoproteins into B/HPIV3 particles should be free of safety concerns about the possible effects of HA or NA on the tropism of B/HPIV3. B/HPIV3/HA, B/HPIV3/HA-TMCT, B/HPIV3/NA, and B/HPIV3/NA-TMCT all replicated in Vero cells (see, Example 3), a widely used substrate for vaccine manufacture, with similar kinetics and to final titers that were not different from the parent B/HPIV3 suggesting that the insertion of the heterologous HA, HA-TMCT, NA, or NA-TMCT genes was well tolerated and did not affect in vitro replication. This was the case even though expression in the infected cells of HPIV3 F protein was reduced for B/HPIV3/NA, and B/HPIV3/NA-TMCT, and that of the HPIV3 HN protein was decreased for B/HPIV3/NA. During in vitro infection, B/HPIV3/HA and B/HPIV3/HA-TMCT efficiently expressed the wt and TMCT forms of HA protein, respectively. As expected, HA was observed as the parent HA0 and its cleavage products HA1 and HA2. However, HA-TMCT was seen in disproportionately greater amount as HA0 with small amounts of HA1 and HA2 suggesting the TMCT substitution reduced the efficiency of HA0 cleavage. The wt HA and NA proteins were packaged in the B/HPIV3 particle and were detected in substantial amounts in the sucrose purified virions. The TMCT versions of HA and NA also were detected in the virions but in much smaller amounts, which was unexpected and converse to previous work with RSV F protein, which was incorporated in the B/HPIV3 particle only in the chimeric form containing the BPIV3 F TMCT (Liang et al., Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored- Vaccine Candidate. J Virol 91, 2017). Without being bound to any particular theory, it could be that the TMCT modification introduced other structural changes in HA and NA proteins that hindered membrane anchoring and/or incorporation into the virion. A change in the structure of HA-TMCT also was indicated by its inefficient cleavage and reduced immunogenicity compared to wt HA protein. Candidate vaccine viruses were evaluated in African green monkeys (AGMs) for replication in the respiratory tract and immunogenicity against AIV H7N9 and HPIV3 (see, Examples 5 and 6). Viruses replicated to similar titers on most days; those expressing HA or HA-TMCT showed reduced titers on day 4 p.i. as compared to those expressing NA but otherwise replicated similarly. PR8-H7N9-BPL, the inactivated recombinant PR8-H7N9 virus, a surrogate of the vaccine developed by the FDA and CDC, was given by IM ^{4239-112370-02} injection for comparison. The inactivated PR8-H7N9-BPL control was based on a preparation of recombinant IAV PR8 [A/Puerto Rico/8/1934 (H1N1)], with the HA and NA genome segments replaced by those encoding the HA and NA of HPAIV H7N9 [strain A/Guangdong/17SF003/ 2016]. Among all, B/HPIV3/HA was the most immunogenic candidate and elicited the earliest and highest titers of serum H7N9-neutralizing antibodies. The immunogenicity of HA-TMCT was lower than that of HA suggesting that the TMCT modification may have resulted in the loss of epitopes for virus neutralization. Nonetheless, a single dose of B/HPIV3/HA and B/HPIV3/HA-TMCT conferred an H7N9-neutralizing antibody response, which was stronger for the former. B/HPIV3/NA and B/HPIV3/NA-TMCT were less immunogenic and required two doses to induce detectable H7N9-neutralizing antibodies. The injectable vaccine PR8-H7N9- BPL, which was added for comparison, was poorly immunogenic and conferred significantly lower H7N9- neutralizing serum antibody titers. Biosafety level 3 challenge was not evaluated, however, sera were analyzed for hemagglutination inhibition (HAI) antibody titer which is considered an important correlate of the protective efficacy of influenza vaccines. Adult serum HAI titers ≥ 1:40 (10^1.6 ) correlate with 50% reduction in the risk of infection and are considered an immunological correlate of protection. However, in children, an HAI titer of 1:40 only provides 22% protection and a higher titer at 1:110 is needed for conventional 50% protection during the entire influenza season. Moreover, HAI titers at 1:215, 1:330, and 1:629 predict pediatric protection rates of 70%, 80%, and 90%, respectively (Black et al., “Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children” Pediatr Infect Dis J 30, 1081-1085, 2011). The AGM sera were analyzed for HAI antibodies and the results were overall consistent with the neutralizing antibody response. A single dose of B/HPIV3/HA stimulated HAI antibody titers ranging from 1:10^1.6 (1:39.8) to 1:10^2.2 (1:158.5) by 2 weeks p.i. that continued to rise to the peak of 1:10^3.4 (1:2,512) in 2 weeks after the booster dose, well surpassing the benchmarks for protection. The highest titer achieved by B/HPIV3/HA-TMCT was 1:10^1.9 (1:79.4). PR8-H7N9-BPL induced HAI antibodies that were detectable only at week 3 in 2 of the 3 animals at titers of 1:10^2.5 (1:316.2) and 1:10^1.3 (1:20) but were undetectable in all later samples despite being boosted at week 4. Thus, B/HPIV3/HA was the most immunogenic candidate and conferred peak HAI titers at 1:2,512 that are 4-fold higher than the HAI titer needed for 90% protection in children. The inactivated PR8-H7N9-BPL was administered IM as two doses, each at 50 µg, containing approximately 15 µg of HA antigen, without adjuvant. The quantity of antigen in each dose was consistent with that in the seasonal influenza vaccines which are also given without adjuvant. The PR8-H7N9-BPL and the B/HPIV3/HA candidate vaccine virus both carry the H7 HA of the highly pathogenic (HP) AIV H7N9 A/Guangdong/ 17SF003/2016, yet (as shown herein) the B/HPIV3/HA candidate vaccine shows exceptionally strong immunogenicity. Without being bound by any particular theory, the lower immunogenicity of the PR8-H7N9-BPL inactivated vaccine might be due to a number of factors, including the process of inactivation, the parenteral route of administration, greater immune stimulation by a live replicating vaccine, and increased delivery of antigen in native conformation by a live ^{4239-112370-02} vaccine. In addition, direct immunization of the respiratory tract also would be expected to induce local immunity that would be effective in protection, although that was not evaluated in this study. In conclusion, here it is shown that B/HPIV3/HA and B/HPIV3/NA administered mucosally were immunogenic against the AIV H7N9, and B/HPIV3/HA in particular stands out in its ability to induce high levels of H7N9 HAI antibodies, exceeding those of other H7N9 vaccines or vaccine candidates. Thus, B/HPIV3/HA is a promising candidate vaccine for further development. However, antibodies against influenza virus NA that inhibit its neuraminidase activity are protective, and their level correlates with reduced severity of disease and shortened duration of replication (Memoli et al., “Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model.” mBio 7, e00417-00416, 2016). Thus, it may be beneficial to develop both B/HPIV3/HA and B/HPIV3/NA vaccines, potentially as a combination for administration, to achieve a broader antigenic coverage. II. Abbreviations AIV avian influenza virus BAL bronchoalveolar lavage B/HPIV3 chimeric bovine/human parainfluenza virus type 3 BPIV3 bovine parainfluenza virus type 3 ELISA enzyme-linked immunosorbent assay HA hemagglutinin HPIV3 human parainfluenza virus type 3 HPAIV highly pathogenic avian influenza virus IC₅₀ inhibitory concentration 50 IN intranasal IAV influenza A virus LA lower airway LRT lower respiratory tract MOI multiplicity of infection NA neuraminidase ND₅₀ neutralizing dose 50 NS nasal swab NW nasal wash ORF open reading frame pc post challenge PFU plaque forming unit pi post infection PIV parainfluenza virus ^{4239-112370-02} PRNT₆₀ 60% plaque reduction neutralization titer RBD receptor binding domain RLU relative light unit RM rhesus macaque S spike protein TCID₅₀ 50% tissue culture infective dose TL tracheal lavage TRF time resolved fluorescence UA upper airway URT upper respiratory tract wt wild-type III. Terms Unless otherwise noted, technical terms are used according to conventional usage. Definitions of common terms in molecular biology may be found in Benjamin Lewin, Genes XII, published by Jones & Bartlett Publishers, 2018; and Krebs et al. (eds.) ISBN:9781284104493; The Encyclopedia of Cell Biology and Molecular Medicine, published by Wiley-VCH in 16 volumes, 2008; and other similar references. In case of conflict, the present specification, including explanations of terms, will control. As used herein, the singular forms “a,” “an,” and “the,” refer to both the singular as well as plural, unless the context clearly indicates otherwise. For example, the term “a protein” includes singular or plural proteins and can be considered equivalent to the phrase “at least one protein.” As used herein, the term “comprises” means “includes.” It is further to be understood that any and all base sizes or amino acid sizes, and all molecular weight or molecular mass values, given for nucleic acids or polypeptides are approximate, and are provided for descriptive purposes, unless otherwise indicated. Although many methods and materials similar or equivalent to those described herein can be used, particular suitable methods and materials are described herein. However, the materials, methods, and examples are illustrative only and not intended to be limiting. To facilitate review of the various aspects of this disclosure, the following explanations of terms are provided: About: Unless context clearly indicates otherwise, the term “about” refers to plus or minus 5% of a reference value. For example, “about 100” refers to the range of 95 to 105. Adjuvant: An agent used to enhance antigenicity. Adjuvants include, but are not limited to, emulsions, mineral salts, liposomes, microbial products, saponins, cytokines, polymers, and microparticles. In an example, an adjuvant is a suspension of minerals (alum, aluminum hydroxide, or phosphate) on which an antigenic composition is adsorbed; or the adjuvant is a water-in-oil emulsion, for example, an antigen composition is emulsified in a mineral oil (Freund incomplete adjuvant), sometimes with the inclusion of killed mycobacteria (Freund's complete adjuvant) to further enhance antigenicity (by inhibiting degradation of antigen and/or causing influx of macrophages). Immunostimulatory oligonucleotides (such as those ^{4239-112370-02} including a CpG motif) can also be used as adjuvants. Adjuvants also include biological molecules (a “biological adjuvant”), such as costimulatory molecules. Exemplary adjuvants include IL-2, RANTES, GM-CSF, TNF-α, IFN-γ, G-CSF, LFA-3, CD72, B7-1, B7-2, OX-40L, 4-1BBL, immune stimulating complex (ISCOM) matrix, and toll-like receptor (TLR) agonists, such as TLR-9 agonists, Poly I:C, or PolyICLC. Adjuvants are further described, for example, in Singh (ed.) Vaccine Adjuvants and Delivery Systems. Wiley-Interscience, 2007. Administration: The introduction of a composition into a subject by a chosen route. Administration can be local or systemic. For example, if the chosen route is intranasal, the composition (such as a composition including a disclosed rB/HPIV3 vector or a virus particle thereof) is administered by introducing the composition into the nasal passages of a subject. Exemplary routes of administration include, but are not limited to, intranasal, intratracheal, oral, injection (e.g., subcutaneous, intramuscular, intradermal, intraperitoneal, and intravenous), sublingual, rectal, transdermal (e.g., topical), intranasal, vaginal, and inhalation routes. Amino Acid Substitution: The replacement of one amino acid in a polypeptide with a different amino acid. Attenuated: A virus that is “attenuated” or that has an “attenuated phenotype” refers to a virus that has decreased virulence compared to a reference virus under similar conditions of infection. Attenuation usually is associated with decreased virus replication as compared to replication of a reference wild-type virus under similar conditions of infection, and thus “attenuation” and “restricted replication” often are used synonymously. In some hosts (typically non-natural hosts), disease is not evident during infection with a reference virus in question, and restriction of virus replication can be used as a surrogate marker for attenuation. In some aspects, a disclosed rB/HPIV3 vector that is attenuated exhibits at least about 10-fold or greater decrease, for example, at least 100-fold or greater decrease in virus titer in the upper or lower respiratory tract of a mammal compared to non-attenuated, wild type virus titer in the upper or lower respiratory tract, respectively, of a mammal of the same species under the same conditions of infection. Examples of mammals include, but are not limited to, humans, mice, rabbits, rats, hamsters, such as for example Mesocricetus auratus, and non-human primates, such as for example Macaca mulatta or Chlorocebus aethiops. An attenuated rB/HPIV3 vector may display different phenotypes including without limitation altered growth, temperature sensitive growth, host range restricted growth, or plaque size alteration. Influenza A Virus (IAV): A pathogenic virus with strains that infect birds and some mammals. It is the only species of the genus Alphainfluenzavirus of the virus family Orthomyxoviridae. Influenza A viruses are classified based on two proteins present on the surface of the virus: hemagglutinin and neuraminidase. For example, "H7N9" designates an IAV subtype that has a type-7 hemagglutinin protein and a type-9 neuraminidase protein. IAV strains can be further classified based on the primary host, for example, the primary host of avian influenza virus (AIV) are birds, though other hosts can also become infected. ^{4239-112370-02} The IAV genome is composed of eight separate single stranded, negative sense, RNA segments that collectively express 12 essential proteins including the non-structural proteins (NS1 and NS2), nucleoprotein (NP), matrix (M1 and M2), polymerase subunits (PA, PB1, and PB2), PA-X, PB-1F2, hemagglutinin (HA), and neuraminidase (NA); several additional strain-dependent accessory proteins are also expressed. HA and NA are the virion surface glycoproteins; HA mediates attachment and fusion; NA possesses neuraminidase activity and cleaves the cell surface sialic acid residues for virus release from the infected cells. HA and NA are the virus neutralization and protective antigens and are the primary vaccine targets; the former is immunodominant and more protective. However, HA and NA proteins are also the most variable. To date, 18 HA and 11 NA subtypes of IAVs have been identified. Each subtype is antigenically distinct and provides little or no cross protection, posing a challenge for vaccine development. Although AIVs primarily infect birds, they can acquire fitness for human infection through reassortment and antigenic drift. AIV subtype H7N9 is a reassortant of several wild bird origin AIVs. The virus has evolved to harbor polybasic amino acids at the HA protein cleavage site, a determinant of greater pathogenicity in poultry, leading to its classification as a “highly pathogenic” AIV (HPAIV). HPAIV H7N9 can cause severe disease when transmitted to humans and has a high mortality rate of 40%. Control: A reference standard. In some examples, the control is a negative control sample obtained from a healthy patient. In other examples, the control is a positive control sample obtained from a patient diagnosed with a disease or condition, such as AIV H7N9 infection. In still other examples, the control is a historical control or standard reference value or range of values (for example, a previously tested control sample, such as a group of patients infected with AIV H7N9 with a known prognosis or outcome, or group of samples that represent baseline or normal values). A difference between a test sample and a control can be an increase or conversely a decrease. The difference can be a qualitative difference or a quantitative difference, for example a statistically significant difference. In some examples, a difference is an increase or decrease, relative to a control, of at least 5%, such as at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 150%, at least bout 200%, at least 250%, at least 300%, at least 350%, at least 400%, at least 500%, or greater than 500%. Degenerate Variant: In the context of the present disclosure, a “degenerate variant” refers to a polynucleotide sequence variant due to degeneracy (redundancy) of the genetic code. For example, many amino acids are specified by more than one codon. Thus, although a degenerate variant has a different nucleic acid sequence than a reference sequence, a degenerate variant and reference sequence encode the same amino acid sequence. Effective Amount: An amount of agent, such as a rB/HPIV3 vector or immunogenic composition described herein, that is sufficient to elicit a desired response, such as an immune response in a subject. It is understood that to obtain a protective immune response against an antigen of interest can require multiple administrations of a disclosed immunogen, and/or administration of a disclosed immunogen as the “prime” in a prime boost protocol wherein the boost immunogen can be different from the prime immunogen. ^{4239-112370-02} Accordingly, an effective amount of a disclosed immunogen can be the amount of the immunogen sufficient to elicit a priming immune response in a subject that can be subsequently boosted with the same or a different immunogen to elicit a protective immune response. In one example, a desired response is to inhibit, reduce, or prevent AIV H7N9 infection or associated disease. The AIV H7N9 infection does not need to be completely eliminated, reduced, or prevented for the method to be effective. For example, administration of an effective amount of the agent can induce an immune response that decreases the AIV H7N9 infection (for example, as measured by infection of cells, or by number or percentage of subjects infected by the AIV H7N9) by a desired amount, for example by at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, or even at least 100% (elimination or prevention of detectable AIV H7N9 infection), as compared to a suitable control. Gene: A “gene” of a rB/HPIV3 vector as described herein refers to a portion of the rB/HPIV3 genome encoding an mRNA and typically begins at the upstream (3’) end with a gene-start (GS) signal and ends at the downstream (5’) end with the gene-end (GE) signal. In this context, the term gene also embraces what is referred to as a “translational open reading frame”, or ORF, particularly in the case where a protein, such as C, is expressed from an additional ORF rather than from a unique mRNA. Heterologous: Originating from a different genetic source. A heterologous gene included in a recombinant genome is a gene that does not originate from that genome. In one specific, non-limiting example, a heterologous gene encoding an AIV HA or NA protein is included in the genome of a rB/HPIV3 vector as described herein. Host Cell: A cell in which a vector can be propagated and expressed. The cell may be prokaryotic or eukaryotic. The term also includes any progeny of the subject host cell to the extent that the progeny are functionally or genetically the same as the parent host cell. It is understood that all progeny may not be identical to the parental cell since there may be mutations that occur during replication. However, such progeny are included when the term “host cell” is used. Infectious and Self-Replicating Virus: A virus that is capable of entering and replicating in a cultured cell or cell of an animal or human host to produce progeny virus capable of the same activity. Immune Response: A response of a cell of the immune system, such as a B cell, T cell, or monocyte, to a stimulus. The response can be specific for a particular antigen (an “antigen-specific response”). In some examples, the immune response is a T cell response, such as a CD4+ response or a CD8+ response. In another example, the response is a B cell response, and results in the production of specific antibodies. Immunogenic composition: Immunogenic material capable of stimulating an immune response. Immunogenic compositions can be administered, for example, to prevent, ameliorate, or treat infections or disease. Immunogenic compositions may include attenuated or killed microorganisms (such as bacteria or viruses), or antigenic proteins, peptides or DNA derived from them. In some examples, an immunogenic composition includes a rB/HPIV3 vector or B/HPIV3 virus disclosed herein. For in vivo use, immunogenic ^{4239-112370-02} compositions are typically included in a pharmaceutically acceptable carrier and may also include other agents, for example, an adjuvant. Isolated: An “isolated” biological component has been substantially separated or purified away from other biological components, such as other biological components in which the component occurs, for example, other chromosomal and extrachromosomal DNA, RNA, and proteins. Proteins, peptides, nucleic acids, and viruses that have been “isolated” include those purified by standard purification methods. The term “isolated” does not require absolute purity, and can include (for example) protein, peptide, nucleic acid, or virus molecules that are at least 50% pure, such as at least 75%, 80%, 90%, 95%, 98%, 99%, 99.9%, or more pure. Nucleic Acid Molecule: A polymeric form of nucleotides, which may include both sense and anti- sense strands of RNA, cDNA, genomic DNA, and synthetic forms and mixed polymers of the above. A nucleotide refers to a nucleic acid monomer, for example, a ribonucleotide, deoxynucleotide, or a modified form of either type of nucleotide. The term “nucleic acid molecule” as used herein is synonymous with “polynucleotide.” A nucleic acid molecule is usually at least 10 bases in length, unless otherwise specified. The term includes single- and double-stranded forms of DNA. A nucleic acid molecule may include either or both naturally occurring and modified nucleotides linked together by naturally occurring and/or non-naturally occurring nucleotide linkages. Operably Linked: A first nucleic acid sequence is operably linked with a second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Generally, operably linked nucleic acid sequences are contiguous and, where necessary to join two protein-coding regions, in the same reading frame. Preventing, Treating or Ameliorating a Disease: “Preventing” a disease refers to inhibiting the full development of a disease. “Treating” refers to a therapeutic intervention that ameliorates a sign or symptom of a disease or pathological condition after it has begun to develop, for example, a reduction in viral load. “Ameliorating” refers to the reduction in the number or severity of signs or symptoms of a disease, such as AIV H7N9 infection. Parainfluenza Virus (PIV): A number of enveloped non-segmented negative-sense single- stranded RNA viruses from family Paramyxoviridae that are descriptively grouped together. This includes all members of the genus Respirovirus (e.g., HPIV1, HPIV3, BPIV3) and a number of members from the genus Orthorubulavirus (e.g. HPIV2, HPIV4, PIV5). PIVs are made up of two structural modules: (1) an internal ribonucleoprotein core, or nucleocapsid, containing the viral genome, and (2) an outer, roughly spherical lipoprotein envelope. The PIV genome is approximately 15,000 nucleotides in length and encodes at least eight polypeptides. These proteins include the nucleocapsid structural protein (NP, NC, or N depending on the genera), the phosphoprotein (P), the matrix protein (M), the fusion glycoprotein (F), the hemagglutinin-neuraminidase glycoprotein (HN), the large polymerase protein (L), and the C and D proteins. The gene order is 3’-N-P-M-F-HN-L-5’, and each ^{4239-112370-02} gene encodes a separate protein encoding mRNA, with the P gene containing one or more additional open reading frames (ORFs) encoding accessory proteins. The rB/HPIV3 vector refers to a human parainfluenza virus 3 (HPIV3) and bovine parainfluenza virus 3 (BPIV3) chimeric vector. Pharmaceutically Acceptable Carrier: Pharmaceutically acceptable carriers of use herein are conventional. Remington’s Pharmaceutical Sciences, Adejare (Ed.), Academic Press, 23rd Edition, 2020, ISBN: 9780128223895/9780128200070, describes compositions and formulations suitable for pharmaceutical delivery of the disclosed immunogens. In general, the nature of the carrier will depend on the particular mode of administration being employed. For instance, parenteral formulations usually comprise injectable fluids that include pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like as a vehicle. For solid compositions (e.g., powder, pill, tablet, or capsule forms), conventional non-toxic solid carriers can include, for example, pharmaceutical grades of mannitol, lactose, starch, or magnesium stearate. In addition to biologically neutral carriers, pharmaceutical compositions to be administered can contain minor amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate. The carrier may be sterile and/or suspended, or contained in a unit dosage form containing one or more measured doses of the composition suitable to induce the desired immune response. It may also be accompanied by medications for treatment purposes. The unit dosage form may be, for example, in a sealed vial that contains sterile contents or a syringe for injection into a subject, or lyophilized for subsequent solubilization and administration or in a solid or controlled release dosage. Polypeptide: A chain of amino acids, regardless of length or post-translational modification (e.g., glycosylation or phosphorylation). “Polypeptide” applies to amino acid polymers including naturally occurring amino acid polymers and non-naturally occurring amino acid polymer as well as in which one or more amino acid residue is a non-natural amino acid, for example an artificial chemical mimetic of a corresponding naturally occurring amino acid. A “residue” refers to an amino acid or amino acid mimetic incorporated in a polypeptide by an amide bond or amide bond mimetic. A polypeptide has an amino terminal (N-terminal) end and a carboxy terminal (C-terminal) end. “Polypeptide” is used interchangeably with peptide or protein and is used herein to refer to a polymer of amino acid residues. Recombinant: A recombinant nucleic acid, vector, or virus is one that has a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two otherwise separated segments of sequence. This artificial combination can be accomplished, for example, by the artificial manipulation of isolated segments of nucleic acids, for example, using genetic engineering techniques. Recombinant Chimeric Bovine/Human Parainfluenza Virus 3 (rB/HPIV3): A chimeric PIV3 comprising a genome comprising a combination of BPIV3 and HPIV3 genes that together make up the full complement of PIV3 genes in the PIV3 genome (N, P, M, F, HN, and L genes). The disclosed rB/HPIV3 vectors are based on a BPIV3 genome having F and HN genes replaced with the corresponding genes from ^{4239-112370-02} HPIV3 (one example of which is discussed in Schmidt AC et al., J. Virol.74:8922-8929, 2000). In some aspects, the structural and functional genetic elements that control replication, such as genome and anti- genome promoters, are derived from BPIV3 (the genome promoter is in the 3’ leader of the genomic RNA and the antigenome promoter is in the trailer region located in the 3’ end of the antigenome). In some aspects, the genetic elements that control gene expression, such as gene-start and gene-end sequences, are also derived from BPIV3, except for the M gene-end, F gene-start, F gene-end, and HN gene-start that are derived from HPIV3 (JS strain). In some aspects, a heterologous gene encoding an AIV HA or NA protein is inserted between the N and P genes of the rB/HPIV3 genome to generate a rB/HPIV3 vector. The rB/HPIV3 vectors described herein are infectious, self-replicating, attenuated, and can be used to induce a bivalent immune response to AIV H7N9 and HPIV3 in a subject. Sequence Identity: The similarity between amino acid sequences is expressed in terms of the similarity between the sequences, otherwise referred to as sequence identity. Sequence identity is frequently measured in terms of percentage identity (or similarity or homology); the higher the percentage, the more similar the two sequences are. Homologs, orthologs, or variants of a polypeptide will possess a relatively high degree of sequence identity when aligned using standard methods. When determining sequence identity between two sequences, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, Adv. Appl. Math.2:482, 1981, by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol.48:443, 1970, by the search for similarity method of Pearson & Lipman, Proc. Nat’l. Acad. Sci. USA 85:2444, 1988, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by manual alignment and visual inspection (see, e.g., Sambrook et al. (Molecular Cloning: A Laboratory Manual, 4^th ed, Cold Spring Harbor, New York, 2012) and Ausubel et al. (In Current Protocols in Molecular Biology, John Wiley & Sons, New York, through supplement 104, 2013). Another example of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and the BLAST 2.0 algorithm, which are described in Altschul et al., J. Mol. Biol.215:403-410, 1990 and Altschul et al., Nucleic Acids Res.25:3389-3402, 1977. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (ncbi.nlm.nih.gov). The BLASTN program (for nucleotide sequences) uses as defaults a word length (W) of 11, alignments (B) of 50, expectation (E) of 10, M=5, N=-4, and a comparison of both strands. The BLASTP program (for amino acid sequences) uses as defaults a word length (W) of 3, and expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff, Proc. Natl. Acad. Sci. USA 89:10915, 1989). ^{4239-112370-02} In one example, once aligned, the number of matches is determined by counting the number of positions where an identical nucleotide or amino acid residue is present in both sequences. The percent sequence identity is determined by dividing the number of matches either by the length of the sequence set forth in the identified sequence, or by an articulated length (such as 100 consecutive nucleotides or amino acid residues from a sequence set forth in an identified sequence), followed by multiplying the resulting value by 100. For example, a peptide sequence that has 1166 matches when aligned with a test sequence having 1554 amino acids is 75.0 percent identical to the test sequence (1166÷1554*100=75.0). The percent sequence identity value is rounded to the nearest tenth. For example, 75.11, 75.12, 75.13, and 75.14 are rounded down to 75.1, while 75.15, 75.16, 75.17, 75.18, and 75.19 are rounded up to 75.2. The length value will always be an integer. Subject: Living multi-cellular vertebrate organisms, a category that includes human and non- human mammals. In an example, the subject is a human. In a non-limiting example, the subject is less than one year old, for example, an infant. Vaccine: A preparation of immunogenic material capable of stimulating an immune response, administered for the prevention, amelioration, or treatment of infectious or other types of disease. The immunogenic material may include attenuated or killed microorganisms (such as bacteria or viruses), or antigenic proteins, peptides or DNA derived from them. An attenuated vaccine is a virulent pathogen that has been modified to produce a less virulent form, but nevertheless retains the ability to elicit antibodies and cell-mediated immunity against the virulent form. An inactivated (killed) vaccine is a previously virulent pathogen that has been inactivated with chemicals, heat, or other treatment, but elicits antibodies against the pathogen. Vaccines may elicit both prophylactic (preventative or protective) and therapeutic responses. Methods of administration vary according to the vaccine, but may include inoculation, ingestion, inhalation or other forms of administration. Vaccines may be administered with an adjuvant to boost the immune response. Vector: A DNA or RNA molecule bearing a promoter(s) operably linked to a coding sequence of an antigen(s) of interest and can express the coding sequence. Non-limiting examples include a naked or packaged (lipid and/or protein) DNA, a naked or packaged RNA, a subcomponent of a virus or bacterium or other microorganism that may be replication-incompetent, or a virus or bacterium or other microorganism that may be replication-competent. A vector is sometimes referred to as a construct. Recombinant DNA vectors are vectors having recombinant DNA. A vector can include nucleic acid sequences that permit it to replicate in a host cell, such as an origin of replication. A vector can also include one or more selectable marker genes and other genetic elements known in the art. Viral vectors are recombinant nucleic acid vectors having at least some nucleic acid sequences derived from one or more viruses. IV. rB/HPIV3 Vectors Recombinant chimeric bovine/human parainfluenza virus 3 (rB/HPIV3) vectors including a heterologous gene encoding an avian influenza virus (AIV) antigenic protein are disclosed herein. The ^{4239-112370-02} disclosed rB/HPIV3 vectors include a full complement of PIV3 genes (from HPIV3 and/or BPIV3), thus the rB/HPIV3 vectors disclosed herein are infectious and replication-competent. However, the rB/HPIV3 vectors disclosed herein are attenuated in humans and non-human primates at least due to the presence of BPIV3 genes. In some aspects, a rB/HPIV3 vector disclosed herein includes a genome, which includes a 3’ leader region, a BPIV3 N gene, a heterologous gene, a BPIV3 P gene, a BPIV3 M gene, a HPIV3 F gene, a HPIV3 HN gene, a BPIV3 L gene, and a 5’ trailer region. In some aspects, a rB/HPIV3 vector disclosed herein includes a genome, which includes a nucleic acid sequence that consists of in 3’ to 5’ order: a 3’ leader region, a BPIV3 N gene, a heterologous gene, a BPIV3 P gene, a BPIV3 M gene, a HPIV3 F gene, a HPIV3 HN gene, a BPIV3 L gene, and a 5’ trailer region. Exemplary nucleic acid sequences of these genes and proteins encoded thereby are provided herein, as are structural and functional genetic elements that control gene expression, for example, gene start and gene end sequences and genome and anti-genome promoters. In some aspects, the genomic backbone of the rB/HPIV3 vectors disclosed herein is a PIV3 backbone, for example, BPIV3. An exemplary BPIV3 genome sequence (Kansas stain) is provided as SEQ ID NO: 28 (see also, GENBANK^TM Accession No. AF178654.1). An exemplary HPIV3 genome sequence (JS strain) is also provided as SEQ ID NO: 29 (see also, GENBANK^TM Accession No. Z11575.1). Although exemplary nucleic acid sequences are provided herein, sequences from these strains can also be used to construct a rB/HPIV3 vector, for example, as described in Schmidt et al., (J. Virol.74:8922-8929, 2000). In some such examples, the HN protein encoded by the HPIV3 HN gene is modified to have threonine and proline residues at positions 263 and 370, respectively. In some aspects, the BPIV3 N gene encodes an amino acid sequence having at least 80% (e.g., 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to SEQ ID NO: 1. In some aspects, the BPIV3 P gene encodes an amino acid sequence having at least 80% (e.g., 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to SEQ ID NO: 2. In some aspects, the BPIV3 M gene encodes an amino acid sequence having at least 80% (e.g., 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to SEQ ID NO: 3. In some aspects, HPIV3 F gene encodes an amino acid sequence having at least 80% (e.g., 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to SEQ ID NO: 4. In some aspects, the HPIV3 HN gene encodes an amino acid sequence having at least 80% (e.g., 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to SEQ ID NO: 5. In some aspects, the BPIV3 L gene encodes an amino acid sequence having at least 80% (e.g., 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to SEQ ID NO: 6. In some aspects, the BPIV3 N gene encodes an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 1. In some aspects, the BPIV3 P gene encodes an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 2. In some aspects, the BPIV3 M gene encodes an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 3. In some aspects, HPIV3 F gene encodes an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 4. In some aspects, the ^{4239-112370-02} HPIV3 HN gene encodes an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 5. In some aspects, the BPIV3 L gene encodes an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 6. In some aspects, the BPIV3 N gene includes or consists of a nucleic acid sequence encoding SEQ ID NO: 1. In some aspects, the BPIV3 P gene includes or consists of a nucleic acid sequence encoding SEQ ID NO: 2. In some aspects, the BPIV3 M gene includes or consists of a nucleic acid sequence encoding SEQ ID NO: 3. In some aspects, HPIV3 F gene includes or consists of a nucleic acid sequence encoding SEQ ID NO: 4. In some aspects, the HPIV3 HN gene includes or consists of a nucleic acid sequence encoding SEQ ID NO: 5. In some aspects, the BPIV3 L gene includes or consists of a nucleic acid sequence encoding SEQ ID NO: 6. In some aspects, the BPIV3 N, BPIV3 P, BPIV3 M, HPIV3 F, HPIV3 HN, and BPIV3 L genes encode an amino acid sequence having at least 95% sequence identity to SEQ ID NOs: 1, 2, 3, 4, 5, and 6, respectively. In some aspects, the BPIV3 N, BPIV3 P, BPIV3 M, HPIV3 F, HPIV3 HN, and BPIV3 L genes include or consist of a nucleic acid sequence encoding SEQ ID NOs: 1, 2, 3, 4, 5, and 6, respectively. The HN protein shown as SEQ ID NO: 5 includes threonine and proline residues at positions 263 and 370 (263T and 370P). rB/HPIV3 including an HN protein with 263T and 370P may be recovered and passaged with reduced occurrence of adventitious mutations, which increases the efficiency of virus production, analysis, and manufacture. Any of the rB/HPIV3 vectors provided herein can include a HPIV3 HN gene encoding HN protein with 263T and 370P amino acid residues (for example, introducing I263T and T370P amino acid substitutions relative to the wild-type HN protein sequence). The HPIV3 F and HN genes and the BPIV3 N, P, M, and L genes included in the rB/HPIV3 vectors disclosed herein are flanked by appropriate gene start and gene-end sequences to facilitate expression from the viral genome. For example: Gene Gene start SEQ ID NO Gene end SEQ ID NO Further, the rB/HPIV3 vectors disclosed herein include appropriate genome and anti-genome promoters, such as those of the BPIV3 Kansas strain as set forth in GENBANK^TM Accession No. AF178654 (SEQ ID NO: 28), which provides genomic promoter as nucleotides 1-96 and the antigenomic promoter as nucleotides 15361-15456. The heterologous gene of the rB/HPIV3 vectors disclosed herein is a gene from avian influenza virus (AIV). In some aspects, the antigenic protein is from AIV strain H7N9. In some examples, the ^{4239-112370-02} antigenic protein of AIV is hemagglutinin (HA) or neuraminidase (NA). In some aspects, the antigenic protein is a wild-type hemagglutinin (HA) or neuraminidase (NA) of AIV H7N9. In some aspects, the heterologous gene of a rB/HPIV3 vector disclosed herein is avian influenza virus (AIV) hemagglutinin (HA). An exemplary amino acid sequence of an AIV HA protein is provided as SEQ ID NO: 7. In some aspects, the heterologous gene encodes an amino acid sequence having at least 80% (e.g., 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to SEQ ID NO: 7. In some aspects, the heterologous gene encodes an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 7. In some aspects, the heterologous gene encodes SEQ ID NO: 7. In some aspects, the heterologous gene consists of a nucleic acid sequence encoding SEQ ID NO: 7. In some aspects, the heterologous gene of a rB/HPIV3 disclosed herein is avian influenza virus (AIV) neuraminidase (NA). An exemplary amino acid sequence of an AIV NA protein is provided as SEQ ID NO: 8. In some aspects, the heterologous gene encodes an amino acid sequence having at least 80% (e.g., 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to SEQ ID NO: 8. In some aspects, the heterologous gene encodes an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 8. In some aspects, the heterologous gene encodes SEQ ID NO: 8. In some aspects, the heterologous gene consists of a nucleic acid sequence encoding SEQ ID NO: 8. The rB/HPIV3 vectors disclosed herein include a 3’ leader region and a 5’ trailer region. In some aspects, the 3’ leader region and/or 5’ trailer region are a PIV33’ leader region or PIV35’ trailer region, respectively. In some aspects, the 3’ leader region and/or 5’ trailer region are a BPIV33’ leader region or BPIV35’ trailer region, respectively. In some aspects, the 3’ leader region includes at least 80% (e.g., 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to SEQ ID NO: 12. In some aspects, the 3’ leader region comprises at least 95% sequence identity to SEQ ID NO: 12. In some aspects, the 3’ leader region includes or consists of SEQ ID NO: 12. In some aspects, the 5’ trailer region comprises at least 80% (e.g., 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to SEQ ID NO: 13. In some aspects, the 5’ trailer region comprises at least 95% sequence identity to SEQ ID NO: 13. In some aspects, the 5’ region includes or consists of SEQ ID NO: 13. In some aspects, a rB/HPIV3 vector disclosed herein includes an antigenomic cDNA sequence comprising at least 80% (e.g., 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to any one of: SEQ ID NO: 11, SEQ ID NO: 32, SEQ ID NO: 33, or SEQ ID NO: 34. In some aspects, a rB/HPIV3 vector disclosed herein includes an antigenomic cDNA sequence comprising at least 95% sequence identity to any one of: SEQ ID NO: 11, SEQ ID NO: 32, SEQ ID NO: 33, or SEQ ID NO: 34. In some aspects, a rB/HPIV3 vector disclosed herein includes an antigenomic cDNA sequence set forth as SEQ ID NO: 11, SEQ ID NO: 32, SEQ ID NO: 33, or SEQ ID NO: 34. In some aspects, the rB/HPIV3 vector disclosed herein includes a nucleic acid sequence consisting of SEQ ID NO: 11, SEQ ID NO: 32, SEQ ID NO: 33, or SEQ ID NO: 34. In some aspects, a rB/HPIV3 vector disclosed herein includes an antigenomic cDNA sequence comprising at least 80% (e.g., 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) ^{4239-112370-02} sequence identity to SEQ ID NO: 11. In some aspects, a rB/HPIV3 vector disclosed herein includes an antigenomic cDNA sequence comprising at least 95% sequence identity to SEQ ID NO: 11. In some aspects, a rB/HPIV3 vector disclosed herein includes an antigenomic cDNA sequence set forth as SEQ ID NO: 11. In some aspects, the antigenomic cDNA sequence of a rB/HPIV3 vector disclosed herein consists of SEQ ID NO: 11. In some aspects, a rB/HPIV3 vector disclosed herein includes an antigenomic cDNA sequence comprising at least 80% (e.g., 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to SEQ ID NO: 32. In some aspects, a rB/HPIV3 vector disclosed herein includes an antigenomic cDNA sequence comprising at least 95% sequence identity to SEQ ID NO: 32. In some aspects, a rB/HPIV3 vector disclosed herein includes an antigenomic cDNA sequence set forth as SEQ ID NO: 32. In some aspects, the antigenomic cDNA sequence of a rB/HPIV3 vector disclosed herein consists of SEQ ID NO: 32. In some aspects, a rB/HPIV3 vector disclosed herein includes an antigenomic cDNA sequence comprising at least 80% (e.g., 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to SEQ ID NO: 33. In some aspects, a rB/HPIV3 vector disclosed herein includes an antigenomic cDNA sequence comprising at least 95% sequence identity to SEQ ID NO: 33. In some aspects, a rB/HPIV3 vector disclosed herein includes an antigenomic cDNA sequence set forth as SEQ ID NO: 33. In some aspects, the antigenomic cDNA sequence of a rB/HPIV3 vector disclosed herein consists of SEQ ID NO: 33. In some aspects, a rB/HPIV3 vector disclosed herein includes an antigenomic cDNA sequence comprising at least 80% (e.g., 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to SEQ ID NO: 34. In some aspects, a rB/HPIV3 vector disclosed herein includes an antigenomic cDNA sequence that comprises least 95% sequence identity to SEQ ID NO: 34. In some aspects, a rB/HPIV3 vector disclosed herein includes an antigenomic cDNA sequence set forth as SEQ ID NO: 34. In some aspects, the antigenomic cDNA sequence of a rB/HPIV3 vector disclosed herein consists of SEQ ID NO: 34. The rB/HPIV3 vectors, or gene sequences therein, herein can include codon-optimized sequences, for example, codon-optimized sequences for expression in a human cell. Several tools and resources are publicly available for codon optimization, for example (and without limitation), the GenScript™ Optimization (GS-opt) algorithm can be used to codon-optimize sequences for human expression. In some aspects, one or more genes encoded by a rB/HPIV3 vector disclosed herein (e.g., the heterologous gene, BPIV3 N gene, BPIV3 P gene, BPIV3 M gene, HPIV3 F gene, HPIV3 HN gene, or BPIV3 L gene) are codon-optimized for expression in a human cell. In some aspects, the heterologous gene (e.g., AIV HA or AIV NA) is codon-optimized for expression in a human cell. A non-limiting example of an AIV HA nucleic acid sequence codon-optimized for expression in a human cell is provided as SEQ ID NO: 14. A non- limiting example of an AIV NA nucleic acid sequence codon-optimized for expression in a human cell is provided as SEQ ID NO: 27. ^{4239-112370-02} The present disclosure encompasses sequence variants of a rB/HPIV3 vector disclosed herein, for example, a rB/HPIV3 vector disclosed herein including one or more nucleic acid deletions, substitutions, or insertions, or a degenerate variant of a rB/HPIV3 vector disclosed herein. The rB/HPIV3 sequence variants disclosed herein retain desired biological function, for example, attenuation or immunogenicity. Sequence variants can be spontaneous or engineered through the use of genetic engineering technique. In some aspects, a sequence variant includes no more than 100 nucleic acid deletions, substitutions, or insertions, for example, no more than 90, 80, 70, 60, 50, 40, 30, 20, 10, or fewer nucleic acid deletions, substitutions, or insertions. A degenerate variant refers to a polynucleotide sequence variant due to degeneracy (redundancy) of the genetic code. Although a degenerate variant has a different nucleic acid sequence than a reference sequence, a degenerate variant and reference sequence encode the same amino acid sequence. Other exemplary modifications include replacement of the 3’ end of the genome with its counterpart from the antigenome, which is associated with changes in RNA replication and transcription. In addition, intergenic regions (Collins et al., Proc. Natl. Acad. Sci. USA 83:4594-4598, 1986) can be shortened or lengthened or changed in sequence content, and the naturally-occurring gene overlap (Collins et al., Proc. Natl. Acad. Sci. USA 84:5134-5138 (1987)) can be removed or changed to a different intergenic region by the methods described herein. In addition, unique restriction sites can be inserted, for example in intergenic regions (e.g., a unique Asc I site between the N and P genes) or elsewhere. Non-translated gene sequences can be removed to increase capacity for inserting foreign sequences. In other aspects, a sequence surrounding a translational start site (such as including a nucleotide in the -3 position) of a selected viral gene can be modified, alone or in combination with introduction of an upstream start codon, to modulate gene expression by specifying up- or down-regulation of translation. Alternatively, or in combination with other modifications disclosed herein, gene expression can be modulated by altering a transcriptional GS signal of a selected gene(s) of the virus. In additional aspects, modifications to a transcriptional GE signal can be incorporated into the viral genome. Introduction of the foregoing modifications into rB/HPIV3 can be achieved by a variety of known methods. Examples of such techniques are found, for example, in Sambrook et al. (Molecular Cloning: A Laboratory Manual, 4^th ed., Cold Spring Harbor, New York, 2012) and Ausubel et al. (In Current Protocols in Molecular Biology, John Wiley & Sons, New York, through supplement 104, 2013). Thus, defined mutations can be introduced by conventional techniques (e.g., site-directed mutagenesis) into a cDNA copy of the genome or antigenome. The use of antigenome or genome cDNA subfragments to assemble a complete antigenome or genome cDNA has the advantage that each region can be manipulated separately (smaller cDNAs are easier to manipulate than large ones) and then readily assembled into a complete cDNA. Thus, the complete antigenome or genome cDNA, or any subfragment thereof, can be used as template for oligonucleotide-directed mutagenesis. A mutated subfragment can then be assembled into the complete antigenome or genome cDNA. Genetic modifications can vary from single nucleotide changes to replacement of large cDNA pieces containing one or more genes or genome regions. ^{4239-112370-02} The term vector as used herein includes naked or packaged (e.g., by lipid and/or protein) nucleic acid vectors. In some aspects, a disclosed rB/HPIV3 vector is naked (e.g., a free nucleic acid). In some aspects, a disclosed rB/HPIV3 vector is packaged (e.g., in a virus particle). The disclosed rB/HPIV3 vectors are self-replicating, that is they are capable of replication following infection of a host cell, and have an attenuated phenotype, for example when administered to a human subject. In some examples, a produced rB/HPIV3 virus carrying the heterologous AIV protein is attenuated about 3- to 500-fold or more in the upper respiratory tract and about 100- to 5000-fold or more in the lower respiratory tract in a subject as compared to control HPIV3. In some aspects, the level of viral replication in vitro is sufficient to provide for production of virus for use on a wide-spread or commercial scale. In some aspects, the level of viral replication of rB/HPIV3 in vitro is at least 10⁶, at least 10⁷, or at least 10⁸ per ml. In some aspects, the rB/HPIV3 vectors can be produced using the reverse genetics recombinant DNA-based technique (Collins, et al.1995. Proc Natl Acad Sci USA 92:11563-11567). This system allows de novo recovery of infectious virus entirely from cDNA in a qualified cell substrate under defined conditions. Reverse genetics provides a means to introduce predetermined mutations into the rB/HPIV3 genome via the cDNA intermediate. Specific attenuating mutations were characterized in preclinical studies and combined to achieve the desired level of attenuation. Derivation of vaccine viruses from cDNA minimizes the risk of contamination with adventitious agents and helps to keep the passage history brief and well documented. Once recovered, the engineered virus strains propagate in the same manner as a biologically derived virus. As a result of passage and amplification, the virus does not contain recombinant DNA from the original recovery. To propagate rB/HPIV3 vector/virus disclosed herein for immunization or other purposes, a cell line suitable for viral growth may be used. Parainfluenza virus grows in a variety of human and animal cells. Exemplary cell lines for propagating rB/HPIV3 vectors/virus for immunization include HEp-2 cells, FRhL- DBS2 cells, LLC-MK2 cells, MRC-5 cells, and Vero cells. Highest virus yields are usually achieved with epithelial cell lines such as Vero cells. Cells can be inoculated with virus at a multiplicity of infection ranging from about 0.001 to 1.0, or more, and are cultivated under conditions permissive for replication of the virus, e.g., at about 30-37ºC and for about 3-10 days, or as long as necessary for virus to reach an adequate titer. Temperature-sensitive viruses often are grown using 32ºC as the “permissive temperature.” Virus is removed from cell culture and separated from cellular components, typically by standard purification procedures, e.g., centrifugation, and may be further purified as desired using known procedures. The rB/HPIV3 viruses disclosed herein can be tested in various known and generally accepted in vitro and in vivo models to confirm adequate attenuation, resistance to phenotypic reversion, and immunogenicity. In in vitro assays, the modified virus is tested for temperature sensitivity of virus replication or “ts phenotype,” and for the small plaque phenotype. Modified virus also may be evaluated in an in vitro human airway epithelium (HAE) model, which provides a means of ranking viruses in the order of their relative attenuation in non-human primates and humans (Zhang et al., 2002 J Virol 76:5654-5666; Schaap-Nutt et al., 2010 Vaccine 28:2788-2798; Ilyushina et al., 2012 J Virol 86:11725-11734). Modified ^{4239-112370-02} viruses are further tested in animal models of HPIV3 or AIV infection. A variety of animal models (e.g., murine, hamster, cotton rat, and primate) are available. Immunogenicity of a rB/HPIV3 vector (including viruses) disclosed herein can be assessed in an animal model (such as a non-human primate, for example a rhesus macaque or African green monkey), for example, by determining the number of animals that form antibodies to AIV after one immunization and after a second immunization, and by measuring the magnitude of that response. In some aspects, a rB/HPIV3 vector (including viruses) disclosed herein has sufficient immunogenicity that about 60 to 80% of the animals develop antibodies after the first immunization and about 80 to 100% of the animals develop antibodies after the second immunization. In some aspects, the immune response protects against infection by AIV. In some aspects, the immune response protects against infection by AIV H7N9. Also provided are isolated polynucleotides comprising or consisting of a genome or antigenome of a rB/HPIV3 vector disclosed herein, vectors comprising such polynucleotides, and host cells comprising such polynucleotides or vectors. Methods of producing a rB/HPIV3 packaged vector or virus disclosed herein are encompassed by the present disclosure. In some aspects, the method includes transfecting a host cell with a rB/HPIV3 vector disclosed herein, incubating the cell in a cell culture, and purifying the rB/HPIV3 vector from the cell culture, thereby producing the rB/HPIV3 packaged vector or virus. In some examples, the host cell is a HEp-2 cell, FRhL-DBS2 cell, LLC-MK2 cell, MRC-5 cell, or Vero cell. Transfected host cells are cultivated under conditions that permit replication of the virus, e.g., at about 30-37ºC and for about 3-10 days, or as long as necessary for virus to reach an adequate titer. In some aspects, transfected host cells are cultured at about 32 ℃ for about 3-10 days, or as long as necessary for virus to reach an adequate titer. Virus can be purified from cell culture by standard purification procedures, e.g., centrifugation, and may be further purified as desired using known procedures. Further methods of producing recombinant parainfluenza virus (such as a rB/HPIV3 vector including a heterologous gene as disclosed herein), methods of attenuating the viruses (e.g., by recombinant or chemical means), as well as viral sequences and reagents for use in such methods are provided, for example, in U.S. Patent Application Publication Nos.2012/0045471, 2010/0119547, 2009/0263883, and 2009/0017517; U.S. Patent Nos.7,632,508, 7,622,123, 7,250,171, 7,208,161, 7,201,907, 7,192,593; PCT Publication No. WO 2016/118642; Liang et al. (J. Virol, 88(8): 4237-4250, 2014), and Tang et al. (J Virol, 77(20):10819-10828, 2003). In some aspects, these methods are modified as needed using the description provided herein to construct a disclosed rB/HPIV3 vector. V. Immunogenic Compositions Immunogenic compositions that include a disclosed rB/HPIV3 vector (including virus particles thereof) and a pharmaceutically acceptable carrier are also provided. Standard methods for preparing administrable immunogenic compositions are described, for example, in such publications as Remington’s Pharmaceutical Sciences, Adejare (Ed.), Academic Press, 23rd Edition, 2020, ISBN: ^{4239-112370-02} 9780128223895/9780128200070. An immunogenic composition disclosed herein can be administered to a subject (e.g., a human) by any suitable route, for example and without limitation, intranasally. Potential carriers include, but are not limited to, physiologically balanced culture medium, phosphate buffer saline solution, water, emulsions (e.g., oil/water or water/oil emulsions), various types of wetting agents, cryoprotective additives or stabilizers such as proteins, peptides or hydrolysates (e.g., albumin, gelatin), sugars (e.g., sucrose, lactose, sorbitol), amino acids (e.g., sodium glutamate), or other protective agents. The resulting aqueous solutions may be packaged for use as is or lyophilized. Lyophilized preparations are combined with a sterile solution prior to administration for either single or multiple dosing. The immunogenic composition can contain a bacteriostat to prevent or minimize degradation during storage, including but not limited to effective concentrations (usually ≦1% w/v) of benzyl alcohol, phenol, m-cresol, chlorobutanol, methylparaben, and/or propylparaben. A bacteriostat may be contraindicated for some patients; therefore, a lyophilized formulation may be reconstituted in a solution either containing or not containing such a component. The immunogenic composition can include one or more excipients, for example, to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents, wetting agents and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, and triethanolamine oleate. In some aspects, excipients that increase shelf-life or stabilization of an immunogenic composition are included. The immunogenic composition may optionally include an adjuvant to enhance the immune response of the host. Suitable adjuvants include, for example, toll-like receptor agonists, alum, AlPO₄, alhydrogel, Lipid-A and derivatives or variants thereof, oil-emulsions, saponins, neutral liposomes, liposomes containing the recombinant virus, and cytokines, non-ionic block copolymers, and chemokines. Non-ionic block polymers containing polyoxyethylene (POE) and polyxylpropylene (POP), such as POE-POP-POE block copolymers, MPL^ (3-O-deacylated monophosphoryl lipid A; Corixa, Hamilton, IN) and IL-12 (Genetics Institute, Cambridge, MA), among many other suitable, well-known adjuvants may be used as an adjuvant (Newman et al., 1998, Critical Reviews in Therapeutic Drug Carrier Systems 15:89-142). These adjuvants have the advantage in that they help to stimulate the immune system in a non-specific way, thus enhancing the immune response to a pharmaceutical product. In some instances, it may be desirable to combine the immunogenic composition disclosed herein, with other pharmaceutical products (e.g., vaccines) which induce protective responses to other viral agents, particularly those causing other childhood illnesses. For example, an immunogenic composition as described herein can further include additional immunogenic compositions or vaccines recommended by the Advisory Committee on Immunization Practices (ACIP; cdc.gov/vaccines/acip) for the targeted age group (e.g., infants from approximately one to six months of age). These vaccines include, but are not limited to, IN-administered vaccines. In some aspects, an immunogenic composition as disclosed herein is administered simultaneously with additional vaccines against, for example, hepatitis B (HepB), diphtheria, ^{4239-112370-02} tetanus, pertussis, pneumococcal bacteria (PCV), Haemophilus influenzae type b (Hib), polio, influenza, rotavirus, COVID-19, measles, respiratory syncytial virus (RSV), rubella, typhoid fever, etc. In some aspects, an immunogenic composition disclosed herein is administered with at least one additional vaccine (e.g., one or more additional vaccines). In some aspects, the at least one additional vaccine includes a respiratory virus vaccine. In some aspects, the additional vaccine is administered within the same week, for example, within the same day or within 3 days, of administering an immunogenic composition disclosed herein. The additional vaccine can be administered at the same time or substantially at the same time as an immunogenic composition disclosed herein. In some aspects, the additional vaccine is administered within the same day as an immunogenic composition disclosed herein, for example, within 30 mins, within 1 hour, within 3 hours, within 8 hours, or within 12 hours, of an immunogenic composition disclosed herein. In some aspects, the additional vaccine is administered within 0 mins to 48 hours (e.g., 0 mins to 36 hours, 0 mins to 24 hours, 0 mins to 12 hours, 0 mins to 8 hours, 0 mins to 3 hours, 0 mins to 1 hour, etc.) of an immunogenic composition disclosed herein. In some aspects, two or more rB/HPIV3 vectors disclosed herein are included in the immunogenic composition, for example, a rB/HPIV3 vector including AIV HA and a rB/HPIV3 vector including AIV NA. In some aspects, the immunogenic composition can be provided in unit dosage form to induce an immune response in a subject, for example, to prevent AIV infection in the subject. A unit dosage form contains a suitable single preselected dosage for administration to a subject, or suitable marked or measured multiples of two or more preselected unit dosages, and/or a metering mechanism for administering the unit dose or multiples thereof. VI. Methods of Eliciting an Immune Response Provided herein are methods of eliciting an immune response in a subject by administering an immunogenic composition disclosed herein to the subject. Upon immunization, the subject responds by producing antibodies specific to AIV and/or HPIV3. In addition, innate and cell-mediated immune responses are induced, which can provide antiviral effectors as well as regulating the immune response. As a result of the immunization the host becomes at least partially or completely immune to AIV and/or HPIV3 infection, or resistant to developing moderate or severe AIV and/or HPIV3-associated disease. A subject who has or is at risk for developing an AIV and/or HPIV3 infection, for example due to exposure (e.g., exposure to birds or humans infected with AIV, or live in an area experiencing an AIV outbreak) or age (e.g., an infant or child under the age of 5), can be selected for immunization. Following administration of a disclosed immunogenic composition, the subject can be monitored for infection or symptoms associated with AIV infection. Nearly all humans are infected with HPIV3 by the age of five and further are at risk of AIV infection. Therefore, the entire birth cohort is included as a relevant population for immunization. This could be done, for example, by beginning an immunization regimen anytime from birth to 6 months of age, from 6 months of age to 5 years of age, in pregnant women (or women of child-bearing age) to protect their ^{4239-112370-02} infants by passive transfer of antibody, family members of newborn infants or those still in utero, and subjects greater than 50 years of age. The scope of this disclosure is meant to include maternal immunization. In several aspects, the subject is a human subject that is seronegative for AIV and/or HPIV3 specific antibodies. In additional aspects, the subject is no more than one year old, such as no more than 6 months old, no more than 3 months, or no more than 1 month old. Subjects at greatest risk of AIV and/or HPIV3 infection with severe symptoms (e.g. requiring hospitalization) include infants, children, young adults, and the elderly. The term infant includes humans that are 1 year old or less. The term child includes humans under the age of 18. The term young adult includes humans between the age of 16 and 26. The term elderly includes humans over the age of 65. In some aspects, the subject is an infant, for example, between 0-12 months, 0-9 months, 0-6 months, 3-12 months, 3-9 months, 3-6 months, 6-9 months, or 6-12 months. In some aspects, the subject is a child between the age of 1-18, for example, between the age of 1-5, 1-12, 1-14.5-12, 5-14, etc. In some aspects, the subject is a young adult, for example, between the age of 16-26, for example, between the age of 16-24, 16-20, 18-26, 18-24, 18-20, 20-25, etc. In some aspects, the subject is elderly, for example, a subject older than 65, 70, 75, 80, etc. The immunogenic compositions disclosed herein are administered to a subject susceptible to or otherwise at risk of AIV and/or HPIV3 infection at an effective amount, which is an amount sufficient to induce or enhance the individual's immune response capabilities against AIV and/or HPIV3. The effective amount may allow for some growth and proliferation of rB/HPIV3 in the subject in order to produce a desired immune response, but will not produce viral-associated symptoms or illnesses. The immunogenic composition may be administered by any suitable method, including but not limited to, via injection, aerosol delivery, nasal spray, nasal droplets, oral inoculation, or topical application. In a particular non-limiting example, the attenuated virus is administered according to established human intranasal administration protocols (e.g., as discussed in Karron et al., J Infect Dis 191:1093-104, 2005). Briefly, infants, children, or adults are inoculated intranasally via droplet with an effective amount of an immunogenic composition, for example, a pharmaceutical composition disclosed herein, in a volume (for example) of 0.5 ml of a physiologically acceptable diluent or carrier. This has the advantage of simplicity and safety compared to parenteral immunization with a non-replicating virus. It also provides direct stimulation of local respiratory tract immunity, which plays a role in resistance to AIV and HPIV3. In all subjects, the precise amount of a rB/HPIV3 vector that is administered, and the timing and repetition of administration, will be determined by various factors, including the patient’s state of health and weight, the mode of administration, the nature of the formulation, etc. Dosages generally range from about 3.0 log10 to about 6.0 log10 plaque forming units (“PFU”) or more of virus per patient, more commonly from about 4.0 log10 to 6.0 log10 PFU virus per patient. In some aspects, 5.0 log10 to 6.0 log10 PFU per patient is administered. In some aspects, 5.0 log10 to 6.0 log10 PFU per patient is administered during infancy, for example, between 1 and 6 months of age. One or more booster doses can be given, for example, 1-6 months after a first administration. In a non-limiting example, an infant is administered 5.0 log₁₀ to 6.0 log₁₀ PFU at ^{4239-112370-02} approximately 2, 4, and 6 months of age, which is the recommended time of administration for a number of other childhood vaccines. In yet other aspects, an additional booster dose is administered at approximately 10-15 months of age. Based on the guidance provided herein and knowledge in the art, the proper dose and administration regimen for immunization can be determined. A desired immune response is to inhibit subsequent infection with AIV and/or HPIV3. The AIV and/or HPIV3 infection does not need to be completely inhibited for the method to be effective. For example, administration of an effective amount of a disclosed rB/HPIV3 vector or immunogenic composition thereof can decrease subsequent AIV and/or HPIV3 infection (for example, as measured by infection of cells, or by number or percentage of subjects infected by AIV and/or HPIV3) by a desired amount, for example by at least 10%, at least 20%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, or even at least 100% (prevention of detectable AIV and/or HPIV3 infection), as compared to a suitable control. Determination of effective dosages is typically based on animal model studies followed up by human clinical trials and is guided by administration protocols that significantly reduce the occurrence or severity of targeted disease symptoms or conditions in the subject, or that induce a desired response in the subject (such as a neutralizing immune response). Suitable models in this regard include, for example, murine, rat, hamster, cotton rat, bovine, ovine, porcine, feline, ferret, non-human primate, and other accepted animal model subjects known in the art. Alternatively, effective dosages can be determined using in vitro models (for example, immunologic and histopathologic assays). Using such models, only ordinary calculations and adjustments are needed to determine an appropriate concentration and dose to administer a therapeutically effective amount of the composition (for example, amounts that are effective to elicit a desired immune response or alleviate one or more symptoms of a targeted disease). Administration of a rB/HPIV3 vector or immunogenic composition thereof as disclosed herein to a subject can elicit the production of an immune response that is protective against disease, such a disease caused by AIV infection (e.g., bird flu or avian flu). While the naturally circulating virus is still capable of causing infection, particularly in the upper respiratory tract, there is a reduced possibility of rhinitis as a result of the immunization and a possible boosting of resistance by subsequent infection by wild-type virus. Following immunization, there are detectable levels of host engendered serum and secretory antibodies which are capable of neutralizing wild-type virus in vitro and in vivo. An immunogenic composition including a disclosed rB/HPIV3 vector can be used in coordinate (or prime-boost) immunization protocols or combinatorial formulations. It is contemplated that there can be several boosts, and that each boost can be a different disclosed immunogen. It is also contemplated in some examples that the boost may be the same immunogen as another boost, or the prime. In certain aspects, novel combinatorial immunogenic compositions and coordinate immunization protocols employ separate immunogens or formulations, each directed toward eliciting an anti-viral immune response, such as an immune response to AIV or HPIV3 proteins. Separate immunogenic compositions that elicit the anti-viral immune response can be combined in a polyvalent immunogenic composition administered to a subject in a ^{4239-112370-02} single immunization step, or they can be administered separately (in monovalent immunogenic compositions) in a coordinate (or prime-boost) immunization protocol. The resulting immune response can be measured or characterized by a variety of methods. These include taking samples of nasal washes or sera for analysis of AIV- or HPIV3-specific antibodies, which can be detected by tests including, but not limited to, complement fixation, plaque neutralization, hemagglutination inhibition, enzyme-linked immunosorbent assay, luciferase-immunoprecipitation assay, and flow cytometry. In addition, immune responses can be detected by assay of cytokines in nasal washes or sera, ELISPOT of immune cells from either source, quantitative RT-PCR or microarray analysis of nasal wash or serum samples, and restimulation of immune cells from nasal washes or blood by re-exposure to viral antigen in vitro and analysis for the production or display of cytokines, surface markers, or other immune correlates measures by flow cytometry or for cytotoxic activity against indicator target cells displaying AIV or HPIV3 antigens. In this regard, individuals are also monitored for signs and symptoms of upper respiratory illness. EXAMPLES The following examples are provided to illustrate particular features or aspects of the disclosure, but the scope of the claims should not be limited to those features exemplified. Example 1 Materials and Methods Virus genome design and H7N9 strain selection. B/HPIV3 was used as a vector to express the H7N9 HA and NA proteins. B/HPIV3 has a chimeric genome consisting of the BPIV3 genome in which the F and HN genes have been deleted and replaced with those from HPIV3 using unique restriction sites introduced into the downstream non-coding regions of the M and HN genes of BPIV3 and HPIV3 (Schmidt et al., “Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates,” J Virol.74(19):8922-9, 2000). The BPIV3 and HPIV3 sequences are from BPIV3 strain Kansas/15626/84 (GenBank # AF178654) and HPIV3 strain JS (GenBank # Z11575), respectively. The HA and NA ORFs are from the highly pathogenic (HP) avian influenza virus (HPAIV) H7N9 A/Guangdong/17SF003/2016 (GISAID isolate ID: EPI_ISL_249309) isolated from an infected human and propagated once in a chicken embryonated egg. This H7N9 strain was selected because it had been chosen by the World Health Organization (https://www.who.int/teams/global-influenza-programme) for developing H7N9 candidate vaccine viruses (CVVs) and reference reagents at the United States Centers for Disease Control and Prevention (CDC) and the United States Food and Drug Administration (FDA). The wt HA ORF (GISAID accession # EPI919607) containing its native polybasic cleavage site and the NA ORF (GISAID accession # EPI919606) were codon optimized for human expression (Genscript, Piscataway, NJ) and the inserts were engineered so that, when inserted into the B/HPIV3 genome, the ORFs ^{4239-112370-02} would be flanked by the BPIV3 P gene-start and N gene-end transcription signals so that they would be transcribed by the B/HPIV3 polymerase as separate mRNAs. The HA or NA insert was placed in the second gene position between the B/HPIV3 N and P genes using AscI site (see, FIGS.1A and B) as previously described (Liang et al., “Chimeric bovine/human parainfluenza virus type 3 expressing respiratory syncytial virus (RSV) F glycoprotein: effect of insert position on expression, replication, immunogenicity, stability, and protection against RSV infection.” J Virol 88: 4237-4250, 2014). The insert encoded either the full- length unmodified HA or NA protein (B/HPIV3/HA and B/HPIV3/NA) or a chimera in which the HA and NA transmembrane and cytoplasmic tail (TMCT) domains were replaced with those of the BPIV3 F (Liang et al., “Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate.” J Virol 91, 2017) and HN (Liang et al., “Effects of Alterations to the CX3C Motif and Secreted Form of Human Respiratory Syncytial Virus (RSV) G Protein on Immune Responses to a Parainfluenza Virus Vector Expressing the RSV G Protein.” J Virol 93, 2019), respectively, as previously described for the RSV F and G proteins (Liang et al. J Virol 91 (2017); Liang et al., J Virol 93, 2019). Two additional viruses were designed from which the HPIV3 F and HN genes were deleted (B/HPIV3^∆FHN), and the genes encoding H7N9 HA and NA were inserted at the second and third gene positions, respectively, with the goal of replacing the attachment, fusion, and neuraminidase functions of the HPIV3 F and HN proteins. One construct contained the full-length HA and NA ORFs (B/HPIV3 ^∆FHN/HA- NA) and the second contained their TMCT versions (B/HPIV3^ΔFHN/HA-TMCT-NA-TMCT). Like other constructs, the HA and NA ORFs were each flanked by the vector P gene-start and N gene-end signals and AscI sites. Sequences flanking each of the HA and NA AscI insert are shown (Fig 1B). The genomes of all six viruses conformed to the paramyxovirus rule-of-six (hexameric genome length) and kept their wt phasing. Cells and viruses. African green monkey kidney Vero cells (ATCC CCL-81), rhesus monkey kidney LLC-MK2 cells (ATCC CCL-7), and baby hamster kidney BHK BSR-T7/5 cells that constitutively express T7 RNA polymerase were maintained as previously described (Buchholz et al., “Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter.” J Virol 73, 251-259 (1999); Liang et al., "Chimeric Bovine/Human Parainfluenza Virus Type 3 Expressing Respiratory Syncytial Virus (RSV) F Glycoprotein: Effect of Insert Position on Expression, Replication, Immunogenicity, Stability, and Protection against RSV Infection" in J Virol.88: 4237-4250, 2014). Human lung epithelial A549 (ATCC, CCL-185) cells were maintained in F-12K medium (ATCC) with 1% L- Glutamine and 10% fetal bovine serum (FBS; Hyclone, Marlborough, MA) at 37^ºC and 5% CO₂. Virus rescue. All viruses were recovered by co-transfection of BHK BSR-T7/5 cells with B/HPIV3 full length anti-genome plasmids containing HA and/or NA inserts and support plasmids expressing the BPIV3 N, P and L proteins as described previously (Liang et al., "Chimeric Bovine/Human Parainfluenza Virus Type 3 Expressing Respiratory Syncytial Virus (RSV) F Glycoprotein: Effect of Insert Position on ^{4239-112370-02} Expression, Replication, Immunogenicity, Stability, and Protection against RSV Infection" in J Virol.88: 4237-4250, 2014). Transfected cells were co-cultured with LLC-MK2 cells to generate P1 virus stocks that were all propagated once more in LLC-MK2 cells to obtain P2 stocks used in all subsequent experiments. Virus titration. Virus stocks were titrated by limiting dilution in LLC-MK2 cells growing in 96- well plates. Infected wells were detected by immunostaining using a hyperimmune rabbit serum raised against partially-purified HPIV3 virions (MS456) as described below for plaque assay. The titers were reported as log₁₀50% tissue culture infective dose per ml (log₁₀ TCID₅₀/ml). Viral genome sequence analysis. Viral RNA was purified from P2 stocks using QIAmp® Viral RNA Mini kit (Qiagen®, Valencia CA) and used for RT-PCR. Automated Sanger sequencing of the overlapping un-cloned PCR products was performed, with full coverage except for the 27 and 28 nucleotides at the 3’ and 5’ genome ends, respectively. P2 stocks with confirmed genome sequences were used for all experiments described below. Multicycle replication in cell culture. Multicycle replication profiles were determined in Vero cells that were infected with each virus in triplicate wells of a 6-well plate at a multiplicity of infection (MOI) of 0.01 TCID50/cell and aliquots of the overlying culture medium were collected over 7 days as previously described (Liang et al., “Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored- Vaccine Candidate.” J Virol 91, 2017). All samples were titrated together by limiting dilutions in LLC- MK2 cells by the TCID₅₀ method described above. Dual-antigen plaque staining. Expression of the H7N9 HA, HA-TMCT, NA, or NA-TMCT protein by individual PFUs was analyzed using a previously described strategy (Liang et al., “Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.” J Virol 89: 9499-9510, 2015). The PIV3-specific antibodies were the above-mentioned MS456 rabbit hyperimmune serum (1:1000 dilution); the HA-specific antibodies were a mix of two HA mouse monoclonal antibodies B1275M (cat# GTX41071) and B1274M (cat# GTX41077) (GeneTex), each at 1:2000 dilution; and the NA-specific antibody was a mouse monoclonal antibody 2F6 (Wan et al., “Comparison of the Efficacy of N9 Neuraminidase-Specific Monoclonal Antibodies against Influenza A (H7N9) Virus Infection.” J Virol 92, 2018), diluted 1:5000. This was followed by staining with IRDye800CW-conjugated goat anti-rabbit and IRDye680LT-conjugated goat anti-mouse secondary antibodies (LI-COR Biosciences®, Lincoln, NE) and scanning using the Odyssey® infra-red scanner (LI- COR Biosciences®). Plaques were pseudo-colored (Image Studio®, LI-COR Biosciences®) to visualize PIV3 antigens in green and H7N9 HA or NA in red. When superimposed, PFUs co-expressing vector and HA or NA antigens appear yellow while those lacking HA or NA would appear green. Viral protein expression in infected cells. Triplicate wells of LLC-MK2 cells in six-well plates were inoculated with each virus at an MOI of 3 TCID₅₀/cell and incubated at 32°C. At 48-hour p.i., the cell monolayers were washed with cold PBS followed by lysis in LDS sample buffer (Thermo Fisher Scientific®, Rockville MD) containing protease inhibitor Ultra and protease inhibitor cOmplete® (Sigma ^{4239-112370-02} Aldrich, Saint Louis, MO). Lysates were incubated at 37℃ for 30 min in the presence of sample reducing agent and electrophoresed in a 4-12% bis-tris gel (Thermo Fisher Scientific®). Lysates of HEK293 cells expressing recombinant H7N9 HA or NA protein were included in parallel as positive controls (SinoBiological®, cat# 40104-V08HL and 40109-V07HL, respectively) under the same reducing and denaturing conditions. Blotted proteins were detected by incubation with primary antibodies overnight at 4°C. The BPIV3 N and P were detected with rabbit HPIV3 hyperimmune serum (MS456), F protein with rabbit polyclonal antibodies against recombinant HPIV3 F ectodomain, and HN was detected with rabbit polyclonal serum raised against an HN peptide. For H7 HA, a mixture containing 1:500 dilution of each of the mouse monoclonal (SinoBiological®, cat #40103-MM06) and a rabbit polyclonal (SinoBiological®, cat # 40103-RP02) antibodies was used that could detect the HA1, HA2, and HA0 fragments. The N9 NA was detected with a rabbit polyclonal NA antibody at 1:500 dilution (Rockland, cat# 600-401-Z05) and tubulin with a rabbit alpha-tubulin antibody (Cell signaling Technologies Cat # 2144) at 1:1000 dilution to serve as a loading control. The secondary infra-red dye conjugated antibodies were goat anti-rabbit 680LT, goat anti-mouse 680LT, and goat anti-rabbit 800CW (LI-COR Biosciences®). Membranes were scanned and analyzed using Odyssey® infra-red scanner system and ImageStudio™ software (LI-COR Biosciences®). Protein packaging in the virus particle. Each virus was propagated in LLC-MK2 cells by infection at an MOI of 0.01 TCID₅₀/cell and incubation at 32°C for 5-7 days. Culture supernatant was collected and subjected to discontinuous sucrose density gradient centrifugation as described previously (Munir et al., “Nonstructural proteins 1 and 2 of respiratory syncytial virus suppress maturation of human dendritic cells.” J Virol 82: 8780-8796, 2008). Virus particles were pelleted and lysed in RIPA buffer followed by protein quantification in each preparation using Pierce BCA assay (Thermo Fisher Scientific®, Rockville MD). Two µg of total virion protein for each virus were denatured and reduced as described above and were loaded on the gel for analysis by Western blotting using the antibodies described above. Evaluation of candidate vaccine viruses in AGMs. The animal study was approved by the Animal Care and Use Committee of the National Institute of Allergy and Infectious Diseases, National Institutes of Health and performed in accordance with the Guide for the Care and Use of Laboratory Animals. The animals were 19 adult African green monkeys (AGMs) weighing ~3-6 kg, which were confirmed to be seronegative for H7N9 and HPIV3, were included in the study (FIG.5A). Groups of 4 animals each were immunized with individual candidate vaccine viruses IN and IT each with 10⁶ TCID50 in 1 ml of L15 medium (Thermo Fisher Scientific®) at each site. Each animal received a single dose on day 0, and two animals per group received a second identical dose on day 28. In addition, a preparation of recombinant PR8 influenza virus (A/Puerto Rico/8/1934; H1N1) that had been subjected to reassortment to contain the HA and NA genes and proteins of HPAIV H7N9 (PR8-H7N9) was inactivated with beta propiolactone (BPL). A group of 3 animals were immunized intramuscularly (IM) in the upper most part of the right arm (deltoid muscle) with 50 µg of BPL inactivated PR8-H7N9 (PR8-H7N9-BPL) in 1 ml 1X PBS, without adjuvant. Each animal in this group received a single dose on day 0, and two animals received a second dose on day 28. ^{4239-112370-02} From all groups, including that receiving the inactivated vaccine, nasopharyngeal (NP) swabs were collected daily from day 0 to 10, then on days 12, 14, 21, and 28. Following the boost on day 28, NP swabs were collected daily from all animals (boosted or not) from day 29 to 38, and then on day 56. Tracheal lavage (TL) samples were collected every other day from day 2 to 14 and on day 21. Following the boost on day 28, TL samples were collected from all animals (boosted or not) every other day from day 30 to 38 and then on day 56. From all groups, sera were collected before immunization (day 0) and on days 14, 21, 28, 35, 42, 49, and 56. All AGMs were under clinical observation daily throughout the study and vital signs were recorded including appetite, behavior, respiratory symptoms, nasal discharge, ocular symptoms, rectal temperature, pulse rate, respiration rate, and body weight. NP and TL samples were titrated by limiting dilution on LLC-MK2 cells as described above and titers reported as TCID50/ml. The stability of HA and NA protein expression by the candidate vaccine viruses during replication in AGMs was evaluated by analyzing NP and TL post-prime samples collected from day 1-8 p.i. by dual antigen staining plaque assay described above. To determine the nature of mutations in the inserted gene, viral RNA was isolated from the NP and TL samples collected on day 8 p.i. from the four B/HPIV3/HA immunized AGMs. RT-PCR was performed to amplify a 3 kb region containing the HA gene insert of 1746 nt length that included the HA ORF and the flanking regulatory transcription signals. The uncloned RT- PCR fragments were analyzed by Sanger sequencing. The immunogenicity of vaccine candidates against H7 HA and N9 NA was evaluated by analyzing AGM sera in a micro-neutralization assay using PR8-H7N9 virus, a recombinant PR8 virus containing the HPAIV (Guongdong strain) H7 HA and N9 NA surface proteins. Immunogenicity against HA also was measured by HAI assay using PR8-H7N9. The induction of serum HPIV3-neutralizing antibodies was assessed by determining the 60% plaque reduction neutralization titers (PRNT60). The assay was performed in Vero cells in the presence of added guinea pig complement (Lonza, Walkersville, MD) using HPIV3 (JS) that expresses green fluorescent protein as described previously (Coates et al., “An antigenic analysis of respiratory syncytial virus isolates by a plaque reduction neutralization test.” Am J Epidemiol 83: 299-313 (1966); Liu et al., “Human parainfluenza virus type 3 expressing the respiratory syncytial virus pre-fusion F protein modified for virion packaging yields protective intranasal vaccine candidates.” PLoS One 15, e0228572, 2020). Example 2 Vaccine Design and Virus Recovery The H7N9 HA and NA ORFs were codon-optimized for human expression and flanked by BPIV3 gene start and gene end signals for transcription as a separate mRNA. The HA and NA ORFs were designed to encode either the wild type (wt) HA (B/HPIV3/HA) or NA (B/HPIV3/NA) proteins or their modified versions in which the transmembrane and cytoplasmic tail (TMCT) domains of HA and NA were replaced with those of BPIV3 F (B/HPIV3/HA-TMCT) and HN (B/HPIV3/NA-TMCT) (FIG.1). ^{4239-112370-02} The TMCT mutation was based on prior work with RSV F protein expressed by the PIV vectors (Liang et al., “Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate.” J Virol 91, 2017; Liu et al., “Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F.” J Virol 91, 2017). The native RSV F is not packaged in the PIV particle but the TMCT mutation mediates efficient packaging and greatly enhances its conformational stability and immunogenicity in hamsters and non-human primates. The design of the BPIV3 derived TMCT sequences in HA-TMCT and NA-TMCT was similar to those of RSV F and G glycoproteins described previously (Liang et al., “Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored- Vaccine Candidate.” J Virol 91, 2017; Liang et al., “Effects of Alterations to the CX3C Motif and Secreted Form of Human Respiratory Syncytial Virus (RSV) G Protein on Immune Responses to a Parainfluenza Virus Vector Expressing the RSV G Protein.” J Virol 93, 2019). Each of the HA and NA genes was inserted at the second gene position of the B/HPIV3 antigenome (FIG.1). A B/HPIV3 based H7N9 vaccine virus replication is expected to be restricted by HPIV3-specific immunity that is present in most older children and adults due to prior natural exposure to HPIV3. Thus B/HPIV3 may be more suitable for immunization of young HPIV3 seronegative children and infants. Modifications were made to the B/HPIV3 vector in effort to reduce sensitivity to restriction by HPIV3 immunity. This was done by deleting the HPIV3 F and HN genes encoding the HPIV3 neutralization antigens and major protective antigens and inserting the H7N9 HA and NA genes. Thus, the HA and NA proteins would be engaged in B/HPIV3 replication, creating a selective pressure for maintaining their expression and improving genetic stability. Wild-type, as well as TMCT versions, of HA and NA were inserted. However, none of these viruses were recovered. This was the case even though the HA, HA- TMCT, NA, and NA-TMCT proteins all were packaged efficiently into the vector particle, and HA0 was cleaved, when expressed as individual inserts. Viruses were rescued by co-transfecting plasmids encoding the BPIV3 N, P, and L proteins together with the full-length anti-genome plasmids. B/HPIV3 containing the HA, NA or their TMCT versions were recovered, but the two constructs based on the B/HPIV3^∆FHN backbone did not yield infectious virus despite several recovery attempts. The passage 1 (P1) stocks (transfection harvest) of the recovered viruses were evaluated for the stability of HA and NA expression by co-immunostaining of plaques for the vector and insert-expressed antigens (see, Table 1). Table 1. Insert expression stability in P1 and P2 viral stocks in vitro. P1 stock P2 stock Virus P1 % PFUs % PFUs stock positive for P2 stocks positive for HA/NA HA/NA ^{4239-112370-02} 1 100 _✓ 98 2 100 B/HPIV3/HA Viruses expressing HA, NA, or NA-TMCT maintained insert expression in 95-100% of plaques. However, in four independent attempts of recovery from cDNA, B/HPIV3/HA-TMCT P1 had HA expression levels of 80%, 20%, 1%, and 90%. Seven additional recoveries were performed (P1 stocks 5- 11), yielding P1 stocks with 12-78% of plaques expressing HA-TMCT. The HA-TMCT clone with 90% stability was grown into a P2 stock whose stability was 95%. The P2 stocks finally selected for further experiments exhibited stability of antigen expression at 98%, 95%, 100%, and 100% for B/HPIV3/HA, B/HPIV3/HA-TMCT, B/HPIV3/NA, and B/HPIV3/NA-TMCT, respectively (see, Table 1 and FIGS.2A- 2B). Purified viral RNA from the P2 stocks was subjected to reverse-transcription polymerase chain reaction (RT-PCR) followed by sequencing of the un-cloned overlapping PCR fragments. B/HPIV3 containing HA, NA, or NA-TMCT insert had no detectable adventitious mutations, whereas B/HPIV3/HA- TMCT had two positions that each contained a mixture of two assignments – in each case, the original assignment of U mixed with the mutant assignment of C, at approximately 50% and 25% of the total, at nt 1896 (UGC->CGC) and 3027 (UAC->CAC), respectively. These mutations were non-synonymous, resulting in C60R and Y437H coding changes in the HA-TMCT ectodomain, and may have contributed to the loss of HA-TMCT detection for 5% of the PFUs in the P2 stock by the HA-specific monoclonal antibodies (Table 1 and FIGS.2A-2B), although this was not specifically investigated. Example 3 ^{4239-112370-02} Replication Kinetics and Expression A multicycle replication experiment was performed to determine virus growth kinetics in Vero cells, a suitable substrate for vaccine manufacture. Cells were infected at an MOI of 0.01 TCID50 per cell, and aliquots of the supernatants were collected daily. The B/HPIV3 empty vector replicates efficiently in Vero cells (FIG.2C). There was no significant difference in the growth profile of any of the other viruses when compared with the empty B/HPIV3 vector over a period of 7 days, suggesting that the presence and expression of a supernumerary H7 or N9 gene insert did not affect vector replication in vitro and all viruses grew to similar final titers. Next, expression of HA, HA-TMCT, NA, NA-TMCT, and the vector N, P, F, and HN proteins in LLC-MK2 cells was examined by Western blot. Monolayers were infected at an MOI of 3 TCID50 per cell, cell lysates were prepared 48 hours after infection, and were analyzed by gel electrophoresis under denaturing and reducing conditions followed by Western blotting. Lysates of HEK293 cells expressing recombinant H7N9 HA or NA protein were included in parallel as positive controls (FIGS.3A and 3C, lane 4). Tubulin was included as a loading control for band quantifications. The wt HA expressed by B/HPIV3/HA appeared as three major bands, i.e., the parent un-cleaved HA0 form and its cleavage products HA1 and HA2 at the predicted sizes (FIG.3A, lane 1). In the case of B/HPIV3/HA-TMCT, the abundance of HA0 was disproportionately greater, and HA1 and HA2 were less abundant, compared to the lysates from B/HPIV3/HA infected cells (FIG.3A, lane 2) suggesting inefficient cleavage of HA-TMCT. As expected, the HA0 precursor and HA2 fragment of HA-TMCT were slightly larger in size compared to those of wt HA due to the TMCT substitution which added 10 additional amino acids to the HA2 fragment resulting in larger HA0 and HA2 products. The total amount of HA in B/HPIV3/HA cell lysates was higher than that of HA-TMCT in B/HPIV3/HA-TMCT lysates, but this was not statistically significant (FIG.3B; mean ± SD of three blots). NA and NA-TMCT were expressed by B/HPIV3/NA and B/HPIV3/NA-TMCT as single major species, as expected (apparent molecular weight: 65 kDa; FIG.3C, lanes 1 and 2). NA-TMCT appeared slightly larger than vector-expressed NA due to the additional 25 amino acids introduced by TMCT substitution. Vector-expressed wt NA was detected at slightly higher amounts compared to NA-TMCT, but this also was not statistically significant (FIG.3D; mean ± SD of three blots). Expression of the B/HPIV3 vector proteins were also evaluated in infected cell lysates compared to the empty B/HPIV3 vector. B/HPIV3 N and P protein expression by viruses expressing either form of HA or NA were similar to the empty B/HPIV3 vector, and thus were largely unaffected by the additional gene (FIGS.3E-3G). The level of F was unchanged for viruses expressing HA or HA-TMCT but was significantly reduced for B/HPIV3/NA and B/HPIV3/NA-TMCT (FIG.3E and 3H) as compared to the B/HPIV3 empty vector. The expression of HPIV3 HN protein was significantly reduced only for B/HPIV3/NA and was similar to the empty vector for the remaining viruses (FIGS.3E and 3I). Example 4 ^{4239-112370-02} Virion Packaging Viruses were grown in LLC-MK2 cells and virions in the culture supernatants were purified by sucrose gradient centrifugation. For each virus, 2 µg of total protein were analyzed by Western blotting to determine if the different forms of H7N9 HA and NA were packaged in the virions and if that influenced packaging of the B/HPIV3 proteins. HA and HA-TMCT were detected in the B/HPIV3/HA and B/HPIV3/HA-TMCT particles but the amount was significantly lower for the latter (FIGS.4A-4B). This was the opposite of the expected effects of TMCT substitution, which was intended to increase rather than decrease incorporation. Both the un-cleaved (HA0) and cleaved (HA1, and HA2) forms of HA were detected in the purified particles suggesting that the unmodified form of HA was efficiently packaged in the B/HPIV3/HA particles. However, for B/HPIV3/HA-TMCT, only low levels of HA0 and HA2 were detected, and HA1 was not detected. Since HA1 and HA2 are equimolar products of HA0 cleavage, the lack of HA1 was unexpected, but might be due to a lower sensitivity of detection of HA1 by this antibody. Thus, the native HA protein was packaged very efficiently in the B/HPIV3 particle, while the TMCT substitution decreased HA packaging. Unmodified NA also was detected in the particles and, like HA, was present in the virions at modestly higher amounts than NA-TMCT, but this difference was not statistically significant (FIGS.4C- 4D). The B/HPIV3 N, F, and HN proteins were present at similar amounts in the particles of all of the vectors as compared to the empty vector, but P protein was significantly reduced in viruses expressing HA or HA-TMCT (FIGS.4E-4I). Example 5 Replication and Immunogenicity in African Green Monkeys Candidate vaccine viruses were evaluated for replication and immunogenicity in AGMs (FIGS.5A- 5C). In brief, four animals per group were immunized on day 0 with each virus at a dose of 10⁶ TCID₅₀, administered by the combined intranasal (IN) and intratracheal (IT) routes. Three additional AGMs were each immunized intramuscularly (IM) on day 0 with 50 µg of beta propiolactone (BPL)-inactivated recombinant influenza virus (PR8-H7N9-BPL). Two animals from each group received a second dose on day 28. The inactivated PR8-H7N9-BPL control was based on a preparation of recombinant IAV PR8 [A/Puerto Rico/8/1934 (H1N1)], with the HA and NA genome segments replaced by those encoding the HA and NA of HPAIV H7N9 (strain A/Guangdong/17SF003/2016), and represents a World Health Organization-recommended CVV for H7N9 pandemic preparedness. This PR8-H7N9-BPL vaccine was prepared to closely resemble and serve as a surrogate for the inactivated CVV that has been developed by the United States Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), and other international health agencies. The study design and sampling schedule are shown in FIG.5A. From all groups, nasopharyngeal (NP) swabs and tracheal lavage (TL) samples were collected on multiple days to analyze vaccine virus replication in the airways. Sera were collected from all animals on day 0 (before immunization) and weekly thereafter starting from day 14 through 56 post-infection (p.i.). ^{4239-112370-02} The animals were under clinical observation throughout the study. Vital signs were recorded, and all remained within the normal physiological range (FIG.5D). Following the first dose of live vaccine virus, virus was detected in the NP swabs from day 1 to 12 with peak titers during days 3-5; virus was detected in the TL samples from day 2 to 10, with peak titers on day 4 p.i., (FIGS.5B-5C). Overall, all four viruses had similar NP replication profiles and peak titers with the exceptions that, on days 2, 4, and 8, B/HPIV3/NA-TMCT, B/HPIV3/NA, and B/HPIV3/HA-TMCT titers were greater than those of B/HPIV3/HA-TMCT, B/HPIV3/HA-TMCT, and B/HPIV3/HA, respectively. Similarly, no significant differences were observed for TL titers. Following the second dose of live vaccine, no virus was detected by infectivity assay of the NP and TL specimens, indicating that the second dose was strongly restricted by the immunity conferred by the first dose. As expected, virus shedding was not detected in specimens from animals immunized with the inactivated PR8-H7N9-BPL vaccine. Next, stability of HA and NA insert expression during replication in AGMs was evaluated. The NP and TL samples collected over day 1-8 p.i. were analyzed by a dual-antigen-staining plaque assay on Vero cells to simultaneously detect the B/HPIV3 vector proteins and HA, HA-TMCT, NA, or NA-TMCT protein and identify PFUs that had lost the insert expression. The P2 stocks of B/HPIV3/HA and B/HPIV3/HA- TMCT used for AGM inoculation contained 98% and 95% of PFUs expressing HA, respectively, whereas both B/HPIV3/NA and B/HPIV3/NA-TMCT had 100% of PFUs positive for NA (FIGS.2A-2B and Table 1). Analysis of the AGM NP specimens showed that, for the four viruses, 75-100% of PFU in individual specimens retained expression of the insert. B/HPIV3/HA had small, insignificant decreases in mean group HA expression over the first 4 days of replication followed by moderate, significant decreases on days 5-8. For example, HA expression was detected in 80-88% of plaques in individual specimens on day 5 and 77-91% on day 8 (FIGS.6A and 6C). Expression of HA-TMCT had moderate, significant decreases in the group mean values on days 3 and 5-8, but was well above 90% for most of the individual specimens and never fell below 84%. Expression of NA and NA-TMCT in the NP ranged between 90-100% and 88-100%, respectively, for individual specimens from day 1-8 p.i.. and had a significant decrease in mean group expression only for NA-TMCT on day 7. In the TL samples (FIGS.6B and 6C), mean HA expression was 91-98% on day 2 followed by moderate, significant decreases to 82-93%, 75-81% and 76-86% on days 4, 6 and 8 p.i., respectively. HA- TMCT expression showed somewhat greater stability and remained at 86-100% from day 2-6 followed by a decrease on day 8 (80-88%). Similar to the NP samples, both NA and NA-TMCT maintained stable expression in the trachea at ≥ 90% till day 6 p.i. and had a significant decrease on day 8. The two versions of HA were more prone to instability as compared to the two versions of NA, which might be due to factors such as the nucleotide sequence of the insert or characteristics of the expressed protein. We used nucleotide sequencing to analyze genetic changes in the insert of B/HPIV3/HA, the most promising candidate, after replication in the respiratory tract. Viral RNA was purified from the NP and TL ^{4239-112370-02} samples collected on day 8 p.i. (first dose) from each of the four AGMs followed by RT-PCR and sequencing. Sequence of the HA gene insert including the HA ORF and the transcription signals (N gene- end and P gene-start) was analyzed. Mutations were detected in only one TL derived specimen- that had 76.7% PFUs positive for HA expression- and involved 7 nucleotide substitutions which invariably were mixed nucleotide populations containing the mutant nucleotide at an estimated fraction of ~50-80% of the total. All were U to C substitutions, one each in the N gene-end and P gene-start signals preceding the HA ORF, and 5 non-synonymous changes in the HA ORF causing amino acid substitutions (L94P, F481L, F532L, F534L, and S537P) (FIG.6D). Lack of HA detection in a fraction of the B/HPIV3/HA plaques might be due to amino acid substitutions in HA resulting in a loss of epitope/s detected by the monoclonal antibodies. The U to C change in the N gene-end and P gene-start also might have contributed in reducing or ablating HA expression. Example 6 Induction of Neutralizing Antibodies in African Green Monkeys AGM sera were analyzed for H7N9-neutralizing antibody titers by a microneutralization assay using the recombinant PR8-H7N9 virus (described above) in place of the H7N9 virus. Following the first IN/IT dose, B/HPIV3/HA and B/HPIV3/HA-TMCT induced H7N9-neutralizing serum antibodies that were detectable as early as 2 weeks p.i. (FIG.7A). Significantly higher titers were achieved by B/HPIV3/HA with mean titers 16-, 32-, and 25-fold higher as compared to B/HPIV3/HA-TMCT at weeks 2, 3, and 4, respectively. In contrast, a single IN/IT dose of B/HPIV3/NA or B/HPIV3/NA-TMCT did not induce detectable levels of H7N9-neutralizing serum antibodies. PR8-H7N9-BPL, the inactivated vaccine that was administered via the IM route, also was weakly immunogenic; a single dose stimulated low H7N9- neutralizing serum antibody titers in only one of the three AGMs, detectable at weeks 2 and 3. The antibody titers induced by B/HPIV3/HA peaked at week 6 (titer of 1:4096), and were similar for one and two doses, suggesting there was no detectable benefit of boosting. Thus, a single IN/IT dose of B/HPIV3/HA was sufficient to achieve high serum antibody titers. B/HPIV3/HA-TMCT antibody titers also peaked at week 6 but were 22-fold lower than those of B/HPIV3/HA. A second dose did not show a clear benefit. B/HPIV3/HA-TMCT titers were consistently lower than those of B/HPIV3/HA indicating that the TMCT modification reduced the immunogenicity of HA protein. The B/HPIV3/NA and B/HPIV3/NA- TMCT elicited H7N9-neutralizing antibodies only after the booster dose, detectable at week 5, in 3 of 4 and 2 of 4 AGMs, respectively. B/HPIV3/NA and B/HPIV3/HA-TMCT induced similar, low titers of H7N9- neutralizing antibodies. Similar to the results with HA-TMCT, the TMCT substitution in NA reduced rather than increasing its immunogenicity, though the difference in titers between animals immunized with B/HPIV3/NA and B/HPIV3/NA/TMCT was not statistically significant. The inactivated PR8-H7N9-BPL vaccine, given IM, induced only low H7N9-neutralizing titers after one dose (1 animal) or two doses (1 ^{4239-112370-02} animal) that remained significantly lower compared to those induced by B/HPIV3/HA throughout 8 weeks and were also lower as compared to B/HPIV3/HA-TMCT from week 5-8. Overall, B/HPIV3/HA, delivered mucosally via the IN/IT route, was the most immunogenic among the candidates. Data also revealed the poor immunogenicity of the inactivated PR8-H7N9-BPL vaccine, included here as a surrogate of the human vaccine developed for pandemic preparedness. Next, H7N9-specific HAI serum antibody titers were analyzed for AGMs immunized with B/HPIV3/HA, B/HPIV3/HA-TMCT, versus the inactivated PR8-H7N9-BPL vaccine. The HAI antibody profiles were similar to those of H7N9-neutralizing antibodies. B/HPIV3/HA induced the highest titers of HAI antibodies that were detectable by 2 weeks at 1:10^1.6 (1:39.8) to 1:10^2.2 (1:158.5) and reached a remarkable peak titer of 1:10^3.4 (1:2,512) by 6 weeks (FIG.7B). The B/HPIV3/HA peak titers were significantly greater compared to those of B/HPIV3/HA-TMCT [1:10^1.9 (1:79.4) at 6 weeks. Despite the absence of detectable vaccine virus replication, the B/HPIV3/HA booster provided a 4-, 8-, 4-, and 2.8-fold higher mean titer at 5, 6, 7, and 8 weeks, respectively, compared to a single dose. Consistent with the weak neutralizing antibody response, PR8-H7N9-BPL elicited HAI antibodies that were transiently detected in 2 of the 3 animals only at week 3 reaching titers of 1:10^2.5 (1:316.2) and 1:10^1.3 (1:20) and remained undetectable at all other sampling times including those after the booster dose, indicating that boosting had no effect with this inactivated vaccine. A B/HPIV3 vectored H7N9 vaccine may be suitable for dual protection against HPIV3 and H7N9. Therefore, sera also were analyzed for the HPIV3-neutralizing antibodies to assess the immunogenicity against the vector antigens. For all four viruses, a single dose stimulated high titers of HPIV3-neutralizing antibodies detectable by 2 weeks after immunization. No appreciable increase in the HPIV3 antibody titers was observed after the boost for any of the four viruses, reflecting the strong restriction of replication of the second vaccine dose. It will be apparent that the precise details of the methods or compositions described herein may be varied or modified without departing from the spirit of the disclosure. We claim all such modifications and variations that fall within the scope and spirit of the claims below.

Claims

4239-112370-02 It is claimed: 1. A recombinant chimeric bovine/human parainfluenza virus 3 (rB/HPIV3) vector, comprising: a genome comprising in a 3’ to 5’ order: a 3’ leader region, BPIV3 N gene, heterologous gene, BPIV3 P gene, BPIV3 M gene, HPIV3 F gene, HPIV3 HN gene, BPIV3 L gene, and 5’ trailer region; wherein the heterologous gene encodes an avian influenza virus H7N9 hemagglutinin (HA) protein at least 90% identical to SEQ ID NO: 7, or an avian influenza virus H7N9 neuraminidase (NA) protein at least 90% identical to SEQ ID NO: 8; and wherein the recombinant B/HPIV3 is infectious, attenuated, and self-replicating.

2. The rB/HPIV3 of claim 1, wherein the heterologous gene is codon-optimized for expression in human cells.

3. The rB/HPIV3 of any one of the prior claims, wherein the avian influenza virus H7N9 HA protein is at least 95% identical to SEQ ID NO: 7, or the avian influenza virus H7N9 NA protein is at least 95% identical to SEQ ID NO: 8.

4. The rB/HPIV3 of any one of the prior claims, wherein the avian influenza virus H7N9 HA protein comprises or consists of SEQ ID NO: 7, or the avian influenza virus H7N9 NA protein comprises or consists of SEQ ID NO: 8.

5. The rB/HPIV3 of any one of the prior claims, wherein: the BPIV3 N gene encodes an amino acid sequence comprising at least 90% sequence identity to SEQ ID NO: 1; BPIV3 P gene encodes an amino acid sequence comprising at least 90% sequence identity to SEQ ID NO: 2; BPIV3 M gene encodes an amino acid sequence comprising at least 90% sequence identity to SEQ ID NO: 3; HPIV3 F gene encodes an amino acid sequence comprising at least 90% sequence identity to SEQ ID NO: 4; HPIV3 HN gene encodes an amino acid sequence comprising at least 90% sequence identity to SEQ ID NO: 5; and/or BPIV3 L gene encodes an amino acid sequence comprising at least 90% sequence identity to SEQ ID NO: 6. 4239-112370-02

6. The rB/HPIV3 of any one of the prior claims, wherein: the BPIV3 N gene encodes an amino acid sequence comprising at least 95% sequence identity to SEQ ID NO: 1; BPIV3 P gene encodes an amino acid sequence comprising at least 95% sequence identity to SEQ ID NO: 2; BPIV3 M gene encodes an amino acid sequence comprising at least 95% sequence identity to SEQ ID NO: 3; HPIV3 F gene encodes an amino acid sequence comprising at least 95% sequence identity to SEQ ID NO: 4; HPIV3 HN gene encodes an amino acid sequence comprising at least 95% sequence identity to SEQ ID NO: 5; and/or BPIV3 L gene encodes an amino acid sequence comprising at least 95% sequence identity to SEQ ID NO: 6.

7. The rB/HPIV3 of any one of the prior claims, wherein: the BPIV3 N gene comprises or consists of a nucleic acid sequence encoding SEQ ID NO: 1; BPIV3 P gene comprises or consists of a nucleic acid sequence encoding SEQ ID NO: 2; BPIV3 M gene comprises or consists of a nucleic acid sequence encoding SEQ ID NO: 3; HPIV3 F gene comprises or consists of a nucleic acid sequence encoding SEQ ID NO: 4; HPIV3 HN gene comprises or consists of a nucleic acid sequence encoding SEQ ID NO: 5; and/or BPIV3 L gene comprises or consists of a nucleic acid sequence encoding SEQ ID NO: 6.

8. The rB/HPIV3 of any one of the prior claims, wherein: the 3’ leader region comprises a sequence comprising at least 90% sequence identity to SEQ ID NO: 12; and/or the 5’ trailer region comprises a sequence comprising at least 90% sequence identity to SEQ ID NO: 13.

9. The rB/HPIV3 of any one of the prior claims, wherein: the 3’ leader region comprises a sequence comprising at least 95% sequence identity to SEQ ID NO: 12; and/or the 5’ trailer region comprises a sequence comprising at least 95% sequence identity to SEQ ID NO: 13.

10. The rB/HPIV3 of any one of the prior claims, wherein: the 3’ leader region comprises or consists of SEQ ID NO: 12; and/or 4239-112370-02 the 5’ trailer region comprises or consists of SEQ ID NO: 13.

11. The rB/HPIV3 of any one of the prior claims, wherein the 3’ leader region comprises a genomic and/or anti-genomic promoter.

12. The rB/HPIV3 of any one of the prior claims, wherein the genome comprises an antigenomic cDNA sequence set forth as SEQ ID NO: 11, SEQ ID NO: 32, SEQ ID NO: 33, or SEQ ID NO: 34.

13. The rB/HPIV3 of any one of the prior claims, wherein the rB/HPIV3 induces an immune response to avian influenza virus H7N9 HA or NA protein, respectively.

14. The rB/HPIV3 of any one of the prior claims, wherein the rB/HPIV3 induces an immune response that neutralizes avian influenza virus H7N9.

15. A nucleic acid molecule comprising the nucleotide sequence of the genome of the rB/HPIV3 of any one of the prior claims, or an antigenomic cDNA or RNA sequence of the genome.

16. A vector comprising the nucleic acid molecule of claim 15.

17. A host cell comprising the nucleic acid molecule of claim 15 or the vector claim 16.

18. A method of producing rB/HPIV3 virus, comprising: transfecting a host cell with the vector of claim 16; culturing the host cell, thereby forming a cell culture; and purifying the virus from the cell culture, thereby producing the rB/HPIV3 virus.

19. The method of claim 18, wherein the cell is a vaccine production cell, optionally wherein the vaccine production cell comprises a HEp-2 cell, FRhL-DBS2 cell, LLC-MK2 cell, MRC-5 cell, or Vero cell.

20. A rB/HPIV3 virus produced by the method of claim 18.

21. An immunogenic composition comprising a pharmaceutically acceptable carrier and the rB/HPIV3 of any one of claims 1-14, or the virus of claim 20. 4239-112370-02

22. A method of eliciting an immune response to avian influenza virus H7N9 in a subject, comprising administering the immunogenic composition of claim 21 to the subject, thereby generating the immune response.

23. The method of claim 22, comprising intranasal administration of the immunogenic composition.

24. The method of claim 22 or claim 23, wherein the subject is a human.

25. The method of claim 24, wherein the human subject is a pediatric subject, optionally wherein the subject is less than one year old.

26. The method of any one of claims 22-25, wherein the immune response is a protective immune response.

27. The method of claim 26, wherein the protective immune response is elicited after a single dose of the immunogenic composition.

28. Use of the rB/HPIV3 of any one of claims 1-14 or the virus of claim 20 to elicit an immune response to avian influenza virus H7N9 in a subject.

29. The method of any one of claims 22-28, wherein the immunogenic composition is administered with at least one additional vaccine.

30. The method of claim 29, wherein the additional vaccine is a respiratory virus vaccine.